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Abstract	  
 
Background and Objectives: The Study of Women Entering and in Endocrine Transition 
(SWEET) was developed to examine differences in metabolic, hormonal, and anthropometric 
parameters in black urban South African women at different stages of the menopause 
transition (MT).  Little data are available on accurate staging of the menopausal transition for 
sub-Saharan African women. There is a plethora of data on this and related subjects in 
Western women, but little available research on changes in body composition or risk of 
metabolic syndrome (MetS) in the MT in midlife black South African women, although 
obesity is prevalent in this group, and there is a high instance of both diabetes and 
hypertension. The prevalence of HIV infection is also high in these women but it is not 
known whether this may affect the symptoms and conditions of the MT, contribute to 
changes in body composition or increased risk of MetS and cardiovascular disease (CVD). 
No prior study in sub-Saharan Africa has used the Stages of Reproductive Aging Workshop 
+ 10 (STRAW + 10) criteria to stage reproductive aging or assessed their reliability in 
classifying ovarian status. The MT is closely associated with changes in body composition 
including lower bone mineral density, decreased lean muscle mass, increased body mass 
index (BMI) and adiposity, particularly increased central adiposity. Abdominal obesity is a 
key risk factor for MetS. This, and the subsequent risk of CVD appear to increase as women 
transition into menopause. It is unclear if this is due to reproductive or chronological aging, 
or both combined.   
 
Aims: (1) To assess the usefulness of the STRAW + 10 criteria in staging ovarian aging in 
black South African women. (2) To determine whether there are differences in body 
adiposity, lean muscle mass, and bone mineral density (BMD) across reproductive groups 
and ascertain the main correlates of these variables. (3) To determine in this population, if 
the risk of MetS and the levels of its components and related metabolic factors, differ 
between women at different stages of the MT and to explore the possible determinants. (4) 
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To investigate whether the high prevalence of HIV infection in these women affects the age 
at menopause, menopausal symptoms, body composition, and metabolic variables in midlife 
black South African women.   
 
Methods: Participants in this cross-sectional study were 702 black urban African women 
aged 40 to 60 years.  The stages of reproductive aging were categorized using STRAW + 10 
criteria. The Menopause Rating Scale was used to measure the prevalence of menopausal 
symptoms including vasomotor symptoms. Study-specific questionnaires were used to 
obtain relevant demographic and lifestyle data. Blood levels of follicle stimulating hormone 
(FSH), estradiol (E2), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate 
(DHEAS), testosterone (T) and sex hormone blinding globulin (SHBG), insulin, lipids, 
glucose, leptin and adiponectin were measured. Simple measures of body anthropometry 
(weight, height, waist and hip circumference) were obtained.  Body composition was 
measured using dual-energy X-ray absorptiometry (DXA) and ultrasonography. Human 
immunodeficiency virus (HIV) status was assessed using a point-of-care method. Metabolic 
syndrome and diabetes were diagnosed using internationally recognized criteria. 
 
Results: Reported age at final menstrual period (FMP) was higher in subjects interviewed 
within 4 years of FMP (49.0±3.80) than in subjects interviewed ≥10 years after FMP 
(42.0±4.06; p<0.0005). Human immunodeficiency virus (HIV) status had no effect on 
menopause symptoms. A BMI ≥35 kg/m2 was associated with severe vasomotor symptoms. 
Estradiol (p<0.0005), SHBG (p<0.0005) and DHEAS (p=0007) were significantly lower in 
post- than premenopausal groups, whilst FSH was higher (p<0.0005). Whole body lean 
mass (p=0.002) and BMD (p<0.0005) were significantly lower in postmenopausal compared 
to premenopausal groups. Multivariable linear regression models and ANCOVA 
demonstrated that the lower lean mass was related to the high postmenopausal FSH levels, 
whilst the lower BMD was partially explained by the low postmenopausal E2 levels. Use of 
antiretroviral therapy (ART) correlated negatively with total fat mass (β=-2.92, p=0.008) and 
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total bone mineral content (BMC; β=-78.8, p=0.003).  The MetS was highly prevalent 
(49.6%). Levels of total cholesterol (p<0.0005), LDL (p<0.0005), triglyceride (p=0.01), 
systolic (p<0.0005) and diastolic (p<0.05) blood pressure were all significantly higher in post-
menopausal compared to pre-menopausal groups whilst there was a trend for glucose levels 
(p=0.05) and MetS prevalence (p=0.05) to also be higher. Multiple regression analyses and 
ANCOVA showed that the higher levels of cholesterol and LDL were related to higher FSH 
concentrations whilst elevation in systolic blood pressure was linked to lower estradiol levels. 
The higher postmenopausal glucose and diastolic blood pressure levels and risk of MetS 
were related to chronological aging.  Adiponectin was strongly correlated with all 
components of the MetS except for blood pressure. 
 
Conclusions: Reporting of age at FMP is unreliable in subjects interviewed ≥ 4 years after 
the event. The STRAW+10 criteria are accurate in staging reproductive aging, as confirmed 
by the significant association of FSH and estradiol levels with menopausal transition stage. 
These guidelines may be appropriate for use in resource-limited settings in the absence of 
biomarkers. The MT in these women is characterized by lower whole body lean mass and 
BMD in post- compared to premenopausal subjects but there are negligible differences in fat 
mass. Lower lean mass and BMD were associated with higher FSH and lower E2 serum 
levels, respectively. Lower fat mass and BMC were associated with ART use. The lipid 
profile was more atherogenic and blood pressure was higher in the post- than the 
premenopausal women. These differences were related to the higher FSH (LDL and total 
cholesterol) and lower E2 (diastolic blood pressure) levels in the postmenopausal women. 
These data suggest that the hormonal changes characterizing the menopause may play a 
role in the etiology of cardiometabolic disease and in the body composition changes that are 
observed in the MT.  The above conclusions should be addressed in longitudinal studies. 
The terminology of STRAW+10 needs to be simplified and the questions 
contextualized, and contraceptive use should be specifically addressed in questions 
on bleeding patterns. In addition there are implications for the use of behavioral interventions 
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in lowering cardio-metabolic risk factors and hence morbidity and mortality in these women. 
Further research is needed to examine health risks associated with snuff use, and the long-
term effects of HIV-infection and different ART regimens. Additional studies should address 
the poor understanding of menopausal health consequences in this population 
with appropriate education programs  
 x 
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Preface 
The past 15 years of clinical practice as a Menopause Counselor,	  studying and researching 
the topic of menopause and wellness, have shown me that women, with access to either 
private or public healthcare, have scant knowledge of the health risks that appear to be 
associated with the menopause transition.  Of paramount interest and concern to me were 
mid-life black South African women, who have very little access to gynaecologists and 
health-care professionals, and almost no knowledge of menopause. In addition, the cryptic 
manner in which the menopause transition appears to be frequently addressed, and lack of 
information from public health care providers in many black communities, adds to the 
opaque nature of the subject. I examined the available literature and confirmed that this was 
a very neglected area of research, with a paucity of literature addressing the physiological, 
psychological, psychosocial aspects of the menopause transition in black mid-life women. 
 
My PhD appears to be the first study of its kind in sub-Saharan Africa, and the results, 
comparing similarities and differences between black postmenopausal South African women 
with those worldwide, were explored. The size of the cohort may allow the data gathered to 
be generalizable to other communities of urban black women in sub-Saharan Africa. Since 
this research examines the menopause transition and the related hormonal, metabolic and 
anthropometric changes that are related to it, it was named: The Study of Women Entering 
and in Endocrine Transition (SWEET). 
 
Access to the mothers and caregivers of the children in the Birth to Twenty study in Soweto, 
whose database is situated at the Developmental Pathways for Health Research Unit 
(DPHRU) at Chris Hani Baragwanath Hospital, provided a discreet, homogenous group of 
midlife women, who were not research naïve, and who understood the benefits of research. 
They were also acquainted with some of the research team members and were familiar with 
data collection processes. The data collection for SWEET was completed within two years. 
 xxii 
Most of these women had never had an annual medical check-up or gynaecological 
examination, although they had heard about menopause.  However, not many understood 
its implications or the process of reproductive aging. Very few of these women had ever had 
the blood assays that act as biomarkers for both metabolic disease and menopausal stage, 
or dual-energy X-ray absorptiometry (DXA) and ultrasound, to measure body composition.  
They were therefore eager to participate in the study and to be informed of these results, 
which would allow them to know more about their health status.  It was agreed that if their 
results were not in the normal range, they would be referred to a primary health care clinic, 
medical practitioner or specialist for further testing and treatment.  
 
The PhD thesis is by publication and includes three manuscripts. The articles have either 
been published or have been submitted to peer-reviewed, accredited medical journals. The 
PhD thesis is in six chapters. 
 
Chapter 1 and Chapter 2 consist of the literature review, contextual background and 
relevance of the research, and a description of the study cohort and methods. 
 
Chapters 3-5 include the three research studies, presented as scientific publications that 
were undertaken for this PhD project. Paper 1 is a cross-sectional study investigating the 
usefulness and validity of staging ovarian aging in black South African women. Paper 2 
examines differences in body composition across groups of black sub-Saharan African 
women at different stages of the menopause transition, and the possible relationship 
between these and an altered hormonal milieu. Paper 3 explores whether reproductive aging 
and the associated hormonal changes are related to a greater risk of metabolic syndrome 
and associated CVD risk factors in this population. 
 
Chapter 6 discusses the findings of these three studies. It contains a conclusion and 
suggestions for further research in this field  
 Chapter	  1. Literature Review	   	  
 2 
1 Literature Review 
This study examines the metabolic, hormonal and anthropometric parameters across the 
menopausal transition stages in black urban South African women. The literature review in 
this chapter provides the background for the research undertaken, highlighting the results 
and recommendations arising from related studies in this research area.  
 
1.1 Background  
 
The World Health Organization estimates that by 2030, 1.2 billion women will be 50 or over. 
This almost triples the number of women who were in that age bracket in 1990 (1). It is 
estimated that by the late 2020’s, 76% of postmenopausal women will be living in developing 
countries (2). Growing numbers of women can expect to live for several decades after 
menopause; however, it is suggested that women living in poor socio-economic conditions 
may have their final menstrual period (FMP) at a younger age (3), while a later menopause 
may be associated with greater longevity (4). There is a great deal of data documenting 
metabolic syndrome as a risk factor for cardiometabolic disease in postmenopausal women 
in Western and developed countries but very little data on this subject is available in 
emerging nations. The Heart of Soweto study (5) showed that cardiovascular disease (CVD) 
is becoming more prevalent in black urban populations. The study population contained 
more women than men and the mean age was 53 years, which suggests that many of these 
women were menopausal, but unfortunately the subjects were not tested to determine 
menopausal status (5). The Soweto researchers discuss the prevalence of hypertension and 
type 2 diabetes, either one of which may suggest the presence of metabolic syndrome. 
Some morbidity in black postmenopausal women in South African women may be due to 
HIV/AIDS or tuberculosis (6). However, HIV positive women may be at greater risk for 
metabolic disease (7), and symptoms and conditions of the menopause transition (MT) in 
midlife women may be affected if they are HIV positive (8). However, if, as the literature 
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shows, women during the MT and in postmenopause show a greater tendency to develop 
metabolic syndrome (9), a better understanding of possible health risks may help these 
women to effect lifestyle changes which could increase longevity. 
 
1.2 An historical perspective of the MT 
1.2.1 Reproductive aging is recognized (350 BC - 6th century AD)  
The idea that the MT is associated with risk of disease is at least 200 hundred years old as 
shown in in Figure 1.1, though the cessation of menses has been mentioned throughout the 
ages. As early as 350 BC, Aristotle, in his seminal work, The History of Animals, wrote: ‘In 
the human species, the male is generative, at the longest, up to seventy years, and the 
female up to fifty; but such extended periods are rare. As a rule, the male is generative up to 
the age of sixty-five, and to the age of forty-five the female is capable of conception’ (10). 
Utian explains that even as early as the sixth century, the Byzantine physician, Aëtius of 
Amida, had described the relationship between menopause and age (Figure 1.1) (11).  
 
1.2.2 Menopause and ill-health (17th century – 19th century) 
However, it was towards the end of the 18th century and at the beginning of the 19th 
century, that several medical tracts, written by doctors in both France and England 
addressed this subject of menopause and disease in depth. In 1777, John Leake described 
several problems experienced by menopausal women that seemed connected to the 
cessation of menses, including as he termed them, ‘hysteric disorders’ (12). John Burns 
(1814), made a connection between increased risk of breast cancer and the end of the 
menses (13). In 1816, a French physician, Charles Pierre Louis De Gardanne wrote a book 
called Avis Aux Femmes Qui Entrent Dans L'âge Critique (Advice to Women Entering the 
Critical Age) where he used the term ‘menéspausie’ (14), which was modified in the second 
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edition (1821) to ‘menopause’ (15). It seems that the term is Greek in derivation; mēn – 
month and pausis – halt (Figure 1.1) (16). 
 
Many 19th century writers believed the onset of menopause and the end of fertility caused ill 
health in women. In the second edition of Gardanne’s book, now called: De la ménopause 
ou de l’âge critique des femmes (On Menopause or the Critical Age of Women), he wrote 
that the diseases that affected women during this critical age were very frequent (15). 
Laurent Cerise (1845), describes numerous problems affecting mid-life women: ‘Douleurs de 
tête, vertiges, hallucinations…météorisme, … palpitations, abattement, agitation, graves 
hémorragies, … insomnie opiniâtre, rêves, cauchemars, inappétence, … chaleur, frissons…’ 
(Headaches, dizziness, hallucinations…bloating, palpitations, depression, agitation, severe 
bleeding,… continuous insomnia, dreams, nightmares, loss of appetite, … heat, chills…) 
(See Figure 1.1) (17). 
 
1.2.3 The medicalization of menopause (19th century – 20th century) 
  
The trend to pathologize the menopause, and to view it as a time of ill-health and increased 
morbidity in women, continued into the mid 20th century (18), culminating in a book called 
Feminine Forever by Dr. Robert Wilson (19). The views expressed in this work; that estrogen 
would protect women from what he described as an estrogen deficiency disease (20), 
reinforced the perspective of menopause in the medical profession of that time (Figure 1.1).  
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Figure 1.1 An Historical Perspective of Menopause: Adapted from ‘Vasomotor 
symptoms in menopause’; Pinkerton et al (21) 
 
Towards the end of the 19th century, three independent trials, where doctors attempted to 
counteract the perceived effects of ovarian aging by administering different forms of ovarian 
tissue from cows, had been conducted (22). However, studies began in earnest at the 
beginning of the 20th century. By 1930, Butenandt and his colleagues had worked out the 
structure of estrogens (estrone and estriol), which had been extracted from the urine of 
pregnant women (23, 24), although it was not until 1940 that estradiol (E2) as shown in 
Figure 1.1, was found in pregnancy urine and the placenta (11). In 1942, conjugated equine 
estrogens (CEE), brand name Premarin (Figure 1.1), were approved by the Food and Drug 
Administration (FDA) of America and by the 1970’s, Premarin had become the most 
prescribed medication in the USA to alleviate menopausal symptoms (25).  
 
 The discovery in the mid 1970’s, as shown in Figure 1.2, that the use of unopposed, 
conjugated estrogen therapy was causing a steep increase in endometrial carcinoma (26), 
caused a temporary decline in the use of Premarin (25). However, when research showed 
that the addition of progestogens to the estrogen regimen reduced the risk of endometrial 
hyperplasia (27), wide use of estrogen therapy resumed (25). In 1986 the FDA approved the 
350$BC$ c.$530)560$ 1777$ 1814$ 1816$ 1821$ 1845$ 1940$ 1942$ 1964$
Aristotle$–$
History(of(
Animals(–$
women$fer>le$
>ll$45(
Aë>us$of$Amida,$)$the$
rela>onship$between$
menopause$and$age$(
John$Leak$–$
‘hysteric(
disorders’$and$
menopause(
John$Burns$–$
increased$risk$of$
breast$cancer$with$
end$of$menses(
Charles$De$Gardanne$)$
Advice(to(Women(
Entering(the(Cri8cal(
Age((
First$use$of$the$
term$$
‘menopause’(
Laurent$Cerise$–
numerous$mid)life$
problems$for$
women$(
Estradiol$found$in$
pregnancy$urine$
and$placenta(
Premarin$
approved$by$FDA(
Robert$Wilson$–$
‘No$more$
menopause’(
 6 
use of estrogens as useful in combating osteoporosis, and this, together with the fact that 
doctors believed that hormone therapy (HT) was effective in combating CVD entrenched its 
use. In 1995, a combination drug called Prempro (Fig. 1.2) combining Premarin and Provera 
was introduced (28) By the end of the 20th century, the use of HT was firmly established, 
and approximately 15 million women in the USA were using it (Fig. 1.2) (29). 
 
 
 
        Figure 1.2 An historical perspective of menopause (cont.) (21) 
 
1.2.4 Menopause, HT and heart disease (late 20th century) 
The historical perspective and belief that menopause was a time of ill-health, informed much 
of the hypotheses in research on menopausal women and heart disease in the late 20th 
century.  As shown above, researchers and clinicians believed that although menopause 
increased the risk of CVD, this could be attenuated by judicious use of estrogen. 
Researchers used qualitative, observational and anecdotal research to confirm their 
hypothesis that women, albeit later in life, were at greater risk for CVD than men. Studies 
about CVD risk focused mainly on men, and these findings were then extrapolated to women 
(30). However, even when studies focused on women, data seemed to indicate that doctors 
were correct in their assumptions about the beneficial effects of HT.  In 1985, data from the 
Nurses’ Health Study suggested that the use of HT reduced the risk of CVD among 
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postmenopausal women, since estrogen appeared to have a protective effect on lipids 
(Figure 1.2) (31). Clinicians generally adhered to this belief, despite data from the 
Framingham Heart Study, which was published in the same issue of the New England 
Journal of Medicine, and showed a 50 percent increased risk of CVD and a greater than two 
fold risk of stroke in women using HT (32).  
 
The practice of prescribing HT to reduce the risk of CVD seemed justified in 1995, when 
results from the Postmenopausal Estrogen/Progestogen Interventions (PEPI) trial found that 
unopposed estrogen, in this case, CEE, increased levels of high-density lipoprotein 
cholesterol (HDL-C) (33) However, in the Heart and Estrogen/Progestogen Replacement 
Study (HERS) (Fig. 1.2), where researchers assessed the possible benefits of HT on 
lowering risk of heart disease, results showed that after four years of using estrogen alone or 
estrogen plus progestogen, the overall risk of heart disease was not reduced. Furthermore 
there was a three-fold increased risk of stroke, an increased risk of gallbladder disease and 
an increase of CVD in the early years.  The HERS researchers felt that HT should not be 
recommended for secondary prevention of CVD (34), and the possibility that HT use might 
increase the risk of CVD in older, postmenopausal women was raised (35).  
 
1.2.5 The WHI - a changing perspective (late 20th century – early 21st century)  
In 1991, a very large longitudinal, randomized controlled clinical trial called the Women’s 
Health Initiative (WHI) sponsored by the National Institutes of Health (NIH), National Heart, 
Lung, and the Blood Institute (NHLBI) was established to investigate the overall risks and 
benefits of HT for a period of 8.5 years (Figure 1.2). Although the study was due to continue 
until 2005, a WHI Data Safety Monitoring Board (DSMB) halted the estrogen plus 
progestogen arm after 5.2 years in 2002.  The board found that there was a greater risk of 
stroke, an increased risk of CVD and breast cancer and that these risks outweighed the 
benefits. A regimen of CEE plus MPA as a primary prevention for CVD was deemed to be 
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unsafe (36). Although some believed that these data might be due to the progestogen 
component, the NIH halted the estrogen-only arm in 2004, since there appeared to be an 
increased risk of stroke, no reduced risk of CVD, or overall benefit. Nevertheless, since the 
fracture risk was lowered with the estrogen alone treatment, and there was a possibility of a 
lower risk of breast cancer in this group, further research was required (Figure 1.2) (37).  
 
In the 10 years since the WHI halted, and although there has been debate concerning the 
apparent discrepancy between those results and those of previous data, the WHI study 
changed the way in which HT had been prescribed for several generations; prescription 
rates dropped precipitously (29). Following the recommendations of certain menopause and 
endocrine societies, clinicians re-evaluated the prescription of HT. Recommendations were 
that HT should be prescribed for alleviation of menopause symptoms, including vasomotor 
symptoms (VMS) and vulvovaginal atrophy, and in certain cases, to decrease fracture risk. 
(38). The WHI study is ongoing and provides a wealth of information about postmenopausal 
women’s health. By 2013, 573 studies had been published concerning various data collected 
in the WHI and the WHI extension study, of which 63 focused on CVD (30, 39).   
 
1.2.6 A new conundrum – the timing hypothesis and CVD risk  
There was ongoing debate after the WHI, and research into the hypothesis that HT was 
effective in reducing the risk of CVD across the MT continued. The timing hypothesis, which 
describes a critical window or time period, when estrogen therapy may have a beneficial 
effect (40), arose from dissatisfaction with the WHI study design and data showing that older 
women might be at greater risk for CVD as a possible result of lowered levels of endogenous 
estrogen (41). Furthermore, the results of the estrogen-only arm of the WHI suggested that 
in 50 to 59 year old women, exogenous estrogen did lower the risk of CVD and the benefits 
outweighed the risks in this sample (40).  
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The focus for proving the timing hypothesis was now on two studies. The first of these was 
the Kronos Early Estrogen Prevention Study (KEEPS), which hypothesized that HT given 
within three years of menopause would reduce the progression of atherosclerosis. However, 
there was no significant difference between the treatment and placebo groups in terms of 
atherosclerosis, although there was a small non-significant trend in terms of less build–up of 
coronary artery calcium (CAC) in those women using HT (42).  
 
The second trial that specifically tested the timing hypothesis in healthy women either less 
than 6 years or more than 10 years since menopause, was the Early versus Late 
Intervention Trial with Estradiol (ELITE). This trial was designed to measure the progression 
of carotid intima-media thickness (CIMT) every six months for three years, and after an 
extension of five years, to measure lesions and calcium in the coronary arteries (43). Results 
from this trial have shown that this regimen of 1mg of oral micronized estradiol daily with 10 
days of vaginal progesterone gel lowered CVD risk factors, when used in younger 
menopausal women near onset of menopause (44). However, there are some problematic 
areas in determining the timing hypothesis. These include the low rate of CVD among 
young, healthy menopausal women and the fact that the long-term effects of this regimen 
still need to be examined in a sufficiently powered cohort study (45, 46).   
 
As discussed earlier, clinicians believed, based mainly on observational studies, that there 
was an association between the MT and increased risk of CVD, and therefore encouraged 
the practice of treating what was described as an ‘estrogen deficiency disease’ with HT to 
improve arterial health. However, the question still remains as to whether chronological or 
reproductive aging is responsible for increased CVD risk in women across the MT. 
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1.3 The biology of reproductive aging 
1.3.1 The menstrual cycle 
Changes in the menstrual cycle are an important marker of reproductive aging. Menopause 
is the result of ovarian aging, so an understanding of the normal menstrual cycle and 
subsequent hormonal changes caused by reproductive aging, is essential. In utero, a 
woman’s two ovaries contain up to two million follicles but by the time she reaches puberty 
only about 500 000 remain. Atresia, begins in utero and continues throughout a woman’s 
reproductive life, with the loss becoming more rapid over the years. Ovulation accounts for 
the loss of approximately 500 follicles over a life span.  Reproductive and chronological 
aging cause changes across the MT, and the decrease in follicles intensifies as a woman 
ages, although chronological age per se cannot accurately predict the time of the MT (47).  
Approximately 3,000 follicles remain by the time a woman reaches menopause (30).  
 
 
 
Figure 1.3 The menstrual cycle (Source: Menopause Practice: A Clinicians Guide (4th 
ed.)) (48) 
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At the beginning of the menstrual cycle, as shown in Figure 1.6, serum levels of estrogen 
and progesterone (P4) are low, causing, through a negative-feedback loop, the 
hypothalamic-pituitary ovarian axis, to increase FSH.  As a result, approximately 1000 
follicles begin to mature, increasing estrogen production, which thickens the endometrium. 
This is known as the follicular phase and by the end of this phase, one of the follicles 
(dominant), matures faster than the others, which begin to degenerate, having supported the 
dominant follicle thus far. The dominant follicle continues to mature, increasing estrogen 
production.  This is the beginning of the periovulatory phase. Raised levels of estrogen 
cause the hypothalamus, through the agency of positive feedback, to reduce the production 
of FSH and to trigger a steep increase in the secretion of luteinizing hormone (LH) leading to 
the luteal phase.  This surge of LH ensures that the dominant follicle continues to mature 
and then rupture. The ruptured follicle is now known as the corpus luteum and begins to 
produce estrogen and increasing amounts of P4, helping to stabilize the endometrium, 
preparing it for the fertilized egg. If there is no pregnancy, the corpus luteum deteriorates 
causing falling levels of estrogen and P4. The endometrium is thus no longer sustained and 
the menses, caused by the degeneration of the endometrium begin (30, 49).   
 
1.3.2 Sex steroid and protein hormones, and the MT 
In this study, and generally in research investigating the MT, specific sex steroid hormones 
are examined, in particular; estrogen (with E2 being the principal estrogen examined in this 
study), FSH and androgens, specifically testosterone, bioavailable testosterone, sex 
hormone-binding globulin (SHBG), dyhdroepiandrosterone (DHEA), dyhdroepiandrosterone 
sulfate (DHEAS) and the free androgen index (FAI). As described earlier, ovarian aging will 
cause hormone levels to fluctuate prior to reaching a plateau in late menopause (50). The 
literature shows that levels of FSH will rise across the MT while levels of E2 will fall (Figure 
1.7) (51). It has been shown that some androgenic hormones, specifically DHEAS, fall 
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across the MT (52) as do levels of SHBG (53).  It appears that testosterone levels do not fall 
across the MT (54), while the fall in DHEAS may be as a result of chronological aging (54, 
55).  
 
 
Figure 1.4 Levels of FSH and E2 shown across the MT (Source: Burger et al) (50)  
 
1.3.3 The process of reproductive aging 
The menstrual cycle functions, unless disturbed by compromising circumstances or by 
pregnancy (30), until the late reproductive stage (56). Since atresia causes an increased 
decline in antral follicles, fertility begins to decline and as a result of a decrease in levels of 
the gonadal peptide, inhibin B, these aging follicles do not respond as they did previously to 
FSH.  When the negative feedback that has regulated the relationship between inhibin B and 
FSH changes, greater levels of FSH are secreted in an attempt to recruit and stimulate 
follicle growth (Figure 1.4.2). This may cause fluctuations in estrogen as well as FSH levels, 
leading to a shorter follicular phase, changes in normal menstrual cycles, and erratic 
ovulation or anovulatory cycles (30, 47).  
 
The stages of reproductive aging as described in STRAW+10 (Figure 1.5) (56), show how 
ovarian aging causes changes both in levels of FSH, E2 (Figure 1.7), and bleeding patterns.  
In late reproductive stage -3b, regular menses continue and there is no change in FSH 
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levels in the follicular phase, but fertility begins to decrease due to the falling antral follicle 
count and declining levels of AMH. In late reproductive stage -3a, changes in bleeding 
patterns may become apparent, cycle length shortens (57, 58),  FSH levels become more 
erratic and start to rise.  In early menopausal transition stage -2, persistent changes of at 
least 7 days in the duration of successive menstrual cycles are seen and serum FSH levels 
increase though they are still erratic. In the late menopausal transition stage -1, amenorrhea 
is experienced for periods of 60 days or more, greater variations in cycle duration and steep 
hormonal fluctuations occur and FSH levels rise and fall, the latter especially when 
associated with high levels of E2 (47, 53). Stage -1 may last between 1 to 3 years and it is 
during this time that VMS and other menopause related symptoms start to become apparent 
(Figure 1.8). The FSH levels continue to rise in the early postmenopausal stage, +1a, +1b, 
with levels of E2 dropping until to two to five years after menopause (Figure 1.7) (51, 59). 
Stage +1a signifies that there have been no menses for twelve months. This stage happens 
in conjunction with the ending of the perimenopause. This period includes the first year after 
the final menstrual period (FMP) (Figure 1.5). Hormonal fluctuations seen in stages +1a and 
+1b, are usually accompanied by VMS and other symptoms. It appears that these hormones 
start to settle in stage +1c, which lasts between 3 to 6 years. Late post menopause +2 
occurs when hormonal changes have stabilized, and is often when the symptom of vaginal 
atrophy becomes very common (38).  
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Figure 1.5 Development of symptoms in the MT (30) 
 
1.3.4 Age at FMP 
Changes in the menstrual cycle are a defining characteristic of the transition into menopause 
(56) and are a sign of reproductive aging. Earlier age at FMP has been shown to affect both 
morbidity and mortality (60), specifically in surgical menopause (bilateral oophorectomy), or 
chemical menopause, (ovaries cease functioning prematurely due to chemical or radiation 
treatments), or with a premature menopause caused by primary ovarian insufficiency, where 
the ovaries cease to function, either temporarily or permanently (48). Median age for natural 
menopause is around 52 years. Premature menopause is defined as happening in women 
younger than 40, while early menopause includes women aged 40 to 45 years (61). In a 
comprehensive editorial, Crawford described several factors related to healthy aging that 
may also relate to age at menopause (62). Factors considered include genetics where 
studies have shown that daughters whose mothers had an earlier natural menopause are 
more likely to experience an earlier menopause relative to the average experience (63).  
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smoking (64), and childhood lifestyle also play a role (65). Several studies have confirmed 
these findings, suggesting that childhood deprivation has an effect on ovarian aging (66, 67). 
Lawlor et al (68) have suggested that there is a strong association between unfavorable 
economic circumstances occurring throughout childhood and into adulthood, and a younger 
age at FMP. 
 
An issue that has been widely discussed amongst those researching the MT is the difficulty 
in accurately ascertaining age at FMP when it is self-reported. Several studies have shown 
that recalling this occurrence many years after it had happened is not always accurate (69). 
A large prospective study generally found that answers, although given on different 
occasions, were similar (70). However, another very large prospective study found that the 
type of menopause experienced, whether surgical or natural, might affect accuracy of 
reporting. Research found that women who had had a natural menopause, reported the date 
within a year or two of the event, but those women who had had a surgical menopause 
reported the date with greater accuracy (71). This was also shown in a population-based 
screening project (72).  Several studies agreed that age at menopause becomes less 
accurate as the number of years since the event increase, and that women who experienced 
an earlier age at menopause have a better recall than those who were older at onset (72, 
73). However, there are other difficulties attendant on accurate recall when reporting age at 
FMP. The transition into menopause is often very gradual and lengthy, with extreme cycle 
variability (74), making it harder, in retrospect, to recall an exact date, which is why data from 
longitudinal studies, using follow-up interviews, may improve accuracy (75). It has been 
argued that menstrual calendars may be useful in reliably assessing this date, but this 
method may not be useful in a population with a very low educational level, that does not 
generally have easy access to primary healthcare clinics or annual medical check-ups. Data 
from a large multi-ethnic study showed poor concordance between an annual report and 
menstrual calendar (76), which may relate to differences in understanding of the menstrual 
cycle changes in the participants as opposed to the researchers (77). As explained, there is 
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extreme menstrual cycle variability during the late reproductive stage, which may be difficult 
to identify and describe, so validated questions that clearly relate to the MT stages as 
described in STRAW+ 10 (56) may be more useful. 
 
1.3.5 Menopause symptoms and the MT 
As described earlier, STRAW+10 suggest that two kinds of menopausal symptoms, VMS 
and vaginal atrophy may be used as supportive criteria in staging menopause. However 
ovarian aging and the accompanying hormonal changes usually mark the onset of a wide 
range of different menopausal symptoms (Table 1.3).  
 
Identifying severity and prevalence of menopausal symptoms is important in research, 
especially in the case of VMS (78). Several studies have found that severe VMS may 
increase a woman’s risk of both CVD and related metabolic variables (79-81).  In addition, 
the genitourinary problems experienced by many women in menopause may seriously affect 
their quality of life (48), as do many of the symptoms related to mood and cognition (82). 
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Table 1.1 Symptoms of the Menopause Transition(30)  
  
Symptoms Symptom Domain 
Vasomotor symptoms 
-hot flushes/flashes 
-night sweats 
-body temperature disturbance 
 
Somatic 
Heart palpitations Somatic 
Breast changes  
-tenderness 
-changes in density 
 
Somatic 
Weight gain  
-android fat deposits 
 
Somatic 
Genitourinary symptoms 
-vaginal atrophy 
-vaginitis 
-dyspareunia 
-changes in sexual functioning 
 -loss of libido 
-hypoactive sexual disorder 
-changes in urinary function 
-urinary and stress incontinence 
-urinary tract infections 
 
Urogenital-sexual 
Sleep disturbance 
-insomnia 
-altered sleep patterns 
-early wakefulness 
-difficulty falling asleep 
Somatic 
Mood swings 
-anger 
-depression 
-generalized and free floating anxiety 
 
Psychological 
Memory issues 
-forgetfulness 
-confusion 
-impaired concentration 
 
Psychological 
Changes in skin and hair 
-thinning hair 
-increased facial hair 
-dry eyes 
-bleeding gums 
Somatic 
Joint pain/muscle aches Somatic 
Low grade fatigue Psychological 
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1.4 Tools to assess menopausal symptoms 
1.4.1 Kupperman Index  
There are several instruments that may be used to assess menopausal symptoms. Initially, 
research into the MT used the Kupperman Index (sometimes called the Blatt-Kupperman or 
Blatt Index), which was formulated in 1952 and modified in 1953 (83, 84).  In line with the 
clinical understanding of the time and based on their clinical experience, Kupperman and his 
colleagues developed an index of 11 menopausal symptoms in order to identify and treat 
what they termed ‘the menopause syndrome’. Their intention was to compare the different 
medications that were being used to treat it. They recommended that three discrete entities 
should be considered; ‘psychotherapy, sedation, and hormonal therapy’ (85). This index, 
which was scored from 0 to 3, depending on prevalence and severity of the 11 symptoms 
listed the following symptoms: hot flushes, paraesthesia, insomnia, nervousness, 
melancholia, vertigo, weakness, arthralgia or myalgia, headache, palpitations, and 
formication. Scores in the 11 categories were added and the total separated into categories:  
0 = none, 5 = mild, 10= moderate or ≥ 15 = severe. In 1959, a refinement of the Kupperman 
Index introduced weighting in selected categories. The weighted categories were divided 
into three: mild = 15-20, moderate = 20 -35 and severe = ≥ 35 (85). In 1998, a 
comprehensive critical review by Alder, described the shortcomings and disadvantages of 
the Kupperman Index (86), and suggested the need for a different  tool. Several reasons 
were given: psychometric standards had advanced, and the index was not psychometrically 
sound due to bias in the assessment. The list of symptoms excluded vaginal atrophy and 
decreased libido, which are both commonly expressed menopausal symptoms.  The former 
is a defining symptom of postmenopause and is related to declining levels of estrogen (56), 
while the latter is one of a group of symptoms that appears to be specifically related to 
menopause (87). In addition, the terms used in the index were not clearly defined, no 
mathematical justification was offered for the symptom weightings used, and the index was 
neither statistically valid nor reliable (86). However, this index was the main tool used to 
 19 
identify menopause symptoms for approximately 40 years, and is still the preferred tool in 
some research studies (88). 
 
1.4.2 Greene Climacteric Scale 
In 1976, Greene, who became the first researcher to use factor analysis to assess 
menopause symptoms, proposed a new menopause scale (89). The symptoms were divided 
into three categories, vasomotor, somatic and psychological. Greene suggested that the MT 
was not a static event and proposed that changes in symptoms, and the association 
between different menopausal stages could be measured using this scale. The scale could 
be used to evaluate treatments, in cross-cultural comparisons, and epidemiological research 
into menopause and the MT. Greene suggested that VMS were a key factor of the MT and 
should be placed in an independent category. The scale was amended in 1998 and 
described as a: ‘a standard measure of core climacteric symptoms’. Seven factorial studies, 
which were in strong agreement as to which symptoms should be included and the specific 
category to which they belonged, were compared (90). However, there were still some 
questions concerning the scale.  Greene did not include the symptom of vaginal dryness, or 
that of breast pain (mastalgia) in either the original or the amended scale (91). Nevertheless, 
the scale is extensively used in women worldwide, and is considered valid, reliable and 
culturally appropriate (92, 93). Researchers have found the Greene Climacteric Scale easy 
to work with (48).  
 
1.4.3 The Menopause Rating Scale (MRS)  
The Menopause Rating Scale is a popular tool for measuring prevalence and severity of 
menopausal symptoms.  This health related quality of life scale was originally developed in 
Germany in 1992 by researchers who wanted an instrument to measure menopausal 
symptoms in aging women and assess how these affected their quality of life (83).  This 
scale was physician administered, but in 1996 a modified version (MRS II) enabled women 
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to perform it themselves (94). The MRS comprises 11 symptoms, within three different 
domains (psychological, physiological and urogenital), which are easily scored using values 
of 0-4 (95).  Strengths of the MRS include its ability to assess quality of life (96) and its 
reliability (97).  In addition, it is cross-culturally applicable, has been internationally validated 
and has been translated into nine different languages (98).  Difficulty in scoring has been 
found in some population groups due to lower education levels and inability to understand 
the values of the scale, but this disadvantage can be addresses if a member of the research 
team administers the scale (99). Studies in the following population groups have used the 
MRS, and found it to be reliable and valid in describing severity and prevalence of 
symptoms: Latin America (100, 101), Oman (102), Nigeria (103), Malaysia (99) and Sri 
Lanka (104). 
 
1.5 Reproductive Aging 
1.5.1 Staging Menopause  
Prior to 2001, there was no specific structure defining the stages of the MT and the system 
of staging menopause developed gradually. Research in the mid 70’s, and focused mainly 
on HT regimens and their outcomes (105). In 1976, the First International Congress on the 
menopause was convened in France (16) to examine issues concerning  HT use and plan 
future research (26).  
 
1.5.2 Defining the terminology of menopause stages 
In 1981 the World Health Organization convened a group of experts to comprehensively 
debate issues relating to the menopause (106). It was agreed that there was a lack of 
consensus in medical research regarding the definitions used to describe the various stages 
of reproductive aging and clear recommendations were made round the terminology relating 
to specific stages. Topics included changes in the level of hormones related to the MT and 
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the need for a culturally appropriate tool to measure menopause symptoms. Issues around 
age at FMP in different cultural and socioeconomic groups and the different cultural 
experiences of menopause were discussed. It became evident that the WHO should play a 
role in addressing these issues, providing direction for further research (106).  
 
 
Table 1.2 Definitions describing the Menopause; WHO Scientific Group on Research 
on the Menopause in the 1990s (107) 
 
 
 
Subsequent to this meeting, a WHO scientific group met in 1996 to evaluate the progress 
made on recommendations from the 1981 meeting, and to discuss emerging research 
issues. As mentioned earlier, the group noted that by 2030, 76% of menopausal women 
would be living in developing countries (1), but there was a paucity of research on the health 
risks associated with menopause in these women, and therefore there was a need for more 
data, to enable the departments in these countries to understand the potential morbidity and 
mortality risks of aging women (2). 
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Natural!Menopause!
The!permanent!cessa-on!of!menstrua-on!resul-ng!from!the!loss!of!ovarian!follicular!ac-vity.!Natural!
Menopause!is!recognized!to!have!occurred!a;er!12!consecu-ve!months!of!amenorrhea!for!which!there!is!
no!other!pathological!or!physiological!cause.!Menopause!occurs!with!the!ﬁnal!menstrual!period!(FMP)!
which!is!known!with!certainty!only!in!retrospect!a!year!or!more!a;er!the!event.!An!adequate!independent!
biological!marker!for!the!event!does!not!exist!
!!
Perimenopause!
The!term!perimenopause!should!include!the!-me!immediately!prior!to!the!menopause!(when!the!
endocrinological,!biological!and!clinical!features!!of!approaching!menopause!commence)!and!the!ﬁrst!year!
a;er!menopause.!
Menopause!Transi2on! The!term!menopausal!transi-on!should!be!reserved!for!the!-me!before!the!ﬁnal!menstrual!period!when!
variability!in!the!menstrual!cycle!is!usually!increased.!
!
Premenopause!
The!term!premenopause!is!o;en!used!ambiguously,!either!to!!refer!to!the!1!!or!2!!years!immediately!
before!the!menopause!or!to!refer!to!the!whole!of!the!reproduc-ve!period!prior!to!the!menopause.!The!
group!recommended!that!the!term!be!used!consistently!in!the!laJer!sense!to!encompass!the!en-re!
reproduc-ve!period!up!to!the!FMP!
!
Induced!Menopause!
The!term!induced!menopause!is!deﬁned!as!the!cessa-on!of!menstrua-on!which!follows!either!surgical!
removal!of!both!ovaries!(with!or!without!hysterectomy)!or!iatrogenic!abla-on!of!ovarian!func-on!(e.g.!by!
chemotherapy!or!radia-on).!
!
Simple!Hysterectomy!
!
Where!at!least!one!ovary!is!conserved!is!used!to!deﬁne!a!dis-nct!group!of!women!in!whom!ovarian!
func-on!may!persist!for!a!variable!period!a;er!surgery!
Postmenopause! The!term!postmenopause!is!deﬁned!as!da-ng!from!the!ﬁnal!menstrual!period,!regardless!of!whether!the!
menopause!was!induced!or!spontaneous!
!
Premature!menopause!
Ideally,!premature!menopause!should!be!deﬁned!as!menopause!that!occurs!at!an!age!less!than!two!
standard!devia-ons!below!the!mean!es-mated!for!the!reference!popula-on.!In!prac-ce,!in!the!absence!of!!
reliable!es-mates!of!!the!distribu-on!of!age!at!natural!menopause!in!popula-ons!in!developing!countries,!
the!age!of!40!!years!is!frequently!used!as!an!arbitrary!cutOoﬀ!point,!below!which!menopause!is!said!to!be!
premature.!
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Menopause stage definitions that had been proposed by the scientific group of 1981 were 
augmented and modified as shown in Table 1.1 Changes in bleeding patterns were 
discussed, including changes in the length of bleeding and time between bleeds . The issue 
of age at FMP was explored and it appeared that women in low resource counties were 
found to have an earlier age at menopause than those in high resource countries (108). The 
roles of sex steroid hormones, proteins and androgens in the MT were evaluated. Symptoms 
of the menopause transition were discussed (2). The recommendations suggested a need 
for more precise definitions than those adopted at the 1981 meeting. The research 
conducted should be culturally appropriate; and attention should be given to the possibility 
that ethnicity may affect perception and reporting of VMS. The effects of chronological 
and/or reproductive aging on health in mid-life women should be noted. A possible 
association between VMS, CVD and osteoporosis risk was identified, as well as a need for 
more sensitive and standardized hormone assays. Future research should examine whether 
changes in hormone levels during perimenopause might be predictive of future health risks 
(2).  
 
The recommendation, from the WHO scientific group, that standardized definitions should be 
used in menopause research, was reinforced in 1999, when the Council of the Affiliated 
Menopause Societies (CAMS) was given the task of defining menopause related 
terminology to prevent confusion and allow a common understanding in global menopause 
studies as shown in Figure 1.3 (109). The International Menopause Society (IMS) board 
approved this terminology and recommended that these definitions should be used 
internationally (109) . The focus of all these groups described above was primarily on the 
terminology related to the MT, and not specifically on the staging of reproductive aging. 
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Figure 1.6 Utian 1999 terminology definitions: Relationship between different time  
periods surrounding the menopause modified from the WHO 96238 report (109) 
1.5.3 Cohort studies and the Staging of Reproductive Aging Workshop (STRAW) 
Throughout the 1990’s, several cohort studies were set up to examine the natural transition 
into menopause, and many of these looked at ways of staging the MT.  These included the 
very large multi-ethnic cohort Study of Women’s Health Across the Nation (SWAN), formed 
in 1994 (110), and the Seattle Midlife Women’s Health Study (SMWHS) begun in 1990 
(111). Accurate staging of reproductive aging is fundamental in understanding many aspects 
of the MT, including symptomatology (112).  In July 2001, 27 experts in the field convened 
the Staging of Reproductive Aging Workshop (STRAW) in Park City, Utah to create an 
accurate staging system (113). The contribution of STRAW to the field of menopause 
research cannot be overestimated and the criteria adopted by STRAW were considered the 
gold standard for staging the MT (114). 
 
The aims of STRAW were to create an appropriate and practical staging tool, incorporating 
standardized terminology that would be useful in both clinical and academic research to 
assess and understand the trajectory of women’s reproductive aging; specifically the length 
and time period of the transition towards menopause. 
 
Final&menstrual&period&
(Menopause)&
Climacteric&
Menopausal&transi5on& Postmenopause&
Perimenopause&
12months&
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The experts present determined that a staging tool should abide by specific, objective 
criteria. Tests used should be consistent, not expensive and easily obtainable. Prospective 
categorization of women should be allowed for appropriate classification (113). The criteria 
discussed were: menstrual cycles (the high levels of variability, and effective ways to confirm 
a woman’s menstrual history), biochemical and endocrinological measures, fertility and 
ovarian ultrasound to determine antral follicle count. Due to fluctuations in hormone changes 
during the MT, FSH was considered the only assay that could be reliably measured in a 
clinical environment as a biomarker for the staging system.   
 
It was recommended by STRAW that changes in bleeding patterns should be one of the 
factors used to stage reproductive aging; STRAW used the definition of a ‘variable cycle 
length, more than seven days different from normal’, and based this on data from three 
important studies (115). These were the Melbourne Women’s Midlife Health Project 
(MWMHP), the SMWHS and the long-running TREMIN Research Program on Women's 
Health (116). These studies described five measures, marking the beginning of the MT 
(115). Lisabeth et al analysed data from TREMIN and concluded that a cycle of more than 
60 days was probably the best indicator of late MT (117). The bleeding criteria suggested by 
the MWMHP were that the start of the MT was marked by ‘irregularity’ meaning that for at 
least 10 menstrual cycles, a woman would have more than two menstrual cycles that were 
not in a span of 21 to 35 days (74). The SMWHS described variations in cycle using two 
terms ‘irregularity’ and ‘skipping’. The former meant that there was a greater variation of 6 
days between ongoing menstrual cycles and the latter that there was no bleeding at all for 
more than 58 days between cycles. Specific changes in the menstrual cycle encompassing 
bleeding flow and the duration of cycles, followed by irregularity as defined above and then 
skipping prior to the FMP were described (58). 
 
It was agreed that menopause symptoms are subjective and their definition may vary 
between socioeconomic groups, cultures and ethnicity (113). The group revised the 
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menopause terminology adopted by WHO in 1996, attempted to find more precise definitions 
and, as shown in Figure 1.4, described reproductive aging using seven stages: -5, -4, -3 
(reproductive stage: early, peak and late); -2, -1(menopausal transition: early and late);  
+1,+2 (postmenopause: early and late). As shown in Figure 1.4 menopause was described 
as the point following the FMP, after 12 months of consecutive amenorrhea. The menopause 
transition is the time defined by rising FSH levels and variations in the menstrual cycle. This 
stage ends with the FMP. Postmenopause comprises two stages – early and late. The 
length of the stages were described as variable for reproductive and menopause transition 
stages, and early post menopause as being five years after the FMP, with a sub-stage (a) 
being 12 months after the FMP and a second sub-stage (b) being 4 years after the FMP. 
Late postmenopause was described as five years after the FMP to the end of a woman’s life.  
Perimenopause, was described as beginning in early menopausal transition and ending a 
year after the FMP. STRAW recommended that the term climacteric no longer be used in 
scientific menopause literature (113).  
 
 
 
Figure 1.7 Stages of Reproductive Aging Workshop (STRAW) – seven stages of 
STRAW (Soules et al) (113) 
 
1.5.4 Staging the MT using bleeding criteria.  
Subsequent to STRAW, investigators began examining the bleeding criteria recommended 
by STRAW in relation to different stages of the MT. The problem was that the bleeding 
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criteria adopted by STRAW were not empirically assessed and had not been validated (118). 
The ReSTAGE Collaboration was thus constituted to evaluate the consistency and validity of 
those bleeding criteria, and to examine whether these could be applied to women in different 
cohorts, both in research and clinical studies. Researchers involved in four cohort studies 
participated in ReSTAGE. The studies were SWAN, TREMIN, MWMHP and SMWHS. 
ReSTAGE analyzed prospective data based on information from menstrual calendars from 
the cohorts (118). Harlow et al focused on whether suggested bleeding patterns defined by 
STRAW marked the start of the late menopausal transition stage and found that the STRAW 
recommendations were essentially valid. The results were robust and confirmed that 60 days 
of amenorrhea marked the start of the late menopausal transition. The STRAW stages 
needed to be further clarified, and an agreement reached as to which measures of menstrual 
bleeding would define the start of the MT (118). Serum FSH data from SWAN and MWMHP 
were analyzed and showed that levels of FSH were closely related to changes in bleeding 
patterns across the MT (119).  
 
This close association was confirmed in data that showed that increased levels of FSH were 
related to bleeding changes associated with the start of the early menopausal transition 
stage (115).  When comparing measures, both inter- and intra-, to facilitate prediction of a 
woman’s nearness to the FMP, the ReSTAGE investigators found that women with natural 
menopause usually had changes in menstrual function as a sign of early transition, 
described by the bleeding criteria proposed by STRAW. The best measure to describe early 
menopausal transition appears to be a difference greater than six days in length of 
menstrual cycle, which seems to happen sooner than in the other suggested markers (115).  
 
The collaborators from ReSTAGE evaluated whether the measures of bleeding patterns, 
endocrinology and symptomatology recommended by STRAW were appropriate in 
determining stages in reproductive aging, and confirmed they were valid. ReSTAGE 
suggested that measures for defining both the early and late menopausal transition stages 
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should be refined. This included a simple bleeding pattern measure of amenorrhea for 60 
days to define the start of late menopausal transition, including an FSH level of ≥ 40 IU/L to 
forecast the time of the FMP more easily, and to use a measure of an ongoing difference of 
7 days or more in cycle duration as the marker for the start of the early menopausal 
transition stage (114). 
 
The work of the ReSTAGE collaboration set the stage for the modification of the original 
STRAW criteria. It became clear that basic measures of bleeding criteria were useful in 
describing the MT, and that a simple questionnaire could be developed so that women’s 
answers could help define at which stage of reproductive aging they found themselves (115).   
 
1.5.5 STRAW +10 
In the 10 years following STRAW, clinicians and researchers in the field of menopause and 
reproductive aging acquired a wider understanding of hypothalamic-pituitary and ovarian 
function during the MT. This encouraged experts to update the STRAW recommendations. 
In October 2011, a workshop: ‘ STRAW + 10: Addressing the Unfinished Agenda of Staging 
Reproductive Aging’ was held in Washington, DC. The aim of the two-day workshop was to 
assess the STRAW criteria for staging menopause, based on the latest data (56). In 
addition, presentations examined the relationship between chronic disease and the difficulty 
of staging the MT in those women who are infected with the human immunodeficiency virus 
(HIV), or have cancer. On September 22, 2011, after careful appraisal of all STRAW stages, 
general agreement on a staging system was reached (Table 1.2). These modifications were 
presented at the annual meeting of the North American Menopause Society (NAMS) (56). 
STRAW+10 retained the measures for an appropriate and practical staging tool suggested 
by STRAW and added some modifications (Figure 1.5).  
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Table 1.3 Consensus of criteria for an ideal staging system (56) 
 
 
 
 
 
STRAW+10 suggested that recommendations from ReSTAGE, which used more accurate 
and less complicated definitions of menstrual cycle measures should be adopted for early 
and late menopausal transition stages (56). 
 
 
Figure 1.8 STRAW + 10 stages of reproductive aging diagram (Source: Harlow et al) 
(56) 
 
Rely primarily on objective data STRAW 
Use widely available, reliable, noninvasive, and inexpensive tests STRAW 
Allow for prospective classification of women STRAW 
Permit unambiguous classification of women into a unique stage STRAW 
Retain the same widely accepted nomenclature STRAW+10 
Consider menstrual cycle criteria to remain the most important criteria 
given the continuing lack of international standardization of biomarker 
assays as well as their cost and/or invasiveness, particularly in the 
context of resource poor countries  
 
STRAW+10 
Consider biomarker criteria as supportive criteria given the lack of assay 
standardization (supportive criteria are to be used only as necessary 
and should not be interpreted as required for diagnosis) 
STRAW+10 
Use criteria that are independent of age, symptoms, and pathology 
(because no universal menopausal syndrome has been established 
across ethnic groups, two key symptoms are incorporated only as 
descriptive additional information that may support other criteria in 
assessing stage) 
 
STRAW+10 
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Bleeding patterns (menstrual cycles) remain the most important criteria for determining the 
stage of the MT because there is no standardization of biomarker assays (56, 115, 118), 
although recently more accurate, standardized testing of estrogen has been recommended 
(120). In addition, low- or middle-income countries may not have the resources for the wide 
use of blood assays in assessing specific stages in the reproductive cycle (121). In 2001, 
STRAW recommended that follicle-stimulating hormone (FSH) level be used as a biomarker 
in the late transition stage. Given the improved understanding of endocrine changes 
involved in ovarian aging (51), STRAW + 10 suggested that FSH and E2, specifically their 
concentrations before and after the FMP, should be used as supportive criteria to verify the 
stage of the MT. It was decided that an FSH serum blood level of >25 IU/L could generally 
define the late menopausal transition. Data also suggest that FSH levels will continue to 
increase until approximately two years post FMP, while E2 levels will decline (51).  
Thereafter these levels will become stable (57). STRAW +10 acknowledged that although no 
set of menopausal symptoms had been specified worldwide due to different ethnicities, VMS 
and vaginal atrophy might be used to support other measures to determine the stage of the 
MT. Since bleeding criteria are used to stage reproductive aging, women who have had 
hysterectomies cannot be staged using STRAW+10, although in these cases, FSH levels, at 
least three months post surgery, may be used as a measure of MT. Important areas for 
ongoing research included the establishment of a standardized assay of anti-Müllerian 
hormone (AMH); the definition of more precise bleeding patterns in the late reproductive 
stages; examining changes in sex steroid hormones in early and late post menopausal 
stages and staging the MT in the HIV-positive women.  It was shown that STRAW+10 is a 
staging tool that may be applied generally to women, irrespective of body mass index (BMI), 
age, lifestyle, or demography (56).  
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1.6 Cultural aspects of menopause 
Among problems found when researching reproductive aging in different populations, are the 
cultural and ethnic differences within diverse groups of women. A wide-ranging body of 
literature examines the problems inherent in attempting to describe the menopause 
experience as uniform amongst women (122). Issues that may play a role, include 
socioeconomic status, cultural mores and ethnicity (123). However, in order to carry out 
cross-cultural comparative research, there needs to be a standardized tool which takes 
cognizance of menopausal symptoms that may be specific to different cultures and 
ethnicities (123). The literature shows that menopause symptoms, specifically VMS and their 
severity and prevalence, are often described and/or perceived differently by women in 
various population groups in spite of the fact that VMS are widely present (124). It has been 
suggested that these variances are informed by several different factors, such as lifestyle 
and cultural norms, and these can also affect the experience of menopause (125). Evidently 
the cultural imperative is a very important factor in understanding a woman’s experience of 
her menopause (126). A powerful review by Melby et al, suggests that a biocultural 
approach, which examines differences in both biological and cultural variables and how they 
affect reproductive aging in women of different population groups, is vital when conducting 
cross-cultural comparisons (127). However other research suggests that while there are 
universal aspects to symptom reporting between different population groups, the way in 
which prevalence and severity are explained are associated with varying cultural imperatives 
(128).  Another problematic area is the difference in menopause perceptions between 
women from high and low-resource countries and the fact that women have a diverse 
understanding of menopause, possibly reflected by the way in which their own culture views 
the transition into menopause (87). It may be important to provide women with culturally 
specific information on menopause (129). Another important aspect to consider when 
researching menopause across different cultures, is heterogeneity within each cultural 
group, since socioeconomic variables may play a part in how women experience the MT in 
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different ways (130). Given this wide range of variables, methodology in cross-cultural 
research determining menopause symptoms needs to be very carefully designed and 
controlled (131). A very large multi-ethnic study suggested that when gathering information 
about the menopause from women of different cultures, control factors, including 
socioeconomic status, lifestyle and education, need to be taken into account (122). 
 
Researchers in the field concur that both open and close-ended questions are useful in 
obtaining information about reproductive aging in different population groups. In addition it 
has been suggested that more attention be paid to a thorough analysis of the cultural mores 
of a population group, and in addition, there should be a clear distinction between etic and 
emic data, whereby data reflecting the areas of interest of the researcher and data reflecting 
that of the participants, should be considered. Although emic data is more complex because 
the researcher needs to thoroughly understand the cultural mores of their research subjects, 
the addition of open-ended questions to close-ended question may go some way to solving 
this problem (132).  As described earlier, biomarkers may also be used as supportive criteria 
in assessing menopause stage through self-reported bleeding patterns (56). Unfortunately 
many low-income countries do not have the resources to perform these assays.  
 
1.7 Menopause, morbidity and mortality 
1.7.1 Menopause and the metabolic syndrome 
A constellation of symptoms described as the metabolic syndrome (MetS) may increase the 
risk of CVD.  The currently accepted definition for this syndrome is the one contained in the 
Harmonizing statement (133), where a number of experts from  different medical  
organizations agreed that if there was a finding of three or more out of the five criteria 
described in the statement, which exceeded the stated cut points, a diagnosis of metabolic 
syndrome may be given.  These five diagnostic criteria are: an increased waist 
circumference, raised triglyceride levels (≥150 mg/dL [1.7 mmol/L]) lowered levels of HDL-C 
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(<50 mg/dL [1.3 mmol/L] females, and <40 mg/dL [1.0 mmol/L] males), hypertension 
(systolic ≥130 and/or diastolic ≥85 mm Hg and raised fasting glucose (≥100 mg/dL[≥ 
5.6mmol/L]). These are the criteria that will be used in this study. The consensus of the 
Harmonizing group was that waist circumference should be gender and population specific 
(133). Thus, the waist cut points for Caucasian males and females were; ≥ 94cm and ≥ 
80cm respectively; ≥ 90cm for Asian males and ≥ 80cm for Asian females, and ≥94cm and 
≥80cm for sub-Saharan males and females respectively. However, studies on mid-life black 
African women suggest that a higher waist circumference cut point of between 91.5cm (7) or 
92cm (134) may be more appropriate than the ≥80cm cut point that was recommended in 
the Harmonizing statement. 
 
A wide body of literature has shown that menopausal women have risk factors related to the 
MetS, and these are discussed in the sections below (Table 4). However, whereas several 
studies suggested that the transition into natural menopause appeared to increase the risk of 
MetS (135-138), other data showed that aging attenuates this association, (139, 140). Data 
from the Study of Women’s Health Across the Nation (SWAN) showed that 13.7% of their 
cohort of 949 women had MetS at the time of final menstrual period (FMP) but suggested 
that this risk seemed to lessen after FMP (110, 141).  Some research has suggested that the 
combination of age and the MT may explain an increased risk of MetS in postmenopause 
(142), while other studies found that menopause is not associated with an increased risk of 
heart disease (143), and even when body composition changes accompany the MT in 
women with a normal BMI, these changes are not indicative of CVD risk (144). Two 
comprehensive reviews (9, 145) examined the relationship between increased risk of MetS 
and the MT and found no obvious association. It appears that several factors, either 
individually or combined, might be associated with the MT and might increase the risk of 
cardiometabolic disease in mid life women, but these risk factors may have existed before 
the transition into menopause (9), so the data remain conflicting. 
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Table 1.4 Overview of important risk factors related to cardiometabolic disease in 
menopausal women 
Risk factors for cardiometabolic 
disease in menopause 
Research hypotheses 
Age and/or MT increase MetS 
risk 
-reproductive or chronological aging or a combination of both 
increases MetS risk 
Changes in body composition 
 
-MT closely related to changes in body composition 
-increased central adiposity associated with NCDs  
-changes in abdominal obesity related to changing hormonal 
milieu across MT 
-changes in abdominal deposition of VAT and SAT during MT 
related to either reproductive and/or chronological aging 
-sarcopenia associated with both chronological and 
reproductive aging 
Obesity 
 
-increased obesity associated with MT 
-obesity associated with metabolic disease 
Sex steroid hormones, FSH, 
SHBG, DHEAS 
 
 
 
-decreased E2 associated with hypertension and dyslipidemia 
-lower estrogen levels associated with increased body fat and 
decreased lean mass (sarcobesity) may increase metabolic 
disease risk 
-changing androgenic milieu associated with increased 
abdominal obesity 
- increasing androgenic milieu and  exposure time to higher 
androgen levels may increase CVD risk 
-declining SHBG levels related to increased insulin levels and 
higher BMI increasing MetS risk 
-DHEAS associated with increased CVD mortality possibly due 
to lower anti-inflammatory effects 
Adipokine levels 
 
 
-adiponectin and leptin associated with metabolic variables that 
may increase CVD risk  
-negative correlation betwen adiponectin and body adiposity, 
atherogenic lipid levels and BP 
-positive correlation between adiponectin with insulin sensitivity  
-leptin levels associated with appetite control, body mass and 
energy expenditure. 
-leptin may be significantly related to insulin resistance and 
MetS independent of its BMI relationship  
Age at FMP 
 
 
-earlier age at FMP may increase risk of CVD and stroke 
-family history may attenuate CVD risk 
-HT prescribed for early menopause may attenuate risk  
VMS 
 
 
-VMS associated with increased TC, LDL-C, triglycerides,  
impaired fasting glucose, increased HOMA index, increased 
carotid intima media thickness, hypertension  
Lifestyle factors 
 
-association between smoking and younger age at FMP 
- VMS more prevalent and severe in smokers 
- Smoking associated with increased visceral fat and impaired 
insulin sensitivity 
-smokers in the MT at greater risk for atherosclerosis 
- nicotine may increase insulin resistance 
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1.7.2 Changes in Body composition across MT and risk of cardiometabolic disease 
The literature shows that the MT is closely associated with changes in body composition 
(146), including lower bone mineral density (BMD) (147), an increase in obesity (148, 149), 
changes in body fat distribution (BFD) (150), particularly increased central adiposity (151), 
and a decrease in lean muscle mass (146, 152). The relationship of the MT with changes in 
abdominal obesity is complex. Several studies have found that increased central adiposity is 
a result of the changing hormonal milieu; increased FSH levels (146), decreased levels of E2 
(153), and changes in androgen levels (154), and there is a strong association with 
reproductive aging (155), particularly for visceral adipose tissue (VAT) (151, 156). Further 
research suggests that changes in the abdominal deposition of VAT and subcutaneous 
adipose tissue (SAT) during the MT are related to chronological aging (157, 158), although 
the metabolic effects of VAT and SAT have been shown to be different (159-161). However, 
other data suggest that both aging and hormone changes may explain the changes in body 
adiposity during the MT (51, 162). As detailed above, abdominal obesity, which can be 
assessed by measuring waist circumference, is one of the principal risk factors for 
cardiometabolic disease, including diabetes and CVD (163). Central adiposity and its strong 
association with non-communicable diseases (NCDs) has been widely described in Western 
literature (164, 165) Although an increase in abdominal adiposity does not appear to be 
related to the MT, but rather to chronological aging, longitudinal research has shown that 
physical activity in mid-life women attenuates weight gain and these women have lower 
waist circumference which may lower their risk for metabolic disease (166). Thus, studies in 
menopausal women have shown that physical activity lowers risk of cardiometabolic 
disease, including diabetes and hypertension (167-169) 
 
Studies show that a decrease in lean muscle mass may be associated with both 
chronological and reproductive aging (146). A comprehensive review by Messier et al (170) 
examines the role of ovarian aging in loss of muscle mass, explaining that although declining 
estrogen levels may contribute to a decrease in lean mass, the role sex steroid hormones 
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play in this process is complex and difficult to determine.  Studies have shown that 
sarcopenia, defined as decreasing lean mass, is associated with an increased risk for 
metabolic disease (171-173). Furthermore, the combination of increased obesity and loss of 
lean mass in post menopausal women, described as sarcobesity, has been shown to be an 
additional risk for NCDs (171).  
 
As discussed earlier, decreased BMD is another change in body composition that takes 
place across the MT and has been examined in a large longitudinal study (174). Finkelstein 
et al show that bone density decreases rapidly during the late menopause transition stage 
and continues to do so in the years following FMP (175). Moreover, research showed that 
this loss of BMD increases for about 1.5 years after FMP and then this decline slowed (176). 
Studies have found that weight is inversely related to the speed at which BMD decreases 
(175) and that women who were not obese had a greater rate of bone resorption (176). 
Further research confirms this relationship (177, 178). However an extremely large 
prospective population based study found that obese postmenopausal women were not 
protected from fracture risk (179). An association between lean mass and BMD has also 
been reported (180, 181).  
 
1.7.3 Sex steroid hormones, SHBG and FSH and the risk of cardiometabolic disease  
The possible link between changing levels of sex steroid hormones across the MT and an 
increasing risk of cardiometabolic disease has been extensively studied (9). Chu et al 
hypothesized that rising levels of FSH were associated with unhealthy lipid levels in 
premenopausal women, which suggested that when postmenopausal levels of FSH become 
progressively higher, these may be a correlation with an increased risk of CVD (182). Rising 
levels of FSH over time have been shown to be associated with sarcopenia (146), which, as 
described earlier, is associated with an increased risk of metabolic diseases.  
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A comprehensive review (183) found that declining levels of estrogen were associated with 
increased risk of CVD. Svendson et al suggested that lower levels of estrogen lead to an 
increase in body fat and a decrease in lean mass, contributing to sarcobesity, which in turn 
increases risk of metabolic disease (184). In addition, research showed that decreasing 
levels of estrogen are related to an increased risk of hypertension (185) and lipid changes 
leading to dyslipidemia (145).   
 
A large body of research has examined the association between the MT, androgens and 
increased risk of metabolic syndrome (186). One of the main risk factors for metabolic 
syndrome is abdominal obesity, and research has shown that as the MT progresses, the 
changing androgenic milieu is related to increased abdominal obesity which in turn may be 
responsible for increased CVD risk (187). Research has suggested that this increasing 
androgenic milieu and the time span that a woman is exposed to higher androgen levels 
may increase her risk for CVD (188).  Although levels of testosterone remain relatively stable 
throughout the MT (54), declining levels of estrogen create what researchers describe as 
‘relative androgen excess’ (189), which increases the risk of metabolic syndrome in women 
transitioning through menopause, as described in the SWAN study (134, 180).  
 
Levels of the glycoprotein SHBG appear to decrease across the MT due to declining levels 
of estradiol, and this occurs concurrently with an increase in the FAI (54). Declining SHBG 
levels are related to increased levels of androgens (190) and insulin (187, 191), and higher 
BMI (192). In addition, these decreased SHBG levels which affect adipokines unfavorably, 
seem to increase the risk of metabolic syndrome in midlife women (193).  This effect has 
been seen in other data which suggested that lower levels of SHBG were associated with 
increased VAT and impaired glucose tolerance (194). In a very large multiethnic, longitudinal 
study, a very significant association between declining levels of SHBG, increased 
bioavailable androgens and a higher prevalence of metabolic syndrome was seen (195). 
The association of lowered SHBG and decreased insulin sensitivity, and its role as an 
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independent risk factor for cardiometabolic disease was shown in a large cross-sectional 
study of Australian women (196). Studies have noted the association of altered lipid profiles 
and raised blood pressure with low levels of SHBG, specifically, decreased serum HDL-C, 
increased total cholesterol and raised diastolic blood pressure (197).  Lower SHBG levels 
and increased FAI were noted in participants from the Women’s Health Study, who had CVD 
and who did not use HT. However, this relationship was attenuated after adjustment for BMI 
and other CVD risk factors (190). 
 
The androgenic sex steroid hormone, DHEAS may decrease the risk for CVD. Thus, data 
from the Women’s Ischemia Syndrome Evaluation (WISE) demonstrated that lower levels of 
DHEAS were associated with higher levels of CVD mortality (198). The mechanisms by 
which DHEAS may affect CVD risk is not known, however studies have shown that this 
hormone has anti-inflammatory effects (199) and may enhance endothelial function (200)     
 
Not all studies show that cardiometabolic disease levels increase across the menopause or 
that changes in hormone levels during the MT are related to cardiometabolic disease risk 
factors. Thus, in a large cross- sectional study, Worsley et al (201) showed that neither 
androgen nor estrogen levels appeared to be associated with a changing lipid profile, while 
findings from a longitudinal cohort study examined several risk factors for metabolic 
syndrome and found no association between the menopause transition and increased CVD 
risk (143).    
 
1.7.4 Adipokines, and risk of cardiometabolic disease 
Research has shown that adipose-derived hormones, adiponectin and leptin are associated 
with metabolic variables that may increase the risk of CVD (202). Adiponectin levels 
correlate negatively with body adiposity, atherogenic lipid levels and blood pressure but 
positively with insulin sensitivity (203), while leptin is associated with appetite control, body 
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mass and energy expenditure (204). Some studies have also found that leptin is significantly 
related to insulin resistance and MetS independently of its relationship with BMI (205, 206).   
 
The role of sex steroid hormones and their relationship to changing adipokine levels and 
metabolism, as they alter during reproductive aging, has been explored (204).  Studies have 
shown that when women in MT are not obese there appeared to be very little risk of lowered 
adiponectin levels and associated insulin resistance, while the MT transition did not appear 
to affect leptin levels.  However during the MT, overweight and obese women are at risk for 
adverse changes in adiponectin levels (207). It appears that estrogen helps to stabilize 
adiponectin levels but in the MT, when estrogen levels start to fall, this protective effect is 
removed (208). Leptin levels were associated with severity and prevalence of VMS in 
menopausal women but interestingly no association was found between leptin levels and 
estradiol. However some research has hypothesized that, in obese women, aromatized 
estrogen from adipose tissue may play a role in increased leptin levels (204, 209). As 
explained earlier, the relationship between lower levels of SHBG and increased adiposity in 
midlife women has been shown (210). Data have shown that lower levels of SHBG and its 
relationship to decreased adiponectin levels lead to a greater risk of metabolic disease 
(193). This may occur because SHBG appears to play a role in controlling adipokine levels 
(211).  
 
1.7.5 Age at Final Menstrual Period and cardiometabolic risk 
Associated risks for metabolic disease during the MT has been widely examined, however, 
an important factor associated with risk for metabolic syndrome is the age at which 
menopause occurs.  In fact, it has been suggested that any changes in menstrual cycle 
length, versus a regular cycle may increase risk for metabolic disease (212). The concern 
that earlier age at FMP may increase risk of cardiometabolic disease has been well 
described (213). In a prospective study, data from an extremely large cohort showed that 
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mortality was decreased by two years in women with a later menopause, and there was a 
decreased risk for both CVD and stroke risk (214, 215). A large multi-ethnic study found that 
when established heart disease risk factors were excluded, earlier age at FMP, was 
associated with both stroke and CVD, although familial CVD history attenuated this (216).  
The effects of premature and early menopause have been well described and include 
increased mortality and CVD risk (4). However, these effects, which appear to be caused by 
a decline in estrogen and androgen levels, may depend on the specific cause of the 
premature or early menopause, since ovaries, post menopause, may still produce small 
levels of estrogens and androgens (217), and, as described above, a changing hormone 
milieu may have diverse risk effects. Although there is no Level 1 evidence to support the 
following, and where it is not contraindicated, recommendations are that women with 
premature or early menopause, should be prescribed HT (either estrogen alone or estrogen 
and progestogen therapy), until the age of natural menopause, since this may help to lessen 
the risks of morbidity (61, 218).   
 
1.7.6 Vasomotor symptoms and cardiometabolic disease risk 
A wide body of research focusing on VMS, a defining symptom of the MT, has shown that 
these are significantly associated with cardiometabolic disease risk (219-221). As explained 
earlier, cultural perceptions may affect how VMS are reported (123). Nevertheless, it is clear 
that most women, as a result of ovarian aging experience VMS, irrespective of their cultural 
background (128, 158). Postmenopausal women experience higher levels of VMS than 
those in the late reproductive stage, though reporting of severity and prevalence may differ 
depending on race and ethnicity (122). Declining levels of estrogen are strongly related to 
presence of VMS (132, 221), as are increased levels of FSH (222). It has been shown that 
menopausal symptoms occur across different cultural groups, and it is highly probable that 
these are related to the changing hormonal environment of the MT (223). However, it is 
important to remember that levels of estrogen or factors that impact on estrogen levels, may 
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be affected by race and ethnicity, as well as demographics, lifestyle habits and cultural 
mores (158). In addition to fluctuating and declining levels of estrogen, there are other 
factors that may affect severity and prevalence of VMS (224).  These include environmental 
and demographic variables such as climate, socioeconomic status and level of education 
(126), cultural aspects (225), psychosocial stressors (226) lifestyle factors, including 
smoking (227, 228), and BMI (229, 230). 
 
Metabolic variables, such as obesity, increased levels of total cholesterol, LDL-C and 
triglycerides are also associated with VMS (221). The relationship between VMS and an 
altered lipid profile that was found in the very large population-based study of nearly 6,000 
women (221), was also seen in a very large multiethnic cohort study (220). Data from the 
above cohorts also found an association between VMS and additional symptoms of the 
metabolic syndrome, impaired fasting glucose and an increased HOMA index. In addition to 
those metabolic risk markers, an increased carotid intima media thickness was found in both 
overweight and obese women, who consistently reported VMS over a two week period (80). 
Obesity, has been shown to be associated with a greater prevalence of VMS (231). The 
hypothesis is that the ability of adipose tissue to retain body heat results in a complex 
thermoregulatory process to maintain homeostasis (232). Hypertension has also been 
reported in association with VMS (221). 
 
It should be noted there are conflicting data as to the association between VMS and 
increased risk of CVD (233).  It has been suggested that researchers should distinguish 
between hot flushes and night sweats rather than combining them in the broader descriptive 
term, VMS.  This distinction is necessary because it has been found that healthier women 
who only experience hot flushes and not night sweats have a lower risk for heart disease 
(234).  This finding is similar to data from the Women’s Health Initiative Observational Study 
(WHI-OS), but here, researchers suggested that the timing of the onset of VMS predicted 
greater risk of CVD in those women who experienced VMS later in menopause (235). 
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Moreover, results from a population-based study showed that women who experienced night 
sweats had a lower risk of death over 20 years (236).  Other research has disputed the 
findings that women with VMS have altered lipid profiles, and showed no difference in lipid 
levels between women who did or did not experience hot flushes, regardless of severity 
(237), although endogenous estrogen concentrations were comparable in both groups. 
However, a previous study found that estrogen levels in women without VMS are much 
higher (221). This variation in findings suggests a need for further research to better 
understand the usefulness of VMS, or hot flushes or night sweats respectively, as an 
important marker for future risk of cardiometabolic disease in menopausal women.  
 
1.7.7 Obesity and black South African women 
A wide body of research has shown that obesity in postmenopausal women is associated 
with risk factors for metabolic disease (202, 238), in particular type 2 diabetes and  
dyslipidemia (239) . It has also been found that these risks are specifically associated with 
abdominal obesity (240), which has been shown to correlate positively with insulin resistance 
(145). For the purpose of this study, the WHO definition of obesity, namely levels of BMI 
≥30kg/m2 is used (241). 
 
Since obesity is a risk factor for MetS, and given the high prevalence of obesity amongst 
midlife black South African women, it is not surprising that there is also a high incidence of 
metabolic disease in this group (242). This high prevalence of obesity in black South African 
women aged 45-55, is shown in Figure 1.9, but BMI starts to fall in this group after the age of 
65, however since the data in the South African National Health and Nutrition Examination 
Survey (SANHANES) is cross-sectional, the fall in BMI may be due to a period rather than a 
cohort effect.  
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Figure 1.9 Prevalence of underweight, overweight and obesity by sex and age, SA 
2012: (Source: SANHANES-1, Shisana, O et al) (6)  
 
 
A high prevalence of obesity in black midlife urban women was also shown in the Heart of 
Soweto study, a large study examining the risk of heart disease in Soweto residents (5).  In a 
dedicated screening study, “Heart Awareness Days”, of black adults in Soweto, 
Johannesburg, Tibzarwa et al (243) examined the association between the increased risk of 
cardiometabolic disease, and, amongst other risk factors, the prevalence of obesity in a 
black urban population.  They found that obesity was more prevalent in mid-life women 
(55%) than in mid-life men (23%) (Figure 1.10).  Likewise, Puoane et al (244), found that 
obesity was more prevalent in black urban South African women than those living in rural 
areas and became greater with age. This was also true of abdominal obesity. This high rate 
of obesity and abdominal obesity was also described in an earlier study of middle-aged 
women from the BT20 cohort that were used as the source of subjects for SWEET. Data 
from this study, demonstrated that elevated levels of abdominal obesity in conjunction with 
low levels of HDL primarily drove the high rate of MetS, with the prevalence of obesity being 
50.1% and MetS, 42.1% (7).   
 
A recent South African National Health and Nutrition Examination Survey (SANHANES-1) 
investigating the ongoing increase in certain NCDs; hypertension, diabetes and heart 
disease, described an increase of obesity, particularly in older females (6).  As shown 
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earlier, obesity in black women is associated with a variety of metabolic risk factors (245) 
and both age and higher levels of obesity were associated with increased risk of diabetes in 
black women (246). In the screening study described above over a third of the participants 
were hypertensive (243).  
 
 
 
 
Figure 1.10 Frequency distribution of body mass index in male and female subjects in 
a black urban South African cohort from Soweto. (Source: K. Tibazarwa et al) (243)  
 
1.7.8 Smoking, smokeless tobacco use and morbidity 
Earlier age at FMP and its related risk for metabolic disease has been described.  Data have 
shown there is an association between current smoking and a younger age at FMP (247). 
Prevalence and severity of VMS have been shown to be a risk factor for metabolic syndrome 
and it has been shown that women who smoke have worse VMS (127, 227). In addition 
smokers in the MT appeared to be at greater risk for atherosclerosis (248). Smoking is 
associated with increased visceral fat and impaired insulin sensitivity (249), and nicotine has 
been shown to increase insulin resistance (250). Smoking is also a significant risk factor for 
osteoporosis and cumulative lower bone density in postmenopausal women (251).  
Although, smoking is not widespread amongst black South African women, use of 
smokeless tobacco or snuff is prevalent among these midlife women (252, 253). Research 
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has shown that intensive use of snuff (snus) is significantly related to metabolic syndrome 
(254).  Given the association between nicotine and insulin resistance, it is important to note 
that levels of nicotine, in the brand of snuff preferred by black South Africans are 
substantially higher than in brands sold in Europe (255), and hypothetically this may further 
impact both the risk of insulin resistance and lower bone density  in black menopausal South 
African women. 
 
1.8 HIV and the menopause transition  
There is a high prevalence of HIV infection in South Africa.  It is estimated that in 2012, 6.4 
million people (12.2%) in South Africa were HIV-positive (256). As shown in Figure 1.11, 
mean HIV infection amongst midlife women aged 40 to 59 years was 18.0%. Due, possibly 
to the increased use of antiretroviral treatment (ART), the prevalence of HIV-infected older 
women was higher in 2012 than in 2008 (256). This may have implications for future 
research in examining whether HIV infection has any effect on reproductive aging and 
related cardio-metabolic morbidity and mortality.  
.  
 
 
Figure 1.11 HIV prevalence, by sex and age, South Africa 2012 (Source: O. Shisana et 
al) (256) 
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There is conflicting research about the effects of HIV on women in MT.  Some studies have 
shown that age at menopause is earlier (47.3 years) in HIV-positive women, and that they 
experience more symptoms (257). However, other research showed no difference in age at 
menopause between HIV-positive and HIV-negative women, with 50 being the median age 
at FMP, which is near to the median age of natural menopause in the USA. However, results 
from this study did demonstrate that HIV-positive women had more VMS (258). In a very 
large cohort, researchers found that median age at FMP was comparable between HIV-
positive and HIV-negative women (259).  
 
One of the issues confronting researchers studying the effects of HIV infection on 
reproductive aging, is that in addition to the association between the MT and increased 
metabolic disease (9), there are independent metabolic effects related to HIV infection and 
ART (260, 261). Studies have shown that HIV-positive women have greater lipoatrophy than 
HIV-negative women and increased VAT (262), which increases risk of metabolic disease. 
Hadigan et al (263) have examined these cardiometabolic risk factors and showed that HIV-
positive adults with lipodystrophy have lower levels of HDL-C and higher levels of LDL-C and 
triglycerides, in addition to impaired fasting glucose and increased diastolic blood pressure. 
They also showed that in HIV-positive women, fat distribution, as a result of lipoatrophy, 
increased their risk of CVD (263). In addition, data have shown that ART has a metabolic 
effect leading to dyslipidemia and decreased insulin sensitivity (264). In a cross-sectional 
study of HIV-positive and HIV-negative women, HIV-infection was related to dyslipidemia, 
and ART use was associated with a more atherogenic lipid profile (265).  
 
Body composition changes in HIV-positive women have been explored and some studies 
found that HIV infected women who had peripheral lipoatrophy did not have increased VAT, 
but that varying ARTs have different effects on VAT (266). A comprehensive review of South 
African adults saw no difference in VAT in women using ART, compared with women in the 
control group, and suggested that increased central adiposity is a result of treating the HIV 
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infection, but is not related to any class of antiretroviral medication per se. Thus the 
increased abdominal adiposity seen in HIV-positive women receiving ART, is similar to the 
fat gain experienced in HIV negative women (267). 
  
Research investigating increased risk for CVD in HIV-positive menopausal women have 
shown that the MT (135), chronological aging (139), and HIV-infection (260)  are all 
independent risk factors. Comprehensive reviews have shown that HIV-positive women 
appear to be at greater risk for certain CVD risk factors, including insulin resistance, higher 
LDL-cholesterol levels and triglyceride levels, lower HDL cholesterol levels (8, 260). In 
addition, a combination of HIV infection and ART may increase the risk of CVD in HIV-
positive women, due to the presence of the factors mentioned above and increased levels of 
inflammatory markers (262). More research is needed to better understand the effects of HIV 
infection and ART in combination with reproductive aging, in groups of HIV-positive and HIV-
negative women, where the MT has been accurately staged (268). 
 
Studies have shown that women transitioning through menopause have lower BMD (269), 
and other data have found that HIV-positive women have decreased BMD, which in these 
HIV infected women, is associated with reduced muscle mass, decreased testosterone 
levels and menstrual cycle irregularities (270). Therefore low BMD in HIV-positive women 
may be related to a combination of menopausal status and the effects of HIV infection. 
However, research that examined BMD in HIV-positive and HIV-negative premenopausal 
urban black South African women did not find BMD was lower in the HIV-positive group 
(271). The effect of HIV infection and subsequent treatment on declining BMD has also been 
examined, suggesting that low bone density in HIV-positive women is related to several 
different variables, including the effects of being underweight, cigarette smoking and low 
vitamin D levels (272). 
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1.9 Menopause research in sub-Saharan Africa  
A comprehensive search of the literature using MEDLINE (1970-2015) suggests that there is 
a paucity of research about menopause in sub-Saharan Africa compared to Western, Asian, 
and Latin American countries. Although there is research on cardiometabolic disease risk (5, 
243, 246) in sub-Saharan African populations, there is almost nothing specifically related to 
women in MT and CVD risk or the deleterious effect of increasing obesity or changes in body 
fat distribution in midlife women from this population. A Ghanaian study (273) described 
body fat distribution changes but only with reference to menopause symptoms, and not 
CVD.  A systematic review of VMS around the world, further highlights this lack, since only 
two African papers, from Nigeria and Ghana, were included in this review, and, in one of 
these, the definition of menopause status was not even described (124). There are several 
studies examining the risk of metabolic disease and changes in body composition in African 
women in Ghana (274), Nigeria (275-277) and the Congo (138), but generally the cohorts 
were small, menopause status was self-reported and not accurately staged, nor confirmed 
with biomarkers. Studies based in Nigeria (103, 278), Tanzania (279), Ghana (273) and 
Zimbabwe (280) examined African women’s experience of the menopause and menopausal 
symptoms.  VMS were widely experienced and joint pain was particularly common (277, 
281, 282). Some research investigated hormone levels during the MT, and, as expected, 
found that levels of FSH were higher and E2 levels lower in postmenopausal women (283, 
284). Age at FMP was also explored in Ghanaian (285), Kenyan (286), Nigerian (287) and 
South African (280) women. Data from these four studies showed an approximate mean and 
median age of 48.04 and 48 years respectively which were significantly lower than age at 
FMP in some Western studies, where age at FMP in a multiethnic American study was 51,4 
years (64), and 54 years in a very large European cohort (288). The problem of accurately 
determining menopause stage in these groups of women remains.   
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1.10 Summary and research gaps 
There is a significant body of research investigating cardiometabolic disease and associated 
risk factors in South African women. Metabolic syndrome (7, 243), obesity (242, 245, 289), 
diabetes (246, 290) and heart disease (5), have all been examined.  However, the MT was 
not staged in these studies of midlife women, so it is difficult to determine whether 
chronological or reproductive aging, or both, may be risk factors for cardiometabolic disease 
in this population. Accurate staging of the MT is important in understanding this complex 
association. However, there appear to be no studies in sub-Saharan Africa using a validated 
staging tool. Most of the studies, described in this African population, rely on self- reporting 
to establish whether women are pre- or postmenopausal (12 months of amenorrhea), and no 
validated staging method has been used. It can therefore be seen that there is a lack of 
research on the MT in sub-Saharan African females, particularly in relation to 
cardiometabolic diseases and body composition. The following list highlights some of these 
knowledge gaps:   
 
 Changing sex steroid hormone levels across the MT have been shown to be 
associated with an increase in the risks of MetS and CVD (9, 145, 182, 183, 188, 
189); however, such studies have not been performed in African females during the 
MT.  
 
 Obesity and a changing hormonal milieu may increase the severity and prevalence of 
VMS (155, 221, 229, 291), but VMS, which have been found to be a risk factor for 
metabolic syndrome (79, 219, 220), have not been assessed in African females.  
 
 Body composition changes during the MT may predispose women to greater risk of 
MetS (9, 155, 292) but there are little data examining these changes in black African 
women.  
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 Bone density has been studied in black South African women (293). Research 
studies dating from approximately 30 years ago suggested black South African 
women have a lower risk of decreased bone density, than their white counterparts 
(294, 295). Although there are studies comparing bone density in black and white 
South African women, those that are available suggest there are fewer differences 
than previously thought (296-298). However, these studies were not controlled for 
menopausal stage.  
 
 Earlier age at FMP is related to increased risk of metabolic disease (212, 213), and 
those women who have experienced economic hardship throughout childhood and 
into adulthood are more likely to experience earlier onset of menopause (66, 67, 
299), but this has not been studied amongst black urban South African women. In 
addition, many women, across the socioeconomic spectrum, have difficulty in 
recalling FMP age accurately (69, 72)This may be compounded by the fact that given 
the inequality between private and public healthcare in South Africa (300, 301), the 
majority of midlife black urban women do not have annual medical or gynecological 
checkups, so there are few accurate records of their ovarian aging.   
 
 Studies have described how HIV infection may affect both age (257) at menopause 
and severity and prevalence of VMS (262).  In addition, ART can affect metabolic 
factors (8). However the MT has not been studied in African HIV-positive women who 
are currently on treatment.  Research has also shown that HIV infection and ART 
may each affect fat distribution (261), which may enhance risk for MetS (302), and 
low BMD (268, 270).  A wide body of research has shown that changes in body 
composition are significantly associated with the MT (146, 303, 304), but since the 
MT has not been accurately staged in black urban South African women, it is difficult 
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to explain whether changes in body composition are related to HIV infection, ART, 
reproductive aging, or to a combination of these factors.   
 
1.11 Study aims and objectives 
The principal aim of this study is to investigate the metabolic, hormonal and anthropometric 
characteristics in black urban South African women at different stages of the MT.  
 
1.11.1 Objectives 
The objectives of this study, which pertain only to black, urban South African women, are 
therefore as follows: 
 
1. To accurately stage reproductive aging in a population of urban African women using 
bleeding patterns and to assess whether STRAW + 10 criteria are appropriate to stage 
ovarian aging in this population, and to measure FSH and E2 levels as supportive criteria in 
determining MT stage. 
 
2. To determine whether obesity is associated with age at FMP and menopausal symptoms, 
particularly VMS, and whether HIV infection is associated with age at FMP and menopausal 
symptoms. 
 
3. To determine whether general body adiposity, BFD, lean muscle mass and BMD are 
associated with stages of the MT and if so what factors may play a role in these 
associations. 
 
4. To determine the prevalence of the MetS, the level of its individual components and 
associated metabolic factors in African females at different stages of the MT and what 
factors play a role in modulating the levels of these variables.  
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1.11.2 Study Hypotheses 
1. STRAW+ 10 is a valid instrument to stage reproductive aging in women in a low resource 
country 
 
2. Body composition changes are associated with both reproductive and chronological aging 
in black urban South African women 
 
3. Black postmenopausal South African women are at greater risk for cardiometabolic 
diseases than those women in the late reproductive stage   
 
1.11.3 Study relevance  
Studies have shown that there is a high prevalence of cardiometabolic diseases in midlife 
black urban South African women (5, 7, 134). A more wide-ranging and in-depth 
understanding of the risk factors associated with these diseases is needed to address the 
gaps in the literature, and the lack of information on the relationship of cardiometabolic 
diseases to the MT in these women.  Data from the women in SWEET should help to clarify 
whether the MT is related to the high prevalence of obesity and metabolic disease in this 
population. Establishing whether a staging tool, using bleeding criteria, can accurately stage 
the MT is the first step in investigating the relationship between reproductive aging and 
cardiometabolic disease.  In addition, assays of several sex steroid hormones that have not 
been previously collected from black South African women during the MT will enable us to 
determine whether these hormones are associated with differences in body composition and 
levels of cardiometabolic disease risk factors in . The examination of body composition will 
include an exploration of BMD in women at different stages of the MT, since there is a 
perception that bone fragility and its attendant health risks is lower in these black African 
women than in Caucasians (294, 295), so a deeper understanding of BMD across the MT 
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will be useful. Assessing HIV status and ART use may provide additional insight into the risk 
of metabolic diseases in HIV-infected menopausal women. An analysis of socioeconomic 
factors, lifestyle and education will examine how these affect both anthropometric and 
metabolic variables in this group of women. This information may help provide information 
that can be used to reduce the risk of cardiometabolic disease among black South African 
women. The research in this study may also inform public policy and improve the quality of 
health care available to midlife black South African women.  
 
1.11.4 Conceptual Framework 
The conceptual framework shown below (Figure 1.12) attempts to highlight the proposed 
relationships between the variables examined in this investigation of the hormonal, metabolic 
and anthropometric differences in African females at different stages of the MT, and to act as 
a guide to the experimental components that have been utilized in this PhD. The 
relationships shown in this diagram have been more fully described in the preceding 
literature review.  
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Figure 1.12 Conceptual framework for the SWEET study
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Chapter 2: Methodology and design 
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2 Methodology and Design 
2.1 Historical context of study  
From 1948 -1994, black South Africans lived under the system of apartheid, which 
segregated people by ethnicity and discriminated against people of colour; politically, legally, 
socially and economically.  White people, who were considered racially superior, benefitted 
exponentially (300). Apartheid had a significant effect on the South African healthcare 
system (305).   When the African National Congress (ANC) came to power in 1994, they 
promised changes to healthcare and created a National Health Plan (301, 306).  However, 
the healthcare system continues to face challenges. The focus, since 1994, has been on 
improving primary healthcare, but though access to healthcare has improved, the quality of 
healthcare continues to deteriorate due to several reasons.  These include the legacy of 
apartheid; years of poverty and inequality that compromised the health of black South 
Africans, incompetent administrators, the burden of NCDs, HIV and tuberculosis, lack of 
training and poor leadership, management and administrative skills (300, 305). 
Administrative problems occurred after 1994 due to changes at senior management levels, 
when white administrators were replaced by their black counterparts, which resulted in what 
Coovadia et al described as a ‘loss of institutional memory’ (300).  
 
The public health sector is under pressure to deliver services to about 84% of the population. 
In contrast, private healthcare caters to the higher income groups in the country, who 
happen to also have health insurance. Approximately 16 % of South Africans belong to 
medical aid schemes and have private healthcare (307). In 2011, the ANC published a green 
paper proposing a National Health Insurance (NHI) plan to address the inequalities in the 
healthcare system (308). 
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South Africa is one of the most unequal countries in the world, and this is underlined by its 
healthcare system (305). Black mid-life South African women generally attend satellite 
clinics (Figure 2.1), which are often poorly equipped and under staffed by inadequately 
trained personnel (300).  Many of the country’s healthcare professionals prefer to work in the 
private sector rather than in these public entities and by 2007, over 70% of South African 
doctors were working in private healthcare, while many others had immigrated. Furthermore, 
they were not specifically trained to work in rural areas with poor primary healthcare 
conditions (300), although, since 2005/2006 graduating doctors must complete a two year 
compulsory community service internship program that was implemented by the Health 
Professions Council of South Africa (HSPCA) (309, 310). An understanding of doctor 
shortages in the public healthcare sector is illustrated by the following statistic, which shows 
that although the doctor to population ratio in South Africa is estimated at 0.77 per 1000, 
there is only one doctor per 4219 people because 73% of doctors practice in the private 
sector (311).  
 
Primary healthcare nurses, who mainly work in the satellite clinics described above, have 
very basic degrees in primary healthcare and full responsibility for diagnosing and 
prescribing medicine for a wide range of medical conditions. Training and quality of nurses 
was compromised when nursing colleges were closed towards the end of the 90’s as a 
reaction to the apartheid legacy (301). In addition, there is a perception that many nurses are 
disinterested in their patients, abusive and uncaring (312). The need to address this problem 
is critical (300).  
 
In South Africa 81% of women are black, and over 4 million women are 40 to 59 years old.  
Life expectancy in females rose from 55.7 in 2002 to 63.1 years in 2014 (313). In addition, a 
recent South African national health survey confirmed that the prevalence of all NCDs 
increases with age (6). Research discussed in Chapter 1 has shown that risk for NCDs is 
high in midlife women, and a need for both information and management of menopause has 
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been identified by the Department of Health (314), but it does not appear that specific 
guidelines have been given. However, in the public health sector in South Africa, there 
appear to be very few clinics specializing in menopause. Research examining metabolic, 
hormonal and anthropometric factors in the MT in this population group is urgently needed.  
 
 
 
 
Figure 2.1 A satellite clinic in Johannesburg, South Africa. (Source: Mooney et al) 
(305)  
 
 
2.2 Study setting and cohort background 
The cohort is part of the well-known Birth to 20 (BT20) study in the MRC/ Developmental 
Pathways for Health Research Unit, Department of Paediatrics, School of Clinical Medicine, 
Faculty of Health Sciences, University of the Witwatersrand. In 2004, it was described as the 
‘largest and longest running longitudinal birth cohort study in Africa’ (315). The cohort 
population derives from Soweto (South Western township), a black urban area known as a 
‘township’, bordering the gold mines of Johannesburg (316).  It was created in line with the 
policy of apartheid, implemented by the Nationalist government of the time, to separate black 
and white South Africans (317). There are approximately 1.3 million people in Soweto 
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(Figure 2.2) (318). Although many houses in Soweto have been upgraded, large sections 
are still informal, and issues of poverty, housing, unemployment and inadequate health 
services present significant challenges (319).  
 
 
 
 
Figure 2.2 A view of Soweto (Source: Antioch University, USA)(320) 
 
 
Towards the end of the 1980’s, there was rapid socio-political change in South Africa, and 
growing urbanization in the form of shack and informal settlements adjacent to designated 
white areas. As described earlier, the legacy of apartheid had impacted healthcare (305), 
and there was concern amongst clinicians and researchers that mortality and morbidity of 
the children, growing up in these informal settlements, where health was already 
compromised by the apartheid system, would experience further deterioration. This would be 
as a result of continuing administrative problems and rapid migration from rural to urban 
areas, which would significantly compromise the available but inadequate healthcare 
services. There was already a high prevalence of HIV/AIDS and tuberculosis in this 
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population, and increasing obesity, diseases of lifestyle and traumatic injuries could further 
exacerbate the situation (300, 321). 
  
In 1989, funding was granted to implement a birth cohort study in Soweto, and enrollment 
began in mid-1990. Several pilot studies were developed to examine the viability of this 
longitudinal research in exploring the ongoing health of these mothers and children. The 
3275 children in the study were those born to women who had been resident in Soweto for 
six months or more prior to the child’s birth (315). Initially, the children, known as ‘Mandela’s 
children’, since they were born in the period from February 11 – March 30, 1990; the 7-week 
period following Mandela’s release from incarceration, were to be studied until they turned 
ten. The study was named Birth to Ten (BT10).  However, in 2000, the name was changed 
to Birth to Twenty (BT20) when the investigators decided to continue the study until the 
children turned 20 (321).  
 
There has been a low attrition rate in BT20, and by 2011 about 2200 participants were still in 
touch with the study (322). One of the reasons for the decreased numbers is difficulty in 
contacting the participants.  It has been noted that the participants in BT20 move frequently; 
within the first 16 years of the study approximately ten percent had changed their addresses 
four or more times.  Other reasons for this attrition include mortality, refusal to be part of 
related studies and possibly a perception that they were not benefitting from the data 
collection process. However, it is postulated that these women, who do not generally have 
annual medical check-ups, may perceive data collection to be similar to healthcare 
monitoring, and may be encouraged to continue to participate (323). The term, ‘caregivers’, 
is used in the BT20 cohort profiles. The explanation is that in this population children may be 
raised by a close female relative in order for the biological mothers to find work in another 
area, or for school-age mothers to continue their education (300).  
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2.3 Data collection process 
2.3.1 Recruitment 
The black urban African women in this cross sectional study were participants in SWEET.  
They were the biological mothers and caregivers of the children in the BT20 cohort. Owing to 
infrastructure and timeline constraints, not all of the 2,200 participants, who were still in 
contact with BT20, could be recruited into the study and the maximum sample size used in 
the study was based on feasibility and costs of recruitment within the 3-year recruitment time 
period. The minimum number of participants in the study cohort would be defined as that at 
which at least 100 women were present in each of the following four study subgroups (based 
on menopause staging using STRAW+10 guidelines (56): late reproductive (stages - 3b and 
-3a), the MT (stages - 2 and - 1), early postmenopause (stages 1a, 1b, and 1c), and late 
postmenopause (stage +2).   
 
As shown in Figure 2.3, a group of 902 women (this was the maximum number of women we 
could contact within the timeframe and infrastructural limits of the study), were randomly 
chosen from the available 2200 women and contacted by a team member who described the 
study and data collection process, and extended an invitation to participate in the study. 
Exclusion criteria were < 40 years and  >60 years, pregnancy and ethnicity other than black 
African. Within this group of 902 women, 200 women did not participate.  The reasons were 
as follows: 35 were now older than 60 years, 79 refused to participate, for several reasons 
including an inability to take time off from work, lack of interest in the study, or that they had 
had their blood tests taken at a local clinic and did not believe the study would benefit them. 
In addition, 37 women were deceased, 3 were terminally ill, and 46 had become 
untraceable, or now lived outside the study area. Every effort was made to trace the last 
group of women. Team members made field visits to the addresses listed on the contact 
sheets, but found in many cases that the participants had moved and were not contactable 
because several occupants had lived at the address since the participant moved. Many had 
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left no forwarding address, and in some cases the initial address that had been given was 
incorrect. Ultimately, 702 women agreed to participate in the study.  
 
 
 Figure 2.3 Flow diagram showing SWEET cohort recruitment 
 
2.3.2 Ethics 
 
Confidentiality for all women was maintained because the participants in BT20 had been 
given an identity number that was also used in the SWEET study. All participants signed 
informed consent forms (Appendices; Page 170). As per the informed consent form, it was 
agreed that if participants’ results were out of the normal range, they would receive a referral 
letter to a primary health care clinic, medical practitioner or specialist for further testing and 
treatment.  At the end of the data collection process, participants were given information 
sheets on menopause and cervical cancer (Appendices; Page 184) The Human Research 
Ethics Committee (Medical) of the University of the Witwatersrand approved the protocol 
(ethics certificate number M090620) (Appendices; Page 165-166). 
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2.3.3 Data management 
 
The data for each SWEET participant was collected in a separate folder. Each participant 
was allocated a BT20 ID number. Each participant had a contact sheet and the information 
on the contact sheet was updated during the check in process. Separate barcode stickers 
with the participant’s ID number were stuck onto each one of the data collection documents. 
Once the data collection was completed the folder containing the documents, and 
subsequently the results of the blood analytes were filed under lock and key under the 
auspices of DPHRU. Data was uploaded into an Excel spreadsheet and transferred to 
Statistica for data cleaning and analysis. All spreadsheets contained only BT20 ID numbers 
and not participant names. 
  
2.3.4 Data capture 
 
Since the participant folders were not allowed, at any stage, to leave the room where they 
were stored, all data was captured on a designated DPHRU computer. Only those with 
access to the identifier code and password were able to capture the data, so that 
confidentiality was maintained at all times 
 
2.4 Questionnaire 
2.4.1 General questionnaire 
In this study there was one general questionnaire (Appendices; page 166) that incorporated 
all the questionnaires described below. There is a list on the front of the general 
questionnaire showing all the questionnaires and collection procedures that participants in 
SWEET needed to complete. The Food Frequency Questionnaire, the Caregiver peripheral 
quantitative computed tomography (pQCT) and the Caregiver carotid intima-media thickness 
(cIMT) measurements have been excluded from the description below because they do not 
pertain to this study. Data from those were used in the study of another PhD candidate, who 
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was collecting data at that time from the cohort. Data from the Utian Quality of Life Scale 
(UQoL) questionnaire, which is included within the general questionnaire, was collected and 
has not yet been analyzed. 
 
There are 11 official languages in South Africa and although English is not the first language 
of most of the participants, it is the language most commonly used, and the majority of the 
participants speak and understand English. It was therefore decided that the questionnaires 
should be administered in English during face-to-face interviews, by a single researcher. 
When necessary, clarification and translation, in the home language of the participants, were 
available by trained members of the team whose first language corresponded with those of 
the participants. A general questionnaire included questions on reproductive health, 
menstrual history, general health and employment, educational level and tobacco and 
smokeless tobacco (snuff) use. Current and former smokers were grouped together and 
compared to subjects who had never smoked. This questionnaire was derived from the 
general health questionnaire formulated and validated in a previous study of the same 
population group (324).  
 
2.4.2 Assessment of menopause transition stage 
Within the general questionnaire (Section B: Menstrual history), women were asked close-
ended questions about bleeding patterns to determine their MT stage. Participants were 
asked the date of their last menstrual period. If they had skipped a menstrual period, they 
were asked when they last had a menstrual period (3 months, 6 months, 12 months, or more 
than 1 year ago). These questions were followed by open-ended questions about bleeding 
patterns, to more specifically ascertain cycle changes. Where possible the date of the FMP 
was obtained. Hormone therapy and contraceptive use were determined; the participant was 
asked whether she knew the names of the medication she was using. Information on 
hysterectomy and oophorectomy was obtained whenever possible. STRAW + 10 criteria (56) 
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were used to ascertain menopause stage. The participants were assigned to a STRAW+10 
stage as follows: late reproductive (-3b, -3a); early and late menopausal transition (-2, -1); 
early postmenopause (+1a, +1b, +1c), and late postmenopause (+2) as shown in Figure 2.4. 
  
  
Figure 2.4 Diagram showing the staging groups for SWEET participants 
 
 
2.4.3 Menopause Rating Scale (MRS) 
Within the general questionnaire, the presence, prevalence and severity of menopausal 
symptoms were measured using the Menopause Rating Scale (MRS). This is an 
internationally validated, standardized scale and has been fully described in (Chapter 1, 
section 1.5.3). The scale allows the participant to rate the presence and intensity of 11 
symptoms on a scale of 0-4, and was graded as absent = 0, mild = 1 or 2, severe = 3 or 4 
(98). A single interviewer administered the MRS, and when necessary, team members were 
trained to interpret the questions in the home language of the participant (Appendices; Page 
173).   
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2.5 Anthropometric measurements  
2.5.1 Simple measures of body anthropometry  
Participants wearing light clothing and without shoes, were weighed and their height 
measured, using respectively, a calibrated electronic scale and a fixed-wall stadiometer, 
(Holtain, Crymych, UK).  A soft measuring tape was used to measure waist and hip 
circumferences to the nearest 0.5cm; the former at the smallest girth above the umbilicus 
and the latter at the greatest circumference of the hips. The intra-observer CVs for height, 
weight, and hip circumference was less than 1% and less than 2% for waist circumference. 
Inter-observer CV for height, weight, hip circumference and waist circumference was less 
than 1%. Body mass index (BMI) was calculated.  Blood pressure was recorded on the left 
arm, while the participant was seated using a digital reader (Omron M6; Omron, Kyoto, 
Japan) and appropriate cuffs. Three readings were taken with a 2-minute interval time 
between each reading. The first reading was discarded and the remaining two values were 
averaged. BMI was calculated as an estimate of obesity by dividing weight (kilograms) by 
height (meters) squared.  
 
2.5.2 Dual-energy X-ray absorptiometry (DXA) measurements  
Whole body DXA scans were performed by a single trained technician using a Hologic 
Discovery A (S/N 83145) DXA machine (Bedford, MA, USA). The participants removed their 
clothing and all metal objects and surgical gowns were worn for the procedure. Whole body 
scans for fat and lean mass were analyzed using whole body less head, since many 
participants wore wigs and hair weaves that could not be removed; these hairpieces are 
similar in density to soft tissue and may have caused measurement artifact, as described in 
a previous study (325). The terms ‘total’ or ‘whole body’ are used in the study papers when 
referring to these sub-total (i.e. whole body minus head) measures of lean and fat mass. 
During data collection a DXA phantom was scanned each morning to examine the CV of the 
DXA machine and the CV was found to be less than 0.5% for all parameters.  
 66 
 
2.5.3 Ultrasound measurements of VAT and SAT 
A trained operator measured visceral and subcutaneous adipose tissue using a GE LOGIQ e 
ultrasound machine with a 2-5.5 MHz 4C-RS curved transducer (GE Healthcare, 
Piscataway, NJ, USA). The VAT thickness was defined as the distance in centimeters from 
the peritoneum to the vertebral bodies and SCAT thickness as the depth in centimeters from 
the skin to the linea alba. In order to visualize the relevant anatomical structures the scan 
depth was set at 15 cm for the VAT and 9 cm for SCAT. The site for both measurements 
was where the xyphoid line and waist circumference meet. The CV for the ultrasound 
measurement for VAT and SCAT was less than 2%. 
 
2.6 Assays of blood analytes 
Fasting blood samples were obtained in the morning before 11am during the 4-hour data 
collection period. Where possible, seven tubes of venous blood were drawn, using standard 
venipuncture techniques. Four SST 10ml tubes were drawn for serum analysis, two EDTA 
5ml tubes were drawn for plasma analysis, and one Fluoride 5ml tube was drawn for glucose 
analysis. The blood was centrifuged (Beckman Coulter, USA) at 642 g (2,500 rpm) for 10 
minutes at 24°C.  Serum and plasma samples were collected and aliquoted into 
corresponding cryovials and immediately stored at -80ºC until assays were performed. 
Levels of follicle stimulating hormone (FSH), estradiol (E2), dehydroepiandrosterone 
(DHEA), dehydroepiandrosterone sulfate (DHEAS), testosterone, lipids, blood glucose, 
leptin, adiponectin and sex hormone binding globulin (SHBG) were measured. 
Immunoassays were performed for E2, FSH and insulin as per manufacturer’s instructions 
(ADVIA Centaur XP Systems, Siemens Healthcare Diagnostics, Tarrytown, NY). The 
principle for E2 is a competitive chemiluminescent immunoassay and the assay range is 
43.6 -11,010 pmol/L (11.8–3000 pg/ml), and intra- and inter-assay coefficients of variation 
(CVs) are 4.2% and 1.9% respectively. For FSH, the principle is a two-site sandwich 
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chemiluminescent immunoassay and the assay range is 0.3 – 200 IU/L, and the intra- and 
inter-assay CVs are 2.4% and 1.5% respectively. The assay range for insulin is 0.5mU/L- 
300mU/L, and the intra- and inter-assay CV’s were 5.9% - 4.8% and 4.6%-3.3% 
respectively.  The immunoassays for SHBG and DHEAS were performed on the Immulite 
2000 Systems analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY). The SHBG was 
performed using solid phase two-site chemiluminescent immunometric assay. The intra-
assay and total CV for SHBG was 3.06% and 4.40% respectively, while the assay range was 
0.02 - 180 nmol/L.  DHEAS was performed using a solid phase competitive 
chemiluminescent enzyme assay.  The intra-assay and total CV for DHEAS was 7.1% and 
9.8% respectively and the reported assay range was 0.41 - 27.0 µmol/L (3.0 - 1000µg/dL). 
The homeostasis model assessment (HOMA) method was used to calculate insulin 
resistance (326). Total cholesterol, HDL, triglycerides, glycated haemoglobin (HbA1C) and 
glucose were measured using the prescribed enzymatic methods on the Advia 1800 
Chemistry Systems analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY). Low density 
lipoprotein (LDL) levels were calculated using the Friedwald formula (327).  The analytical 
performance of each assay is as follows: cholesterol, assay range 0.26 -17.48mmol/L (10.0 - 
675mg/dL), and intra-assay CV is 0.3%; HDL assay range is 0.1-3.0mmol/L (5.0 - 115mg/dL) 
and the intra-assay CV is 1.0 - 2.3%; triglyceride analytical range was 0.0 - 6.22mmol/L (0.0 
- 550mg/dL) with an intra-assay CV of 0.5% - 1.6%; HbA1C assay range is 0.23% - 17.8% 
and the intra-assay CV is 0.8% - 1.3% ; the assay range for glucose is 0.2 - 38.9mmol/L (4.0 
- 700mg/dL) with an intra-assay CV of 0.4 - 0.5% and a total CV ranging from 0.9% at a 
lower concentration to 0.7% at the higher concentration of 16.5mmol/L.  
 
The DHEA immunoassay (ELISA) was performed with the solid phase competitive binding, 
enzyme-linked immunosorbent assay, (DRG instruments Gmb-H, Marburg, Germany). The 
assay range is 0.0 – 30.0ng/mL, and the intra- and inter-assay CVs were 5.1% and 6.8% 
respectively. Leptin was measured with an ELISA (Biovendor Research and Diagnostic 
Products, Candler, NC). The assay range is 0.2 - 50ng/mL, and the inter-assay CV is 4.4% - 
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6.7% and the intra-assay CV is 4.2 - 7.6%. Adiponectin was measured with an ELISA 
Quantikine kit (R&D systems, Boston Biochem, Cambridge, MA). The assay range is 0.079 - 
250ng/mL, and the intra-assay CV is 5.8% - 6.9% and the inter-assay CV is 2.5% - 4.7%. 
Testosterone extraction was performed using a liquid-liquid extraction method according to 
Benton et al (328). Ten microliters of sample was injected onto an ultraperformance liquid 
chromatography mass spectrometer (Micromass Quattro micro API Mass Spectrometer, 
Waters, Milford, MA). The lower limit of detection was 0.25nmol/L (7.2ng/dL) and average 
intra- and inter-assay CVs were 7.85% and 9.23% respectively. Free and bioavailable 
testosterone levels were calculated using the method of Sodergard et al (329). 
 
All biochemical analyses were performed in the laboratory of Department of Chemical 
Pathology/ National Health Laboratory Services, Faculty of Health Sciences, University of 
Witwatersrand, Johannesburg, South Africa.  
 
2.7 HIV testing  
All participants were offered a voluntary HIV antibody test, Alere Determine ™ HIV-1/2 
(Alere San Diego, Inc. San Diego, CA). This test has been shown to be easy to use and has 
a very high sensitivity and specificity (330). 
 
Participants who knew their status and disclosed this information were noted. Those women 
who wished to know their status were offered pre- and post-test counseling by a trained 
nurse/HIV counselor in accordance with recommendations from the Department of Health 
(331) as shown in Figure 2.5, and were assured of full confidentiality (Appendices; Page 
180)  
 
If the result was positive, referrals were made to a local HIV clinic for confirmatory 
serological testing and CD4 count and management. Both HIV positive women who were 
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being treated with antiretroviral medication and HIV positive women, who were not, were 
maintained in the study.   
 
Figure 2.5 Procedure for voluntary HIV testing of SWEET participants: adapted from 
policy guidelines for HIV testing and counseling adapted from the policy guidelines 
from the National Department of Health, South Africa (331) 
 
 
2.8 Statistical analysis 
The statistical analyses used in this investigation have been fully described in chapters 3, 4 
and 5 as the statistical methodology used was specific to each results chapter. 
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Chapter 3: Staging reproductive aging using STRAW+10 in black 
urban African women in the Study of Women Entering and in 
Endocrine Transition 
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3 Staging reproductive aging using STRAW+10 in black urban 
African women in the Study of Women Entering and in 
Endocrine Transition 
 
3.1 Introduction  
 
The World Health Organization estimates that by 2030, 1.2 billion women will be 50 years or 
older. This is nearly triple the number of women who belonged to that age bracket in 1990. A 
growing number of these women can expect to live for several decades after menopause, 
and it is estimated that 76% of postmenopausal women will be living in developing countries 
by 2030 (2).   
 
Research shows that the menopause transition (MT) is accompanied by clear physiological 
changes, some of which are temporary whereas others are long term (9). The Study of 
Women Entering and in Endocrine Transition (SWEET), was developed to examine changes 
in metabolic, hormonal and anthropometric parameters in black urban South African women 
across the MT, because research suggests that these changes may increase the risk for 
cardiometabolic disease.(137). Obesity is highly prevalent in middle-aged, urban African 
females (244) but very few studies have analyzed the relationship between obesity and the 
MT in this population. In addition, data on obesity and its effects on the prevalence of 
vasomotor symptoms (VMS) in this population have been limited; studies of Western women 
have shown a strong correlation (332). VMS are one of the defining symptoms of the MT 
(333), and have been linked to an increased risk of cardiovascular diseases(79, 80, 332).   
Accurate staging of reproductive aging is fundamental to understanding the relationships 
discussed above (112). However, there is a paucity of research on accurately determining 
mean age at final menstrual period (FMP) and on MT staging in sub-Saharan African 
women. In 2001, the Stages of Reproductive Aging Workshop (STRAW) (113) identified 
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criteria defining the different stages of reproductive aging, to help clinicians and research 
scientists stage the reproductive cycle. Harlow et al (114) considered these criteria to be the 
gold standard for staging the menopause transition. However, research in the 10 years 
following STRAW has enabled clinicians in the field to have a wider understanding of the 
hypothalamic-pituitary and ovarian function of the MT. At a recent workshop, ‘STRAW+ 10: 
Addressing the Unfinished Agenda of Staging Reproductive Aging’, the criteria for staging 
menopause were revised and updated based on the latest data (56).  Bleeding patterns 
(menstrual cycles) remain the most important criteria to determine the stage in the MT, since 
there is no international standardization of biomarker assays (56, 115, 118). In addition, low 
or middle-income countries do not have the resources for the wide use of blood assays in 
assessing specific stages in the reproductive cycle. In 2001, STRAW recommended that 
follicle stimulating hormone (FSH) levels could be used as a biomarker in the late transition 
stage. Given the improved understanding of endocrine changes involved in ovarian aging 
(51), Stages of Reproductive Aging Workshop + 10 (STRAW +10) suggested that FSH and 
E2 - specifically the concentrations before and after the final menstrual period (FMP) - be 
used as supportive criteria to verify the stage of MT.(57) In addition, VMS and vaginal 
atrophy may be used to support other measures to determine the stage of MT (56). 
 
It appears that no prior study in sub-Saharan Africa has used the STRAW+10 guidelines for 
staging MT. In this study, the reliability of this method for classifying ovarian status in a 
population with a high prevalence of obesity was assessed (6).  Data from this same 
population of women (mean age, 43 years) showed that diabetes and metabolic syndrome 
are very common (7).  A high incidence of human immunodeficiency virus (HIV) infection has 
been observed in this group of women (334) and some studies show that being HIV- positive 
may affect the symptoms and conditions of the MT in midlife women.(257, 335)  
 
This study aims to examine reproductive aging in a population of urban African women to 
assess the usefulness of STRAW + 10 criteria in staging ovarian aging in these women by 
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determining bleeding patterns. Vasomotor symptoms (VMS) severity, FSH levels and E2 
levels were determined as supportive criteria. It was hoped that the research would 
determine whether obesity has any effect on the MT, FMP and menopausal symptoms, 
particularly VMS. Age at FMP was noted, and HIV status was obtained (where possible) to 
analyze whether HIV infection was associated with age at FMP and menopausal symptoms.  
 
3.2 Methods 
 
The following methods were used: questionnaires for determining education level, use of 
ART, understanding of menopause, FMP, menopausal stage (using STRAW+10 criteria) 
and frequency and severity of menopausal symptoms (using the MRS); measurement of 
waist circumference, weight and height; BMI calculated; assays of serum E2 and FSH levels; 
measurement of HIV status.  Each of these methods has been fully described in Chapter 2.  
 
3.2.1 Statistical analyses 
 
Non-normally distributed data were log transformed to normality before being used in any of 
the statistical analyses. These data are presented as median (interquartile range) in the 
tables and text, whereas normally distributed data are expressed as mean ± SD. Continuous 
variables were analyzed across groups using analysis of variance (ANOVA; or analysis of 
covariance [ANCOVA] with adjustment for possible confounders), and paired means were 
compared using Tukey post hoc test. Hormone levels, BMI, waist circumference and age 
were compared across the 7 menopausal stage groups shown in Figure 3.1. Menopause 
symptoms were compared across the 4 menopausal stage groups shown in Figure 3.1, to 
increase the power of the analysis. Percentage values were compared using the χ2 test. Age 
at FMP was calculated using probit analysis. Logistic regression was used to identify the risk 
of selected menopausal symptoms across menopausal stages with and without adjustment 
for possible confounding variables (ie. age, BMI, FSH level and E2 level). These variables 
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were added individually to each model and also added all together.  A multiple regression 
model was developed to identify the principal determinants of age at FMP. Independent 
variables included in the initial model were chosen based on biological plausibility and 
previous statistical analyses. These variables were: BMI (used as a categorical variable with 
BMI<25.0 coded as 0 and BMI≥25.0 coded as 1), waist circumference, education (coded 
with dummy variables using as the reference the group who did not attend high school), FSH 
level and E2 level. Backward, stepwise regression was performed, with variables removed 
one at a time (based on their p-level) until only variables with p<0.05 remained in the model.  
Pearson univariate correlation analysis was used to determine the relationship between the 
reported age at FMP and the length of time that had elapsed up until this age was reported 
to the study investigators (i.e. years post-FMP). Participants were also divided into quartiles 
of years post-FMP and the reported age at FMP for each quartile was compared by ANOVA 
 
3.3 Results 
 
3.3.1 Descriptive data for study population 
 
Table 3.1 provides the descriptive data of the study cohort. The analytical sample contained 
702 women; HIV status was recorded for 404 of these women, of whom 21.3% were HIV-
positive.  The frequency of antiretroviral use was 55.3% within the HIV-positive women. 
Participants had a mean age of 49.2 ± 5.29 years (Table 3.1). The mean age at FMP (n = 
234) was 46.0 ± 4.63 years, which was very low. The data were therefore analyzed in 
greater detail in subsequent statistical analyses (see Table 3.2 and its associated 
description). The prevalence of obesity (BMI ≥ 30.0 kg/m2) and extreme obesity (BMI ≥ 40 
kg/m2) were 67.8% and 16.8% respectively. Within the study population 61.9% had an 
understanding of menopause.  Only 30% had finished high school.   
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Table 3.1 Descriptive data of study cohort 
 
Variables Valuesa Ranges 
 
Age (years) 
 
49.2 ± 5.29 40.0 - 61.0 
 
Age at FMP (years)b 
 
46.0 ± 4.63 27.0 - 57.0 
 
Waist (cm) 
 
99.1 ± 14.6 47.0 - 151 
 
BMI (kg/m2) 
 
33.4 ± 7.32 16.6 - 61.6 
 
BMI ≥ 30 (%) 
 
67.8 - 
 
BMI ≥ 40 (%) 
 
16.8 - 
 
HIV-positive (%)c 
 
21.3 - 
ARV use (%)d 55.3 - 
 
Education (%):  
- Junior school only 
- High school, but did 
not finish 
- Finished high school 
with or without higher 
education 
 
 
 
12.3 
 
57.7 
 
 
30.0 
 
- 
- 
 
- 
 
Understand menopause 
(%) 
 
61.9 - 
 
FMP = final menstrual period; BMI= body mass index; HIV = human immunodeficiency virus;  
ARV = antiretroviral; a Data are presented as mean ± SD or percentage; b n = 234; c n = 404;  
d n = 85 (n = 702 for the remaining variables) 
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Figure 3.1 Diagram showing menopause staging groups for SWEET participants 
 
 
3.3.2 Age, BMI, waist, E2 level, and FSH level by menopause stage 
 
Menopausal stage could not be ascertained in 112 (15.5%) of the women because of 
contraceptive use (n= 64), hysterectomies (n=47), and unknown reason (n=1). The number 
of women in each menopausal stage, as assessed using STRAW+10 was as follows: -3b, 
164; -3a, 30; -2, 49; -1,73; 1a, 1b, 34; 1c, 110; +2, 130 (Figure 3.1).  Serum FSH levels 
(Figure 3.2 [A]) increased across seven groups, and this trend was highly significant 
(p<0.0005 from ANCOVA adjusted for age and BMI).  As shown in Figure 3.2 [A], mean 
serum E2 levels decreased across the menopause stages (p<0.0005 from ANCOVA 
adjusted for age and BMI). Figure 3.2 [B] shows, as expected, that age was strongly related 
to menopause stage (p<0.0005 from ANOVA). BMI, adjusted for age, tended to fall across 
the menopause stages (p=0.003 for trend from ANCOVA) and there was a weak, non-
significant relationship between menopause stage and waist circumference (p=0.07 from 
ANCOVA adjusted for age; data not shown). 
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Figure 3.2  E2 (- - -) and FSH (—) levels by menopause stage: -3b, (n=164); -3a, (n=30);   
-2, (n=49); -1, (n=73); 1a, 1b, (n=34); 1c, (n=110); +2, (n=130). The p-values for trend 
(ANCOVA) are p<0.0005 for both E2 and FSH, and are adjusted for age and BMI (A). 
Age (—) and BMI (- - -) by menopause stage (the n’s are the same as for A). The p- 
value for trend (ANOVA) for age is p<0.0005, whilst for BMI p=0.003 (ANCOVA, 
adjusted for age) (B). Data given as mean ± SD or median (interquartile range) 
 
 
Given the very low age at FMP that was observed for all women who reported an age for 
FMP (n=234), further statistical analysis of this data was undertaken. Probit analysis gave a 
median age at FMP of 46 years. However, Pearson univariate analysis demonstrated a 
significant inverse relationship between reported age at FMP and the number of years that 
had elapsed since that event (i.e. years after FMP; r=-0.59, p<0.0005, n=234). This suggests 
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that women who had their FMP recently reported an older age at FMP than those who had 
their FMP much earlier. This is confirmed by the data in Table 3.2 that shows that women in 
the lowest quartile of years post-FMP (≤ 3 years post-FMP), reported a significantly higher 
age at FMP than women in each of the other quartiles. Within the lowest quartile there was 
no significant relationship between reported age at FMP and years after FMP (r=-0.04, 
p=0.77, n=58). When women were divided into tertiles of years post-FMP and a similar 
univariate analysis was performed for women in the lowest tertile (≤ 4 years post-FMP) a 
near-significant inverse relationship was observed (r=-0.22, p=0.05, n=78). These women 
reported a mean age at FMP of 48.5 ± 3.92 years. The data suggest that the reported age 
for FMP in women within the lowest quartile for years after FMP (49.0 ± 3.80 years; Table 
3.2) is the most reliable. When age at FMP was calculated for women who were 2 years or 
less from FMP (49.1 ± 3.94 years; n=36), it was found to be very similar to that of women 
who were 3 years or less from FMP. Data in Figure 3.2 [B] confirm that the age at FMP is 
49.0 years. This shows that women at menopause stages occurring immediately before and 
immediately after the FMP (i.e. stages -1, 1a, and 1b), have mean ages of 48.7 ± 3.76 and 
50.4 ± 3.94 years, respectively. Age at FMP must fall between these two ages, and 49.0 
years does.  
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Table 3.2 Age at FMP by quartiles of years after FMP 
 
 
Years post FMP 
 
 
 
n 
 
Age at FMP  
(years) 
 
≤ 3 years 
 
 
59 
 
49.0  ± 3.80a 
 
> 3 and ≤ 6 years 
 
 
62 
 
46.6 ± 3.50a,b 
 
> 6 and ≤ 9 years 
 
 
50 
 
46.6 ± 4.00a,b 
 
> 9 years 
 
 
63 
 
42.0 ± 4.06 
 
Combined 
 
 
234 
 
46.0 ± 4.63 
 
Data are presented as mean ± SD; FMP = final menstrual period; ap<0.0005 versus > 9 years, 
bp<0.005 versus ≤ 3 years 
 
 
Table 3.3 Age at FMP by BMI group in women 3 years or less after FMP 
  
 
 
BMI group 
 
 
 
n 
 
Age at FMP 
(years) 
 
 
<25 
 
 
11 45.7 ± 3.00 
 
≥ 25 and < 30 
 
 
13 49.8 ± 4.32a 
 
≥ 30 and < 35 
 
 
18 49.0 ± 3.27a 
 
≥ 35 
 
 
17 49.0 ± 3.3.75a 
Data given as mean ± SD; FMP = final menstrual period; BMI = body mass index; 
ap<0.05 versus < 25 
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Among participants with reliable estimates of age at FMP (i.e. those ≤ 3 years after FMP), 
age at FMP was lower in women with a BMI < 25 kg/m2 compared with women in the higher 
BMI groups (p<0.05 for all comparisons; Table 3.3).  
 
3.3.3 Determinants of age at FMP 
 
Multiple regression analysis was used to identify the principal determinants of age at FMP. 
The women included in this analysis were those who provided details of age at FMP within 3 
years of this event (n=59). The variables that showed a significant association with age at 
FMP within the final multiple regression model were BMI (β=0.41, p=0.0007) and education 
(completed high school vs. not gaining entry to high school: β=-0.31, p=0.009). The r2 value 
for the full regression model was 0.27 (p<0.0005). 
 
3.3.4 Prevalence of menopause symptoms at any level by menopause stage 
 
There was a significantly higher prevalence of VMS and sexual problems in early 
postmenopause than in the late reproductive stage (p<0.05; Table 3.4). Irritability was more 
prevalent in late postmenopause than in the late reproductive and early postmenopause 
stages (p<0.05 for both). None of the other menopausal symptoms assessed using the MRS 
showed any significant trends across the menopause stages. 
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Table 3.4 Prevalence of selected menopause symptoms by menopause stage 
 
 
Menopause stage 
 
na 
 
Vasomotor 
symptoms 
 
 
Sexual 
problems 
 
Irritability 
 
 
 
-3b and -3a 
 
 
194 
 
55.7 
 
65.8 
 
60.8 
 
-2 and -1 
 
 
123 
 
64.2 
 
75.5 
 
68.3 
 
1a, 1b & 1c 
 
 
153 
 
69.3b 
 
79.6b 
 
57.9 
 
+2 
 
 
133 
 
58.6 
 
77.8 
 
72.9b,c 
 
All groups combined 
 
 
603 
 
61.5 
 
72.2 
 
64.2 
Data expressed as percentage; an for subjects who answered question on sexual problems within each 
menopausal stage group: -3b and -3a (n= 161);stages -2 and -1 (n=90); stages 1a, 1b and 1c (n= 103), 
stage +2 (n= 72); total (n= 426); bp<0.05 versus stage -3b and 3a;  cp<0.05 versus stages 1a, 1b, 1c  
 
 
3.3.1 Prevalence of symptoms by BMI group and by HIV status 
 
Table 3.5 shows that although the prevalence of VMS of any level did not change across the 
BMI groups, the prevalence of severe/very severe VMS was significantly higher in the group 
with BMI ≥35.0 kg/m2 (28.2%) compared with both the group with BMI of 30.0 kg/m2 to 34.9 
kg/m2 (20.2%%; p<0.05) and the group with BMI < 30.0 kg/m2 (20.1%; p<0.05). Sleep 
problems were significantly more common in women with a BMI of ≥35 kg/m2 compared with 
women with BMI between 30.0 kg/m2 and 34.9 kg/m2. Irritability was significantly more 
common in the highest BMI group compared with the lowest BMI group, whereas joint 
problems were less common in the lowest BMI group when compared with both of the higher 
BMI groups. 
 
No significant difference in the prevalence of any of the menopause symptoms was noted 
between HIV-negative women (n=318) and HIV-positive women receiving (n=47) or not 
receiving (n=39) antiretrovirals.  However, owing to the low number of HIV-positive women it 
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is possible that the study had insufficient power to detect differences in prevalence.  
 
 
Table 3.5 Prevalence of symptoms by BMI group 
 
 
BMI group 
 
n 
 
Vasomotor 
symptoms 
 
 
Irritability 
 
Sleep 
problems 
 
Joint 
problems 
 
< 30.0 
 
225 61.6  59.5a 62.7      62.9b,c 
 
≥ 30.0, < 35.0 
 
208 56.7 65.7  56.0* 76.3 
 
≥ 35.0 
 
266 61.6 69.8 65.0 76.8 
 
All groups combined 
 
699 60.2 65.3 61.6 72.2 
 
Data expressed as percentages; BMI = body mass index; ap<0.05, bp<0.005 vs ≥35 kg/m2; cp<0.005 
vs ≥30 kg/m2, <35 kg/m2   
 
 
3.3.2 Effects of menopause stage on symptom risk 
 
Table 3.6 shows that the odds ratio (OR) for VMS was significantly increased in early 
postmenopause compared with the late reproductive stage, but that the OR was attenuated 
after adjustment for FSH levels but not after adjustment for age, BMI or E2 levels.  When all 
four of these possible confounding variables were included together in this model, the results 
were similar to those found for the model in which only FSH levels were included (Table 3.6).  
 
The OR for sexual problems was significantly elevated in the early postmenopause stage, 
and there was also an increased OR in late menopause but this failed to reach statistical 
significance (p=0.07). These associations were significantly weakened after adjustment for 
age, but not after adjustment for FSH level, E2 level or BMI. When all four of these possible 
confounding variables were added together to model 2, the results found were similar to 
those observed with just the inclusion of age in the model (Table 3.6). 
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The OR for irritability was significantly increased at stage +2 (Table 3.6), and adjusting for all 
possible confounders (ie. age, BMI, FSH level or E2 level, either individually or all together), 
did not weaken this relationship. Although BMI did not attenuate the significant OR for 
irritability observed in stage +2 of menopause, it was itself associated with a significant OR 
for irritability (1.03; 95% CI, 1.00-1.06; p=0.03). This confirms the data in Table 3.5, which 
shows an increasing prevalence of irritability with rising BMI.  
 
 
Table 3.6 Logistic regression showing effects of menopause stage on symptom risk 
 
 
Model number 
and 
adjustments 
 
Dependent 
variable 
 
Independent 
variable Unadjusted OR (95% CI) 
Adjusted OR (95% 
CI)a 
 
Model 1 
without and 
with 
adjustment for 
FSH 
 
 
Vasomotor 
symptoms 
 
Stage -2 & -1: 
Stage1a,b,c: 
Stage +2:  
FSH:                            
 
1.43 (0.90, 2.28); 0.13  
1.80 (1.15, 2.81); 0.01 
1.13 (0.72, 1.77); 0.59 
- 
 
 
1.22 (0.73, 2.03); 0.44 
1.12 (0.64, 1.95); 0.68 
0.74 (0.41, 1.35); 0.33 
1.01 (1.00, 1.02); 0.02 
 
Model 2 
without and 
with 
adjustment for 
age 
 
 
Sexual 
problems 
 
 
 
Stage -2 & -1:  
Stage 1a,b, c:    
Stage +2: 
Age: 
 
1.60 (0.90, 2.87); 0.11  
2.02 (1.13, 3.62); 0.02 
1.82 (0.95, 3.46); 0.07 
- 
1.26 (0.68, 2.32); 0.46 
1.19 (0.59, 2.37); 0.65 
0.82 (0.35, 1.93); 0.65 
1.09 (1.03, 1.16); 
0.005 
 
Model 3 with 
no adjustment 
 
Irritability 
 
 
 
Stage -2 & -1:  
Stage 1a,b,c:    
Stage +2:            
 
 
1.39 (0.86, 2.24); 0.18  
0.88 (0.57, 1.37); 0.58 
1.73 (1.07, 2.80); 0.02 
- 
 
 
  -             -           - 
  -             -           - 
  -             -           - 
 
The reference group is stage -3b, -3a (late reproductive); all models were adjusted for each possible 
confounder i.e. FSH, estradiol, body mass index and age one at a time. Vasomotor symptoms and 
irritability: stages -3b and -3a (n = 194); stages -2 and -1 (n = 123); stages 1a, 1b, and 1c (n = 153); 
stage +2 (n = 133). Sexual problems: stages -3b and -3a (n = 161); stages -2 and -1 (n = 90); stages 
1a, 1b, and 1c (n = 103); stage +2 (n = 72); OR = odds ratio; FSH = follicle-stimulating hormone. Only 
the models in which adjusting for a possible confounder affected the outcomes, are shown 
 
3.4 Discussion 
 
The aims of this study were to examine reproductive aging in black urban South African 
women, and to determine whether STRAW +10 is an accurate and reliable method of 
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staging reproductive aging, as this method has not previously been used in sub-Saharan 
women. The age at which FMP occurred and whether obesity has any effect on the MT or 
has any association with menopause symptoms, especially VMS, were also noted. 
 
3.4.1 STRAW+10 criteria in staging the MT using FSH and E2 as supportive criteria 
 
As suggested by Harlow et al (56), reproductive aging was staged based on reported 
changes in the menstrual cycles of participants. Bleeding pattern definitions as described in 
STRAW+10 were technically complicated and the participants in the pilot study found the 
terminology difficult to understand. Therefore the menstrual history and bleeding change 
related questions used in the final questionnaire were basic, and the interviewer used open-
ended questions to clarify the responses.  This mixed approach to self-reported VMS has 
been recommended in studies and reviews where cultural differences are apparent (123, 
158). The accuracy of menopause staging is strongly dependent on the participants 
understanding of the terms used when asked about bleeding patterns as described by 
Smith-DiJulio et al (77).  Although more than two thirds of the participants had a very low 
educational level and nearly half of the cohort did not understand the meaning of the term 
menopause, the women were able to give reasonably precise information about changes in 
bleeding patterns, such that their reproductive aging could be staged using STRAW + 10 
criteria. This correct staging was confirmed by the FSH and E2 trends. The results showed a 
strong association between the reproductive stages, as described by STRAW+10 and serum 
FSH level, serum E2 level, and age. The two defining endocrine changes that occur during 
the MT are rising FSH levels and falling E2 levels (59, 336). In this study, FSH levels 
increased gradually from the late reproductive stage through the late MT, accelerated rapidly 
around the time of FMP, and reached a plateau during the postmenopause stages. The E2 
levels decreased consistently from the early MT stage to the last postmenopause stage. 
These changes in serum FSH and E2 levels across the MT were comparable with those 
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observed in a large longitudinal investigation of menopause-associated endocrine changes, 
the Study of Women's Health Across the Nation (SWAN) (51). 
 
3.4.2 Age and recall of age at FMP 
The mean age at FMP was lower than that observed in Western women. In SWAN, the 
median age at natural menopause was 51.4 years (64); in a recent European study where 
age at menopause was estimated in 5,288 women, it was 54.0 years (337). When recall bias 
was taken into account, the mean age at FMP in SWEET was 49.0 years. This is similar to 
that of other African studies (273).  A very small study of 88 women in Zaria, Nigeria, 
reported a mean age for FMP of 46.1 years (338).  However, in a larger study of Nigerian 
women (N=402), Ozumba et al reported mean age at FMP at 49.4 years (339), whereas in a 
smaller study of Ghanaian women (N=152), mean age for FMP was 48.05 years (285). 
 
It seems that the number of years since FMP affects accurate recall of FMP among SWEET 
participants; those 3 years or less from FMP reported a mean age at FMP of 49.0 years, 
whereas those who were interviewed more than 9 years after FMP had a reported mean age 
at FMP of 42.0 years.  Hahn et al (69) found that inaccurate recall of FMP increases with 
years since menopause and is greater in women with natural menopause. A study in 
Sweden found that 565 women who first reported age at FMP in 1992 recalled it reasonably 
accurately after nearly 20 years. In a cross-sectional study, Rödström et al (340), suggested 
that recall of age at menopause among women aged 60 years or younger is more reliable 
than recall of age at menopause among women long past menstruation. Other studies have 
also shown that age at menopause is recalled less accurately with increasing time from 
FMP, but none has observed a systematic lowering of the reported age at FMP with 
increasing time from the FMP (69-71, 73).  However, all these studies have involved a 
comparison of recalled age at menopause at two different time points after menopause (i.e. 
to test for reproducibility) compared with the current study where age at FMP was obtained 
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at one time point only. Sievert (75) suggested that the transition into menopause is gradual; 
thus, when women are asked to recall age at FMP, they often have to rely on memory, 
looking back across a long time continuum to recall the exact time of cessation. A limitation 
in the estimation of age at menopause is that this current study was a cross-sectional 
analysis. Age at FMP can be more accurately predicted in longitudinal studies, where the 
participants use menstrual calendars (76). A limitation in the estimation of age at menopause 
is that this current study was a cross-sectional analysis. Age at FMP can be more accurately 
predicted in longitudinal studies, where the participants use menstrual calendars (76).    
 
It is not clear why the women in the current study had poor recall of FMP. A lack of 
understanding about the menopause transition and a poor primary health care system with 
limited access to gynecologists may affect this recall, because these women were not 
questioned about their MT and therefore did not need to recall information about it.  In 
addition, economic status and cultural values on menopause and aging may also have 
played a role in the women in the study. Further examination, as to whether the MT has the 
same level of importance for black urban South African women as it seems to have in 
Western women, is needed.  
 
A strong negative association between level of education and age at FMP was found in 
SWEET participants. This finding differs from other studies, where low levels of education 
are associated with younger age at menopause (64, 341). This association was difficult to 
explain, but the small sample number in this group (n=59) may be a factor; it is possible that 
this association could be explained by a confounding variable that was not measured in the 
study. Another factor that has been shown to modulate age at FMP is smoking status. 
Research has shown that current smoking is associated with earlier age at natural 
menopause (64, 342). The effect of smoking status on age at FMP was not analyzed since 
only 3% of the women in the study were current smokers.  
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3.4.3 BMI and age at FMP 
The reported FMP was significantly lower in women with a BMI less than 25 kg/m2 compared 
with those participants with higher BMI. Akahoshi et al (343) found that higher BMI was 
associated with later menopause unlike SWAN, where Gold et al (64) found that BMI was 
not related to age at natural menopause. However, this negative association between age at 
FMP with BMI was observed in a small sub-sample of the SWEET participants (n=59), and 
needs to be confirmed in a much larger cohort with accurate recall of age at FMP.  
 
3.4.4 Prevalence and severity of menopause symptoms across the MT 
In the current study, the prevalence of severe/very severe VMS was significantly higher in 
very obese women. Data from SWAN also showed a positive association between VMS and 
body fat level (231). Thurston and Joffe (332) found that obesity is a strong risk factor for 
VMS, especially in the late MT and early postmenopause stage. In the SWEET participants, 
VMS was also strongly associated with the early MT, late MT, early postmenopause stage, 
and increased FSH levels. Thurston et al report findings (332) similar to Cray et al (344), 
who found similar results in participants from the Seattle Midlife Women’s Health Study. The 
reproductive staging criteria from STRAW +10 describe VMS in the late MT and early 
menopause (56). Other than VMS, only two other symptoms were strongly associated with 
menopause stage in the SWEET participants: sexual problems and irritability. Sexual 
problems manifested most strongly in the early and late postmenopause stages and were 
associated with age. There was a significant risk of increased irritability in late menopause, 
which is similar to the findings of Rahman et al (345) who also used the MRS to determine 
prevalence and severity of menopausal symptoms in their participants. However, in a similar 
study in Omani women, the association of increased irritability was not significant at this 
stage (102). In the current study, no possible confounders (BMI, age, or FSH level, or E2 
level) weakened the association of irritability with late postmenopause, although increased 
BMI was associated with a higher prevalence and a higher OR for irritability.  Among the 
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symptoms described in the psychological domain of the MRS (depression, irritability, anxiety, 
mental exhaustion), irritability was the only symptom in the cohort, associated with 
menopause stage.  Several studies have shown that there is an increased risk of depression 
and mood problems during the perimenopause (346), but Kornstein et al (347) found that 
irritability was more prevalent in  premenopausal women, whereas postmenopausal women 
were more likely to experience depressive episodes. 
 
The prevalence of VMS reported in the current study for women in the late reproductive 
stage was higher than those in other studies that used the MRS to determine frequency and 
severity. Blumel et al (100) reported a VMS prevalence of 37.1% in the premenopause stage 
in their participants, and a similar prevalence (35.4%) was reported in Malaysian women 
(348), compared to the 55.7% VMS prevalence in the participants. The prevalence of VMS in 
the current study is associated with increased levels of FSH. However, there may also be a 
cultural determinant in the way that women from SWEET describe hot flashes. Many cross-
cultural studies have suggested that there are both biological and cultural determinants in 
describing VMS, and they recommend using a biocultural approach (123, 132). Gold et al 
(333) suggested that vasomotor symptoms are highly associated with menopause stage, 
whereas differences in absolute rates are related to cultural differences. Other studies 
suggested that night sweats and hot flashes be reported and analyzed separately, rather 
than being grouped together as VMS (349). 
  
3.4.5  Effect of HIV-infection on VMS 
No difference was found in the prevalence of menopausal symptoms between HIV-positive 
and HIV-negative women. However, several studies reported that HIV infection is associated 
with increased risk of VMS (335, 350, 351). Boonyanurak et al (257) found that the HIV-
positive women in their study had a high prevalence of hot flushes, but the number of HIV-
positive women in the current study was small (n =86) compared with their sample number 
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(N=268). Therefore, it is possible that the current study had insufficient power to detect 
differences in the prevalence of VMS and other menopausal symptoms between HIV-
positive and HIV-negative women. Although some studies found that HIV infected women 
had younger age at menopause (352), the effect of HIV-infection on age at FMP, could not 
be analyzed,  as the women in the current study became infected or were tested for HIV 
antibodies after FMP. In their comprehensive review of HIV and menopause, Kanapathipillai 
et al (8) suggested that research to date has failed to show that age at menopause in HIV-
positive is younger or older than that in HIV-negative women, and more research is needed. 
The high prevalence of HIV infection found in this study may be a reflection of population 
bias. Thus, a large proportion of subjects refused to have their HIV-status assessed and it is 
therefore possible that those who agreed to be tested may represent a biased sample.	  
 
3.4.6 Study limitations and advantages  
A limitation of this study was its cross-sectional format. However, the sample numbers were 
large, and menopause status was accurately determined.  A further limitation of the present 
research was that English was not the first language of the participants, and although 
interpreters were available, some idiomatic meaning may have been lost in translation (127).  
An additional limitation was that information on HIV status was only available in 58% of the 
participants. A strength of the study was the consistency in interpreting reported information 
on menstrual cycle changes (each participant was interviewed by a single interviewer). 
 
	  
3.5 Conclusions 
 
STRAW+10 is appropriate for staging menopause in resource-limited countries that use 
information on self-reported bleeding criteria, but there is a need for validated interviewer 
questions and simplification of technical terms to improve accuracy. The terminology used 
by STRAW +10 may not be easily generalizable to other groups of women in rural and 
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informal urban settlements. Years since FMP affects accurate recall and is most accurate in 
women less than 4 years from FMP.  In this group, lower education levels are associated 
with older age at FMP, whereas leanness is related to an earlier menopause. Only three 
symptoms (VMS, sexual problems and irritability) are significantly related to menopausal 
stage.  As expected, FSH levels affect the prevalence of VMS across the menopausal 
stages, and obesity is strongly associated with a risk for severe VMS. Longitudinal 
investigations in this group of women are needed to further clarify the issues discussed 
above.  
 
Several of the stated aims of this research, including the usefulness and suitability of using 
STRAW +10 criteria to accurately stage the MT, an understanding of whether changes in 
FSH and E2 levels might be used as supportive criteria in defining MT stage, whether 
obesity and HIV infection have an effect on age at FMP, and menopausal symptoms in black 
urban South African women, have been explored and described in this chapter. The 
research in the following chapter examines the differences in body composition across 
groups of black sub-Saharan African women at different stages of the menopause transition, 
and the relationship between the anthropometric measures and possible modifying 
variables, including hormone levels, menopausal stage and HIV-ART status.  
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4 Body composition in the Study of Women Entering and in 
Endocrine Transition (SWEET): an African perspective  
4.1 Introduction   
The menopause transition (MT) is closely associated with changes in body composition 
including lower bone mineral density (BMD) at many skeletal sites (181), an increase in 
obesity (148), a decrease in lean muscle mass (353), increases in body mass index (BMI) 
(148), and changes in body fat distribution (BFD) (150), particularly increased central 
adiposity (155). Abdominal obesity is a principal risk factor for cardiometabolic disease 
(163). Some studies suggest changes in the abdominal deposition of visceral (VAT) and 
subcutaneous adipose tissue (SAT) during the MT are related to chronological aging (157), 
while others find a strong association with reproductive aging (292), suggesting that central 
adiposity is a result of the changing hormonal milieu (155). Other data show that both may 
explain changes in body adiposity and a decrease in lean muscle mass (sarcopenia) during 
the MT (146).  
 
Obesity is widely prevalent amongst mid-life, black South African women (244).  The data 
from the Study of Women Entering and in Endocrine Transition (SWEET) show a high rate of 
obesity at menopause (68%) (354) and previous investigations have shown that diabetes 
and metabolic syndrome are very prevalent in these women (7). The causes of this are not 
known, but given the strong association between MT and changes in BFD and lean muscle 
mass reported in non-African populations (152), the MT may play a role. The subject of 
central adiposity and its strong association with non-communicable diseases (NCDs) (165), 
the relationship between androgens and VAT deposition during MT (355), and the fall in 
BMD at various skeletal sites observed during the MT is well reported in women from high-
income countries (181) but no such data appear to be available in sub-Saharan African 
menopausal women. A recent study from South Africa demonstrated a strong relationship 
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between lean mass and BMD in African male and female subjects (325). However, it is not 
known whether this relationship occurs across the MT and whether changes in lean mass 
during this period will affect BMD. In addition, the prevalence of HIV infection is high in 
populations of urban, mid-life black South African females (11), but it is not known whether 
this contributes to changes in body composition.  
 
The aims of the study were to determine whether general body adiposity, lean muscle mass, 
BFD and BMD are associated with stages of the MT in these women, and if so, whether this 
association is related to differences in the serum concentrations of follicle stimulating 
hormone (FSH), estradiol (E2), androgens and sex hormone binding globulin (SHBG). An 
additional aim was to determine if HIV-infection and the related antiretroviral therapy 
influenced body composition and hormone levels in mid-life African females.  
 
4.2 Methods 
 
The following methods were used: questionnaires for determining education level, use of 
ART, tobacco and smokeless tobacco (snuff) use, menopausal stage (using STRAW+10 
criteria); assays of serum E2 and FSH, DHEA, DHEAS, testosterone and SHBG levels; 
measurement of HIV status; measurement of waist circumference, weight and height; BMI 
calculated; measurement of body composition (using dual-energy X-ray absorptiometry 
(DXA); measurement of VAT and SAT (using ultrasound).  Each of these methods has been 
fully described in Chapter 2 
 
4.2.1  Statistical analyses 
Data that were not normally distributed (all hormone measures) were log transformed to 
normality before being used in the statistical analyses. These data are presented as median 
(interquartile range) in the tables and text, whilst data with a normal distribution (all 
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anthropometric measures) are expressed as mean ± SD. Continuous variables were 
analyzed across groups using ANOVA and ANCOVA, and paired means were compared 
using Tukeys post hoc test.  Multivariate linear regression analysis was used to identify the 
principal correlates of each of the body anthropometry variables. Independent variables 
included in each model were chosen based on scientific plausibility and correlation with the 
outcome variable in univariate analyses, with p<0.50. Backward, stepwise regression was 
performed. Height, total fat mass and total lean mass were included in all initial regression 
models to reduce the chance of confounding, but exceptions to this were the models for BMI 
(only total lean mass included), total fat mass (only height and total lean mass included), and 
total lean mass (only height and total fat mass included). Collinearity was tested using the 
variance inflation factor (VIF) and variables were excluded if VIF was greater than 10.0. 
Collinearity was present for total, free and bioavailable testosterone and SHBG, and from 
these 4 highly inter-related variables only SHBG and free testosterone could be included in 
the same regression models. Collinearity was also observed for BMI and total fat mass and 
therefore only the latter variable was included in the relevant regression model.  
 
4.3 Results  
4.3.1 Subject characteristics  
Menopausal stage was not determined in 112 women due to hysterectomy (n=47), 
contraceptive use (n=64) and unknown reason (n=1). Participants in each stage were as 
follows: late reproductive (n=194); early and late menopausal transition (n =122); early 
postmenopause (n=144) and late postmenopause (n=130) (Figure 4.1).  
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Figure 4.1 Diagram showing menopause staging groups for SWEET participants 
 
The characteristics of this study population have been reported previously (11). However, a 
brief overview of this population will be provided here, as this is relevant to the current study. 
Thus, obesity was highly prevalent at 67.8%, with a mean BMI (±SD) of 33.4 ± 7.32. The 
mean age (±SD) was 49.2 ± 5.29 years, and was much higher (p<0.0005) in the 
postmenopausal than the premenopausal groups (Table 4.1). Amongst the participants, 404 
knew or agreed to have their HIV status measured and 21.3% were HIV positive, of whom 
55.3% were receiving antiretroviral therapy (ART). Table 4.1 shows that HIV-positivity was 
less common in the group at menopause stage +2 than at menopause stage -3b, -3a 
(p<0.05). The use of ART did not differ significantly between the menopausal stages (Table 
4.1). Within the study cohort 30% had finished high school, as previously reported (354), the 
employment level was 57% and 20.9% of the participants were snuff users.   
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Table 4.1 Age, HIV status and ART use, and anthropometric measurements across 
menopausal stages 
 
Anthropometric variables 
Menopausal stages (from STRAW+10) and n’s 
P-value 
for trend -3b & -3a 
n = 194 
-2 & -1 
n = 122 
1a, 1b & 1c 
n = 144 
+2             
n = 130 
Age (years) 45.1 ± 3.30 48.3 ± 3.75 51.8 ± 3.86 55.3 ± 3.50 <0.0005 
HIV infection (%)a 28.8 24.2 17.3 14.8 0.02c 
ART use (%)b 59.4 50.0 57.1 69.2 NSd 
BMI (kg/m2) 33.5 ± 7.64 34.5 ± 8.03 33.4 ± 7.28 32.0 ± 6.32 0.06 
Waist (cm) 99.3 ± 14.9 101 ± 16.3 99.6 ± 14.8 98.3 ± 12.6 0.60 
Hip (cm) 118 ± 15.7 120 ± 15.8 119 ± 16.4 116 ± 13.2 0.22 
Visceral fat (cm2) 94.4 ± 40.6 97.7 ± 42.8 96.3 ± 38.9 89.4 ± 34.3 0.35 
Subcutaneous fat (cm2) 400 ± 134 408 ± 133 395 ± 121 367 ± 109 0.05 
Arm fat (kg) 3.77 ± 1.31 3.88 ± 1.38 3.68 ± 1.19 3.70 ± 1.24 0.61 
Arm lean (kg)  4.62 ± 0.86 4.48 ± 0.95 4.31 ± 0.83 4.29 ± 0.70 0.001 
Leg fat (kg) 14.3 ± 5.00 14.2 ± 4.49 14.1 ± 4.75 14.0 ± 4.48 0.97 
Leg lean (kg) 16.1 ± 2.88 15.6 ± 3.19  15.2 ± 3.01 15.1 ± 2.38 0.007 
Trunk fat (kg) 14.3 ± 5.09 15.1 ± 5.54 14.6 ± 5.14 14.2 ± 4.88 0.55 
Trunk lean (kg) 22.4 ± 3.39 22.1 ± 3.84 21.2 ± 3.39 21.3 ± 2.93 0.003 
Whole body fat (kg) 32.3 ± 10.4 33.2 ± 10.3 32.4 ± 10.3 32.0 ± 9.63 0.82 
Whole body lean (kg) 43.2 ± 6.74 42.2 ± 7.68 40.7 ± 6.93 40.7 ± 5.62 0.002 
Whole body BMD (mg/cm2) 935 ± 77.9 931 ± 80.5 889 ± 77.6 866 ± 76.2 <0.0005 
Whole body BMC (g) 1702 ± 232 1661 ± 247 1566 ± 242 1539 ± 232 <0.0005 
Data expressed as percentage or mean ± SD; BMD = bone mineral density, BMC = bone mineral 
content, NS = non-significant; a subject numbers per menopausal stage who agreed to an HIV test 
were 111, 66, 81 and 88 respectively; b subject numbers per menopausal stage who were HIV-
positive were 32, 16, 14 and 13, respectively; c p-value from χ2 test for menopausal stage -3b, -3a 
versus stage +2; d using the χ2 test no differences were noted in frequency of ART use across the 4 
groups 
 
 
 
4.3.2 Anthropometric variables and menopause transition stages  
Anthropometric measurements (Table 4.1) show a trend of lower BMI  (p=0.06) and SAT 
(p=0.05) in females in the postmenopausal groups, whilst whole body lean mass (p=0.002), 
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and lean mass at all body sites were lower. Whole body BMD and BMC were significantly 
lower in the postmenopausal groups (p<0.0005 for both).    
 
4.3.3 Hormone levels and menopause transition stages 
 
As expected E2 levels were lower (p<0.0005) and FSH (p<0.0005) levels were higher in the 
postmenopausal groups (Table 4.2). These data are shown in detail in a previous publication 
(354). Both SHBG and DHEAS respectively, were significantly lower (p<0.0005 and 
p=0.007) in the postmenopausal groups.  
 
 
Table 4.2 Hormone concentrations across menopausal stages 
  
Hormones 
Menopausal stages (from STRAW+10) 
P-value 
for trend -3b & -3a 
n = 194 
-2 & -1 
n = 122 
1a, 1b & 1c 
n = 144 
+2             
n = 130 
 
Estradiol (pmol/L) 
 
315 (369) 130 (362) 63.0 (74.0) 20.0 (52.0) <0.0005 
 
FSH (IU/L) 
 
7.55 (7.80) 26.2 (52.4) 57.6 (41.7) 67.7 (25.9) <0.0005 
 
Total T (pmol/L) 
 
650 (430) 610 (410) 612 (340) 595 (460) 0.18 
 
Bioavail. T (pmol/L) 
 
256 (155) 255 (133) 267 (128) 254 (138) 0.88 
 
Free T (pmol/L) 
 
10.0 (6.79) 10.3 (5.56) 10.3 (4.59) 10.1 (6.52) 0.74 
 
SHBG (nmol/L) 
 
61.0 (33.8) 52.2 (36.3) 49.7 (28.1) 50.3 (28.3) <0.0005 
DHEA (ng/ml) 
 2.90 (2.80) 2.50 (2.50) 2.50 (3.30) 2.45 (3.20) 0.73 
 
DHEAS (µmol/L) 
 
1.40 (1.40) 1.30 (1.00) 1.10 (1.10) 0.95 (1.00) 0.007 
Data expressed as median interquartile range (IQR); T= testosterone, and Bioavail = bioavailable 
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4.3.4 Effect of HIV on anthropometric and hormonal variables  
Table 4.3 shows that the groups of HIV-positive, ART-naïve (p<0.05) and HIV-positive, ART-
treated (p<0.0005) women were both younger than the HIV-negative women, and also had 
higher total testosterone (p<0.005 for both groups) and SHBG (p<0.05 and p<0.005 
respectively) levels. The HIV-positive, ART-treated subjects had higher BMI (p<0.0005 and 
p<0.005 respectively), hip circumference (p<0.0005 and p<0.005 respectively), 
subcutaneous fat area (p<0.0005 and p<0.05 respectively), whole body fat (p<0.0005 and 
p<0.05 respectively) and lean mass (p<0.005 and p<0.05 respectively), whole body BMD 
(p<0.05 for both) and BMC levels (p<0.0005 and p<0.005 respectively) and serum DHEAS 
levels (p<0.005 and p<0.05 respectively) than the HIV-negative and HIV-positive, ART-naive 
groups. The HIV-negative group had a higher waist circumference (p<0.0005) and more 
visceral fat (p<0.005) than the HIV-positive, ART-treated group. As shown by ANCOVA none 
of the differences in hormonal levels across the groups were explained by the differences in 
age or anthropometry.  
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Table 4.3 Anthropometric measures and hormone levels according to HIV status and 
therapy 
 
Variables HIV-negative (n=318) 
HIV-positive, ART- 
naïve (n=39) 
HIV-positive, ART-
treated (n=47) 
Age (years) 49.7 ± 5.33 47.6 ± 5.19* 46.3 ± 5.04*** 
BMI (kg/m2) 33.2 ± 6.25††† 33.5 ± 7.88†† 28.8 ± 7.86 
Waist (cm) 99.7 ± 13.4††† 96.7 ± 13.3 91.4 ± 16.1 
Hip (cm) 118 ± 13.2††† 119 ± 16.6†† 109 ± 16.7 
Visceral fat (cm2) 94.3 ± 37.5†† 82.8 ± 36.9 73.5 ± 42.4 
Subcutaneous fat (cm2) 389 ± 106††† 387 ± 137† 315 ± 129 
Whole body fat (kg) 32.8 ± 9.17††† 31.7 ± 9.98† 25.6 ± 12.3 
Whole body lean (kg) 42.0 ± 6.76†† 41.9 ± 7.22† 38.1 ± 6.66 
Whole body BMD (mg/cm2) 911 ± 84.0† 916 ± 77.4† 872 ± 70.8 
Whole body BMC (g) 1634 ± 247††† 1654 ± 228†† 1482 ± 235 
Estradiol (pmol/L) 85.0 (272) 88.0 (322) 116 (306) 
FSH (IU/L) 29.8 (60.2) 41.5 (53.5) 24.5 (60.1) 
Total T (pmol/L) 580 (360) 770 (470)** 760 (600)** 
Bioavail. T (pmol/L) 250 (136) 272 (139) 286 (160) 
Free T (pmol/L) 9.92 (5.66) 11.8 (5.52) 11.2 (7.16) 
SHBG (nmol/L) 51.6 (36.5) 67.9 (34.2)* 77.1 (56.3)** 
DHEA (ng/ml) 2.40 (2.30) 2.40 (2.30) 2.20 (1.60) 
DHEAS (µmol/L) 1.20 (1.00)†† 1.10 (1.0)† 0.80 (1.00) 
Data expressed as mean ± SD or median interquartile range (IQR); BMD = bone mineral density, 
BMC = bone mineral content, T = testosterone, and Bioavail = bioavailable; *p<0.05, **p<0.005, 
***p<0.0005 vs HIV-negative; †p<0.05, ††p<0.005, †††p<0.0005 vs HIV-positive with ART; all analyses 
adjusted for age  
 
 
4.3.5 Correlates of anthropometric variables  
In the univariate analyses preceding multiple regression (Table 4.4), age correlated 
significantly only with visceral fat (r=0.08, p=0.04).  Models 1 and 2 show that ART use and 
SHBG have negative relationships with BMI and total fat mass, whilst DHEAS serum levels 
show a negative correlation with total fat mass only. Total lean mass correlated with BMI and 
total fat mass, whilst height correlated negatively with total fat mass. Model 3 demonstrates 
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that levels of FSH and SHBG correlate negatively with total lean mass, whilst DHEAS 
correlated positively. Height and total fat mass also correlated with total lean mass. The FSH 
levels also correlated negatively with BMI (outcome variable) in a univariate regression 
model (β=-1.26, p=0.006) but this relationship was severely attenuated (β=0.43, p=0.15) if 
total lean mass was included as an independent variable. Models 4 and 5 show that women 
with a high school education, compared to those who did not, have a smaller waist 
circumference and less visceral fat. A negative effect of employment and serum SHBG 
levels is observed for both variables, and a positive effect of age and snuff use on waist and 
visceral fat area respectively, was noted. Model 6 demonstrates a positive correlation of 
serum DHEA levels with subcutaneous adipose area. Height (negatively), total fat and total 
lean mass all correlated significantly (p<0.0005) with waist, visceral and subcutaneous fat 
area. Model 7 shows that total BMD displayed a negative but weak relationship with SHBG 
and positive correlations with E2 and DHEAS. BMD was lower in the postmenopausal 
stages of the MT when compared to the late reproductive stage, and was significantly 
reduced in women who used snuff when compared to those who did not. Total lean mass 
correlated strongly with BMD. In regression model 8, total BMC was shown to correlate 
negatively with ART use and positively with serum E2 levels. Height and total lean mass 
both correlated strongly with BMC.   
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Table 4.4 Multivariate regression models for anthropometric measures 
 
Model 
number Dependent variable 
Independent variable with 
unstandardised β (p-value) 
Adjusted  R2 (p–
value) for full model 
1 BMI (kg/m2) 
Lean mass            0.68 (<0.0005) 
0.64 (<0.0005) Use of ART          -1.49 (0.02) 
SHBG (log)          -1.71 (0.04) 
2 Total fat mass (kg) 
Height                 -0.12 (0.04) 
0.60 (<0.0005) 
Lean mass            1.13, (<0.0005) 
Use of ART          -2.92 (0.008) 
SHBG (log)         -3.29 (0.02) 
DHEAS (log)       -1.61 (0.04) 
3 Total lean mass (kg) 
Height                   0.29 (<0.0005) 
0.64 (<0.0005) 
Fat mass               0.42 (<0.0005) 
FSH (log)             -1.65 (<0.0005) 
SHBG (log)          -2.19 (0.003) 
DHEAS (log)         1.06 (0.005) 
4 Waist (cm) 
Height                  -0.31 (<0.0005) 
0.70 (<0.0005) 
Fat mass               0.60 (<0.0005) 
Lean mass            0.86 (<0.0005) 
SHBG (log)          -5.05 (<0.0005) 
Employed            -1.44 (0.02) 
Age                       0.15 (0.009) 
Graduated HS     -1.77 (0.008) 
5 Visceral fat (cm2) 
Height                  -0.51 (0.007) 
0.46 (<0.0005) 
Fat mass               1.11 (<0.0005) 
Lean mass            2.32 (<0.0005) 
SHBG (log)         -17.9 (0.0007) 
Employed            -5.37 (0.02) 
Graduated HS     -7.02 (0.006) 
Take snuff             6.66 (0.02) 
6 Subcutaneous fat (cm2) 
Height                  -6.64 (<0.0005) 
0.91 (<0.0005) 
Fat mass               7.16 (<0.0005) 
Lean mass            6.37 (<0.0005) 
DHEA (log)          12.7 (0.003) 
7 Total BMD (mg/cm2) 
Lean mass            4.79 (<0.0005) 
0.33 (<0.0005) 
SHBG (log)        -31.5 (0.05) 
DHEAS (log)       16.1 (0.01) 
Estradiol (log)     20.0 (0.002) 
Stage 1a,1b,1c   -20.2 (0.01) 
Stage 2               -37.9 (<0.0005) 
Take snuff          -14.6 (0.04) 
8 Total BMC (g) 
Height                   9.65 (<0.0005) 
0.59 (<0.0005) 
Lean mass          20.6 (<0.0005) 
Estradiol (log)     69.5 (<0.0005) 
Use of ART        -78.8 (0.003) 
Variable coding: employed were compared to unemployed subjects, those who used snuff were 
compared against those who did not and subjects who used ART were compared with those who 
were ART naïve; subjects who attended but did not graduate and subjects who graduated high school 
(HS) were compared with those who did not attend; for menopausal stages, stage -3b with -3a was 
used as the reference group.  
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4.3.6 Investigation of explanatory anthropometric variables across different 
menopause transition stages  
Differences across the MT observed for lean mass, BMD and BMC, which were analyzed 
using ANOVA (Table 4.1), were further analyzed using ANCOVA to determine which 
variables may confound these results. Variables correlating with lean mass, BMD and BMC 
in the regression models (Table 4.4) were likely to be possible confounders and these were 
used as co-variates in the ANCOVA, with menopausal stage used as the grouping variable 
and lean mass and BMD as the dependent variables. The ANCOVA for lean mass 
demonstrated that including FSH as a co-variate dramatically reduced the unadjusted F-
value for the grouping variable from 4.90 (p=0.002) (Table 4.1) to 0.05 (p=0.98). The 
ANCOVA for BMD showed that including E2 as a co-variate reduced the unadjusted F-value 
from 25.2 (p<0.0005; (Table 4.1)) to 7.89, but with no major lessening of significance 
(p<0.0005). With regards to BMC, the unadjusted F-value (F=15.5, p<0.0005; (Table 4.1)) 
was reduced by including ART use (F=7.77, p<0.0005) or estradiol (F=5.31, p=0.001), but 
including both variables in the same ANCOVA had a far more dramatic effect (F=1.89, 
p=0.13). Adjusting for other co-variates in any of the three ANCOVAs had minimal effects. It 
is possible that the relationships between hormones and body composition are bi-directional 
and therefore to test this hypothesis an ANCOVA was performed in which the dependent 
variable was FSH or E2 and the co-variate was lean mass or BMD, respectively. An 
ANCOVA with E2 as the dependent variable and BMC as the co-variate was set up. These 
analyses (data not shown) showed that the presence of lean mass, BMD or BMC as a co-
variate had minimal effects on the F- or p-values within these ANCOVAs, suggesting that the 
relationships are unidirectional with body composition being influenced by hormone levels 
and not vice versa.   
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4.4 Discussion  
This is the first study to analyze body composition and hormone levels during the MT in sub-
Saharan black African females. This cross-sectional study, demonstrates that within this 
population group, and as shown previously in other populations, significant relationships 
exist between hormone levels and body adiposity, BFD (204), lean mass (356) and skeletal 
measures (357). However, despite these relationships minimal differences were observed 
between the MT groups in body adiposity or BFD, whilst lean mass and skeletal measures 
(BMC and BMD) were significantly lower in the postmenopausal compared to the 
premenopausal groups. With regards to hormone levels, FSH was higher, and E2, SHBG 
and DHEAS were lower, in post- compared to premenopausal women.  
   
4.4.1 Body composition and the menopause transition  
There was a tendency (p=0.06) for BMI to be lower in the postmenopausal than the 
premenopausal women in the cohort. This is in contrast to a large longitudinal multi-ethnic 
study in the USA found an increase in BMI across the MT (358), as did a sizeable European 
cross-sectional study (359). A multi-ethnic cross-sectional survey found, after adjusting for 
age, that women with natural menopause did not have increased BMI compared to 
premenopausal women (360), and some longitudinal studies found no difference in BMI 
between pre- and postmenopausal women, although differences in BFD with reproductive 
aging were noted (9). Thus, data from various studies, both longitudinal and cross-sectional, 
have produced conflicting results with regards to the change in BMI observed across the MT. 
This may be due to differences in study methodology, sample size and lack of adjustment for 
possible confounding variables. Also these conflicting results may be caused by cross-
sectional period effects versus longitudinal changes in women in cohort studies, 
Furthermore, there may be ethnic differences in the response of adipose tissue to the 
changing metabolic and hormonal milieu that is characteristic of the MT, and this requires 
further detailed investigation. Mauriége et al (361) found a fall in SAT levels across the MT, 
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as was found in the current study, although the effect was quite small (p=0.05). As shown in 
the SWAN study (166), no effect of the MT on BFD and waist circumference was found in 
the SWEET participants, although other investigators have found an association (155). It 
was observed that lean mass was lower at all body sites in the postmenopausal groups in 
the current study, which has been observed previously in several studies (9, 146, 184), 
although this was not found in one small cross-sectional study (152). Bone mineral density 
and BMC were both lowest in the postmenopausal groups in the current study, a trend that 
has been observed in a number of other studies (362).   
 
4.4.2 Hormone levels, the menopause transition and HIV infection  
As expected, the results showed a trend of significantly higher FSH and lower E2 serum 
levels when moving from pre- to postmenopausal groups. While no difference was found 
across the subject groups in concentrations of total or bioavailable testosterone, or DHEA, 
levels of both SHBG and DHEAS were significantly lower in the postmenopausal women.  
These results are similar to data from the longitudinal Melbourne Women’s Midlife Health 
Project, which found that SHBG decreased, whilst levels of total testosterone did not change 
across the MT (53). However, not all studies have shown a fall in SHBG levels across the 
MT (363). It was observed that DHEAS was lower in the postmenopausal groups in the 
present study, but there was a transitory rise in the late menopausal transition group; these 
results mimic those described in a large longitudinal study (52), although this was not shown 
in another large cross-sectional study (363). 
 
The prevalence of HIV-infection was lower in postmenopausal than premenopausal females, 
which is probably a consequence of the age difference between these groups. The 
frequency of use of ART did not differ between the different stages of the MT as defined 
using the STRAW+10 criteria. 
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The data found that total testosterone and SHBG levels were higher in HIV-infected than 
non-infected women, irrespective of ART. A previous study has shown that SHBG levels are 
higher but total testosterone levels are lower in HIV-positive, premenopausal women (364), 
but there are no data on androgen levels for HIV-infected, menopausal or postmenopausal 
women. These findings must therefore be confirmed in future studies. The present study 
demonstrated lower DHEAS levels in HIV-positive women receiving ART than in both HIV-
negative and HIV-positive, ART-treated women. There is no comparable data on the effect 
of ART on DHEAS levels in menopausal women.   
 
4.4.3 Age and body composition  
Within univariate analyses, the only variable correlating with age was visceral fat, and this 
relationship was lost after inclusion in a multiple regression model. The reason for the lack of 
association between age and adipose tissue measures may be that adiposity (as measured 
using BMI) in black South African women aged 40-60 years is fairly static, as described in a 
large nationwide health survey (244).  
 
4.4.4 Relationship between hormone levels and body composition  
The current study demonstrated that levels of SHBG were negatively correlated with a 
number of anthropometric variables, confirming data from other studies showing 
relationships of SHBG with BMI, total fat mass, lean mass, waist (355) and VAT (154). The 
negative relationship observed between SHBG levels and BMD in this study, has been 
described previously (357).  
 
The data showed a positive association of DHEAS with lean mass and BMD, and a negative 
relationship with fat mass, although this relationship was quite weak (p=0.04). This finding 
differs from that of a small, multi-ethnic cohort which showed that although DHEAS levels 
were lower in postmenopausal women, they were not associated with body adiposity (240). 
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As with the current study’s findings, results from SWAN show that DHEAS levels are 
negatively associated with BMI (365) and these data confirm the association between BMD 
and DHEAS found in a large longitudinal study (366).  
 
The research identified a strong inverse association between FSH levels and total lean 
mass, as observed in previous studies (146, 367). A large longitudinal study showed a 
negative correlation between BMI and serum FSH levels in menopause (365), however, total 
lean mass was not reported in this study. The current study showed that a significant 
negative relationship between BMI and FSH exists but is rendered non-significant with the 
addition of lean body mass to the regression model. The negative association between FSH 
and lean mass is currently not fully understood. It is hypothesized that FSH may be related 
to lean mass through an indirect mechanism since there appears to be no evidence that 
FSH receptors exist in lean tissue.  
 
4.4.5 Education, ART and snuff and body composition  
There appears to be little research on the relationship of waist circumference with levels of 
education and employment in subjects during the MT. Donato et al found no association 
between educational level and waist circumference in menopausal females (155), but a large  
European study agreed with the present study’s findings, showing a negative association 
between waist circumference and education levels (368). The data from both ANOVA and 
multiple regression analysis demonstrate a negative relationship of ART with both total body 
fat and BMC in the current study. In a recent systematic review of the lipodystrophic effects 
of ART it was shown that the use of antiretroviral agents is associated with lipoatrophy, and 
thus lower BMI (267). Studies have also shown that ART is associated with reduced bone 
mass (369). It has also been shown that ART-naive women with HIV experience decreases 
in bone density (272), but this was not observed in the current study. Amongst the 
participants, snuff use was significantly associated with lower BMD and elevated visceral fat 
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area. Snuff use is prevalent among black South African women, and nicotine in popular snuff 
brands used by these women appears to be very high (255) and potentially more detrimental 
to bone health than snuff products used in other countries. Lower BMD was shown with 
combined use of cigarettes and snuff in black South African women (252) and data from a 
small cross-sectional study (370) suggested smokeless tobacco use may be an additional 
risk for decreased BMD. Snuff use has been linked to increased obesity and thus may 
increase risk of metabolic syndrome (254), and it has also been observed that smoking 
increases abdominal girth (249). Therefore, it is plausible that nicotine-laden snuff may have 
an effect on visceral fat.  
 
As reported earlier, levels of DHEA correlated positively with subcutaneous fat area in the 
participants. No other studies appear to have analyzed the relationship between 
subcutaneous fat area and DHEA levels during the MT. However, one Italian study 
performed in 28 premenopausal females did show a negative relationship between serum 
DHEA levels and subcutaneous fat measures (371). Further studies are required to fully 
investigate the effect of DHEA on body fat distribution during the MT. Estradiol levels in the 
current study correlated positively with BMC and BMD, as observed in other studies (181), 
and statistical analyses suggested that the fall in both bone measures observed across the 
MT groups may be related to the decline in E2 levels. It is well recognized that E2 plays an 
important role in bone maintenance through effects mediated by bone estrogen receptors 
(372). The data further showed, in multiple regression models and ANCOVA, that BMD 
correlates strongly with menopause stage independently of other variables, suggesting that 
factors in addition to E2, but not measured in this study, may be involved in BMD differences 
across the MT.  
 
The relationship between hormones and body composition during the MT is complex. It is 
uncertain whether differences in adiposity are driven by an altered hormonal milieu or vice 
versa, although recent longitudinal data from SWAN suggest that alterations in body fat 
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modulate hormone levels (373). However, testosterone and E2 receptors are expressed in 
adipocytes (204), thus the subcellular machinery necessary for sex steroids to influence 
adipose tissue deposition is in place. Within the present study, body adiposity appeared to 
fall instead of rising across the MT groups, in the face of lower E2 levels. The cross sectional 
nature of the study allows associations to be noted, but does not allow the causal direction of 
these relationships to be determined, however ANCOVA showed that differences in BMD 
and lean mass across the MT groups are strongly related to serum levels of E2 and FSH, 
respectively, and these relationships are unidirectional. These are only statistical 
relationships and should be verified in longitudinal studies.   
 
4.4.6 Study limitations and advantages  
A limitation of this study was its cross-sectional format. However, the sample numbers were 
large, and menopause status was accurately determined (354). Another limitation was the 
inability to collect serum samples during the follicular stage of the menstrual cycle (days 2- 
5) in premenopausal women. However, ovarian function becomes progressively more 
dysfunctional in the late reproductive and early menopause transition stages (50), making it 
more difficult to determine the follicular stage, so timing of E2 assessment may become less 
important. In spite of the fact that a timed serum sample was not obtained, women in the 
early stages of the MT were characterized by much higher levels of E2 and much lower 
levels of FSH than observed in women in the early and late postmenopausal stages, as 
would be expected. An additional limitation was that information on HIV status was only 
available in 58% of the participants. Studies have shown that intra-abdominal fat can be 
accurately measured by ultrasound measurements (374). Although computed tomography 
(CT) scans and magnetic resonance imaging (MRI) are gold standard measurements in 
assessing visceral fat, they are expensive and often unavailable, while results from 
ultrasound have been shown to be highly reproducible (374). The Sodergard equation was 
used to calculate free and bioavailable testosterone (329), which has been shown  to be 
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reliable (375). Immunoassays for testosterone can be compromised by cross reaction with 
related steroids and a lack of sensitivity (376), therefore testosterone levels were measured 
using liquid chromatography-mass spectrometry, which has been shown to be an accurate 
assay method (328). Further positive aspects of this investigation are that the serum levels 
of a wide variety of relevant hormones and a number of anthropometric and demographic 
variables were measured within a menopausal population group for which no such data was 
previously available.   
 
4.5 Conclusions  
In conclusion, the principal body composition outcomes observed in this study were lower 
lean mass, BMD and BMC in post- than in premenopausal women. The lower lean and bone 
mass in the postmenopausal groups may be related to higher levels of FSH and lower levels 
of E2, respectively. Antiretroviral treatment was associated with lower body adiposity and 
BMC whilst snuff use was associated with lower BMD but higher levels of visceral fat. Thus, 
both physiological and environmental factors appear to modulate body composition during 
the MT in this population group. These findings may help to determine whether MT-related 
sarcopenia is associated with changes in cardiometabolic disease risk factors. This research 
has implications for the use of behavioral interventions to lower morbidity and mortality in 
this population group. Exercise programs to help maintain lean mass and reduce adiposity 
and an education campaign to explain the health risks associated with snuff use may be 
beneficial. In addition, recommendations for the use of ART regimens with a more bone 
sparing effect may be considered 
 
 
The differences in body composition across groups of black sub-Saharan African women at 
different stages of the menopause transition and the relationship between these 
anthropometric measures and possible modifying variables have been explored and 
described in this chapter. The prevalence of the MetS, the level of its individual components, 
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and associated metabolic factors at different stages of the MT in these women, and factors 
that play a role in modulating the levels of these variables, are examined in Chapter 5.  
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5 Reproductive aging and associated hormonal changes are 
related to metabolic syndrome and cardiovascular disease risk 
factors in menopausal African women 
5.1 Introduction 
Research suggests that the metabolic syndrome (MetS) increases the risk of cardiovascular 
disease (CVD) (377). Further studies show that the risk of MetS increases in midlife women 
(141), and that heart disease is more prevalent as women transition into menopause (378, 
379). Physiological changes occurring across the menopause transition (MT) stages may 
increase the risk of MetS, although other studies have shown that aging attenuates the 
association of reproductive aging with the MetS (139). These findings are predominantly 
derived from studies of Western women, but whilst investigations have shown that obesity is 
prevalent in midlife black South African women (244, 354), and that they are at risk for both 
MetS and heart disease in middle age (5, 7), this has not, except in a small Ghanaian study 
(274, 380), been studied in relation to the menopause transition in sub-Saharan African 
women. 
 
Research shows that several factors may be responsible for the increased risk of MetS in 
midlife women. Some data show that menopausal status, may increase this risk (135), while 
data from the Study of Women Across the Nation (SWAN), a large longitudinal study,  
showed that 13.7% of a cohort of 949 women had MetS at the time of the final menstrual 
period (FMP), but suggested that this risk seemed to lessen after FMP (110). Studies have 
shown that the individual components of the MetS i.e. high-density lipoprotein (HDL) (381), 
triglycerides (9), glucose levels (382), blood pressure (383), and waist circumference (384) 
do change across the MT, leading to an increased prevalence of the MetS. Hormonal 
changes across the MT, including those of the adipose tissue-derived hormones leptin and 
adiponectin, may also be associated with a higher risk of MetS (193, 385). Data from SWAN 
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showed that an increasing androgenic milieu, as defined by the ratio of testosterone to 
estrogen, across the MT appears to predispose women to an increased risk of MetS (189). 
In terms of changes in body anthropometry that occur during the MT, a study has shown that 
changes in visceral fat may drive the increased risk for MetS in midlife women (240). In 
addition, lean mass has been shown to fall across the MT (354), and research has shown 
that sarcopenia, a combination of low lean mass and obesity, may also be related to 
metabolic disease (133, 172). 
 
As described above, data suggest that changes in metabolic, hormonal, and anthropometric 
parameters across the MT may increase the risk of metabolic disease in midlife women. 
Therefore, the aims of this research were to: (i) determine the prevalence of metabolic 
syndrome, its individual components and related metabolic disorders; (ii) to measure the 
levels of these variables across the MT groups; and (iii) to determine the principle correlates 
of these cardiovascular risk factors in a population of midlife, urban African women for whom 
accurate menopausal staging was available.   
 
5.2 Methods  
The following methods were used: questionnaires for determining education level, use of 
ART, tobacco and smokeless tobacco (snuff) use, menopausal stage (using STRAW+10 
criteria), and frequency and severity of menopausal symptoms (using the MRS); assays of 
serum E2 and FSH, DHEA, DHEAS, testosterone, SHBG, lipids and blood glucose levels, 
leptin and adiponectin levels; insulin resistance calculated; blood pressure recorded; 
measurement of HIV status; measurement of waist circumference, weight and height; BMI 
calculated; measurement of body composition (using dual-energy X-ray absorptiometry 
(DXA); measurement of VAT and SAT (using ultrasound).  Each of these methods has been 
fully described in Chapter 2  
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5.2.1 Statistical analyses  
Normally distributed data are expressed as mean ± SD in the text and tables, whilst data that 
is not normally distributed are expressed as median [interquartile range].  The latter data 
was log transformed to normality before being analyzed. 
 
The principal correlates of all the metabolic variables, and blood pressure, were isolated 
using univariate correlation analyses (Pearson test) for continuous variables and ANOVA for 
categorical variables followed by backward, stepwise linear regression analyses. The 
independent variables included in the regression models were those that correlated with the 
dependent variable at p<0.50 in the univariate analysis. Only scientifically plausible variables 
were used in the initial univariate analyses. Collinearity was tested using the variance 
inflation factor (VIF) where any variable with a VIF>10.0 was excluded from the regression 
model. Total, free and bioavailable testosterone, and SHBG were highly collinear and from 
these 4 variables only SHBG and free testosterone could be included in the same regression 
models. Within the multivariate regression models menopausal stage was defined as pre- or 
post FMP as this produced more significant effects than using the four STRAW+10 groups. 
Collinearity between the anthropometric variables was minimal as was that between 
menopausal stages and FSH and E2 levels (VIFs<3.0). 
 
Mean values were compared across the four STRAW+10 menopause groups or between 
pre- (STRAW+10 groups -3a, -3b, -2 and -1) and post FMP (groups 1a, 1b, 1c and 2) 
women using ANOVA or Students t test respectively, whilst categorical data was analyzed 
using the χ2 test. If significant trends were detected in the ANOVA, an ANCOVA was 
performed using as a co-variable any independent variable that correlated significantly with 
the respective dependent variable in the multiple regression models described previously. If 
more than one co-variable was used, each one was added to the ANCOVA on its own.   
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5.3 Results 
5.3.1 Description of the study cohort  
The mean age of the participants (±SD) was 49.2 ± 5.29 years. Reproductive aging could 
not be staged in 15.9% (n=112) of the participants due to hysterectomy (n=47), 
contraceptive use (n=64), and reason not known (n =1) (Figure 3.1). There was a high 
prevalence of obesity at 67.8% and the mean BMI was 33.4 ± 7.32. Mean waist 
circumference was 99.1 ± 14.6 cm. Amongst the 404 women who knew or agreed to have 
their HIV status measured, 21.3% (n= 86) were HIV positive and of those, 55.3% (n=47) 
were receiving antiretroviral therapy (ART). Within the study cohort, 8.0% of the participants 
described themselves as previous or current smokers and 20.9% of the women used snuff. 
With regards to menopausal symptoms, 60.1% of the women had vasomotor symptoms 
(VMS), while 61.7% were experiencing sleep problems. The data on educational status 
showed that 12.3% of participants had only completed junior school while 30% had finished 
high school, and 57% had attended high school but did not graduate.  
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Table 5.1 Prevalence of diabetes, metabolic syndrome* and  
related disorders 
 
Disorder N Prevalence (%) 
Diabetes 
(fasting glucose ≥7mmol/L)  643 8.86 
Impaired fasting glucose 
(≥5.6mmol/L) 643 7.62 
High waist 
(>80cm) 698 89.7 
Hypertension  
(SBP ≥130 and/or DBP ≥85mmHg)  686 65.0 
Hypertriglyceridemia 
(≥1.7mmol/L) 651 15.4 
Low HDL 
(<1.3mmol/L) 651 59.7 
Elevated LDL 
(≥3.0mmol/L) 649 36.4 
Hypercholesterolemia 
(≥5.0mmol/L) 649 29.9 
Metabolic syndrome 645 49.6 
* Metabolic syndrome is defined in the SWEET study using the harmonized 
guidelines (fully described in 1.7.1) 
 
5.3.2 Prevalence of metabolic disorders  
Table 5.1 summarizes the prevalence of diabetes, MetS and related disorders in the cohort. 
The prevalence of impaired fasting glucose and diabetes was 7.6% and 8.9% respectively 
(16.5% combined), and MetS was high at 49.6%. The most common components of the 
MetS were high waist circumference (89.7%), hypertension (65.0%) and low HDL levels 
(59.7%). Hypercholesterolemia was highly prevalent (29.9%), as was the presence of high 
LDL levels (36.4%), whilst hypertriglyceridemia (15.4%) was less common.   
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5.3.3 Trends across menopausal stages 
Table 5.2 describes the level of metabolic variables and the prevalence of MetS at each 
stage of the MT, with the stages of menopause defined using the STRAW+10 guidelines 
(56). There was some evidence for glucose levels to be higher in the post- than the 
premenopausal group  (F=2.65, p=0.05), but this was not observed for HbA1c and HOMA 
levels. In an ANCOVA, adjustment for age caused the trend for increasing glucose levels to 
become non-significant (F=0.89, p=0.44). Both levels of total cholesterol and LDL became 
significantly higher (F=8.05 and 7.80, respectively; p<0.0005 for both trends) in the 
postmenopausal groups, with a weaker trend for higher triglyceride levels (F=3.72, p=0.01). 
Within an ANCOVA, adjustment for FSH severely attenuated the trend for higher cholesterol 
levels (F=1.51, p=0.21). This same adjustment in an ANCOVA for LDL also attenuated the 
trend (F=1.58, p=0.19), as did adjustment for age (F=0.43, p=0.73). The trend for higher 
triglyceride levels was not significantly attenuated by any co-variable adjustment. Leptin did 
not vary across the stages of menopause whilst there was a slight trend for serum 
adiponectin levels to become higher (p=0.08). Systolic blood pressure was significantly 
higher in the postmenopausal groups (F=6.43, p=<0.0005) with a weaker trend for higher 
diastolic blood pressure (F=3.83, p=0.01). The ANCOVA for systolic blood pressure 
demonstrated that inclusion of age as a co-variable dramatically reduced the significant 
trend observed in the ANOVA (F=0.60, p=0.62). A similar analysis for diastolic blood 
pressure showed that the inclusion of E2 as a co-variable led to a weakening of the trend 
(F=1.30, p=0.27). There was a tendency for a greater prevalence of MetS across the MT 
stages (p=0.05).   
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Table 5.2 Metabolic measurements and prevalence of metabolic syndrome across 
menopausal stages 
Metabolic variables 
Menopausal stages (from STRAW+10) F-value  
(p-level)a 
F-value  
(p-level)b -3b & -3a 
n = 194 
-2 & -1 
n = 122 
1a, 1b & 1c 
n = 144 
+2             
n = 130 
Glucose (mmol/L) 4.72 ± 0.51 4.84 ± 0.58 4.79 ± 0.49 4.89 ± 0.55 2.65 (0.05) 0.89 (0.44)
c 
HbA1c (%) 5.77 ± 0.64 5.93 ± 0.54 5.82 ± 0.66 5.89 ± 0.67 1.42 (0.23) - 
HOMA 2.08 [1.88] 2.27 [1.78] 1.84 [1.70] 1.99 [1.48] 0.24 (0.87) - 
Cholesterol (mmol/L) 4.26 ± 0.92 4.42 ± 1.02 4.67 ± 1.01 4.80 ± 1.23 
8.05 
(<0.0005) 1.51 (0.21)
d 
LDL (mmol/L) 2.53 ± 0.83 2.67 ± 0.90 2.81 ± 0.85 3.01 ± 0.99 
7.80 
(<0.0005) 
1.58 (0.19)e 
0.43 (0.73)f 
HDL (mmol/L) 1.20 [0.40] 1.20 [0.50] 1.20 [0.45] 1.20 [0.40] 0.37 (0.78) - 
Triglyceride (mmol/L) 1.10 [0.60] 1.00 [0.60] 1.15 [0.65] 1.20 [0.60] 3.72 (0.01) - 
Leptin (ng/ml) 29.3 [33.9] 28.9 [26.7] 27.6 [26.4] 24.2 [23.8] 1.37 (0.25) - 
Adiponectin (µg/ml) 6.67 [6.06] 6.64 [4.71] 7.73 [6.51] 7.32 [5.49] 2.22 (0.08) - 
Systolic bp (mmHg) 129 ± 19.4 135 ± 20.6 137 ± 21.6 139 ± 24.4 
6.43 
(<0.0005) 0.60 (0.62)
g 
Diastolic bp (mmHg) 85.8 ± 12.8 89.0 ± 11.9 89.8 ± 12.1 89.5 ± 12.9 3.83 (0.01) 1.30 (0.27)
h 
Metabolic syndrome 
(%) 42.3 48.6 52.4 53.6 - (0.05)
b - 
Data expressed as median [interquartile range], mean ± SD or percentage; ap-value from ANOVA 
except for bp-value from χ2, stage -3b, -3a versus stage 2; bp-values from ANCOVA with adjustments 
for c,f,gage, d,eFSH  and hE2      
 
 
5.3.4 Multivariable linear regression models  
Table 5.3 shows the multiple linear regression data for the metabolic variables. Model 1 
demonstrates that age and waist circumference correlate positively with levels of glucose, 
whilst levels of adiponectin and SHBG correlate negatively. Model 2 demonstrates 
adiponectin has a negative association with HbA1c levels, whilst age and visceral fat both 
correlate positively.  Model 3 demonstrates that there is a strong positive correlation of both 
lean mass and leptin with HOMA. There was a strong negative association of adiponectin 
and hip circumference with HOMA. Waist and employment (negatively) were weakly 
associated with HOMA. Model 4 shows that women who are HIV positive, but ART naïve 
(n=39) tend to have lower cholesterol levels, whilst FSH levels correlate positively with 
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cholesterol. In model 5, a strong positive relationship of FSH, and a strong negative 
relationship of adiponectin with LDL were observed, whilst age was weakly related. 
Regression model 6 demonstrates that levels of HDL are strongly associated with both 
adiponectin and lean mass (negatively). There was a weak negative relationship of HDL with 
both contraceptive use and the presence of HIV infection. Model 7 shows that triglyceride 
levels correlated positively and strongly with visceral fat, smoking and being post FMP, 
whilst adiponectin, SHBG and DHEAS all associated strongly and negatively with 
triglycerides. Triglyceride correlated negatively with BMI. This was not due to collinearity as 
all independent variables in model 7 had VIFs < 2.00. Removal of visceral fat from model 7 
attenuated the relationship between BMI and triglyceride levels (BMI β=-0.001, p=0.30) 
whilst the removal of any other independent variable had a minimal effect. As seen in model 
8 both age and waist circumference were strongly associated with systolic blood pressure 
whilst there was a weaker relationship with VMS, smoking and employment (negative). 
Model 9 shows that diastolic blood pressure has a strong positive association with waist and 
smoking, and a strong negative relationship with E2 levels. Education was weakly related to 
diastolic blood pressure. 
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Table 5.3  Multivariate regression models for metabolic variables 
 
Model 
number Dependent variable 
Independent variable with unstandardized 
β (p-value) 
Adjusted R2 (p–value) for 
full model 
1 Glucose (mmol/L) 
Age                              0.01 (0.009) 
Waist                           0.005 (0.003) 
Adiponectin (log)        -0.31 (0.0006) 
SHBG (log)                 -0.31 (0.005) 
0.10 (<0.0005) 
2 HbA1c (%) 
Age                              0.02 (<0.0005) 
Visceral fat                   0.002 (0.005) 
Adiponectin (log)         -0.26 (0.02) 
0.06 (<0.0005) 
3 HOMA (log) 
Lean mass                   0.008 (0.001) 
Waist                            0.003 (0.02) 
Hip                              -0.007 (<0.0005) 
Leptin (log)                   0.34 (<0.0005)       
Adiponectin (log)         -0.25 (<0.0005) 
Employment                -0.06 (0.02) 
0.28 (<0.0005) 
4 Cholesterol (mmol/L) FSH (log)                      0.52 (<0.0005) HIV positive                 -0.47 (0.009) 0.08 (<0.0005) 
5 LDL (mmol/L) 
Age                              0.02 (0.01) 
Adiponectin (log)        -0.47 (<0.0005) 
FSH (log)                     0.29 (<0.0005) 
0.08 (<0.0005) 
6 HDL (log; mmol/L) 
Lean mass                  -0.004 (<0.0005) 
Adiponectin (log)          0.15 (<0.0005) 
HIV positive                 -0.05 (0.01) 
Contraception use       -0.04 (0.04) 
0.21 (<0.0005) 
7 Triglycerides (log; mmol/L) 
BMI                             -0.004 (0.002) 
Visceral fat                   0.001 (<0.0005) 
Adiponectin (log)         -0.17 (<0.0005) 
SHBG (log)                  -0.15 (<0.0005) 
DHEAS (log)               -0.05 (<0.0005) 
Smoking                       0.07 (0.008) 
Postmenopausal          0.04 (0.003) 
0.19 (<0.0005) 
8 Systolic bp (mmHg) 
Age                              0.87 (<0.0005) 
Waist                           0.25 (<0.0005) 
Smoking                      6.14 (0.03) 
Employment               -3.28 (0.04) 
VM symptoms              3.96 (0.01) 
0.09 (<0.0005) 
9 Diastolic bp (mmHg) 
Waist                           0.24 (<0.0005) 
Estradiol (log)             -2.58 (0.002) 
Smoking                      4.83 (0.006) 
Education                    1.99 (0.04) 
0.09 (<0.0005) 
Variable coding: employed were compared to unemployed subjects; current and former smokers were 
combined and compared to those who never smoked; HIV-positive subjects who used ART or were 
ART-naïve were each compared with those who were HIV-negative; subjects who attended but did 
not graduate and subjects who graduated high school were each compared with those who did not 
attend; postmenopausal were compared to premenopausal subjects; women who used 
contraceptives were compared to non-users; women who experienced vasomotor (VM) symptoms 
were compared to those who did not 
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5.3.5 Multivariate regression models for metabolic variables 
 
Table 5.4 shows the results of a multiple logistic regression analysis to isolate the major 
correlates of MetS. The model demonstrates that age, BMI, visceral fat, insulin resistance 
and smoking are positively associated with MetS, whilst raised adiponectin levels are 
negatively associated. A univariate logistic regression model demonstrated that being post 
FMP was positively associated with MetS (odds ratio with 95% CIs: 1.40 [1.00, 1.96]; 
p=0.05), and this effect was attenuated only by age (0.79 [0.50, 1.25]; p=0.32).  
  
Table 5.4 Logistic regression analysis for identification of risk factors for metabolic  
syndrome 
 
Categorical variable Independent variables with odds ratio (95% CI’s); p-value 
Presence of metabolic syndrome 
Age                     1.07   (2,15, 1.32); <0.0005 
BMI                     1.05   (1.02, 1.09);   0.003 
Visceral fat          1.007 (1.001, 1.01); 0.03 
Adiponectin         0.95   (0.91, 0.99);   0.008 
HOMA                 1.32   (1.17, 1.48); <0.0005 
Smoking              2.15   (1.11, 4.18);   0.02     
 
 
5.4 Discussion 
Although there is a plethora of research examining the prevalence of MetS, its individual 
components and related metabolic disorders across the MT in Western literature (386, 387), 
there is very little research on this subject in sub-Saharan African (SSA) women, although 
the relationship between metabolic variables and the MT has been studied in Ghanaian 
women (274). The current study is the largest and most comprehensive study of metabolic, 
hormonal and anthropometric parameters ever undertaken in an indigenous sub-Saharan 
African (SSA) population of menopausal females using accurate estimation of menopausal 
staging.  
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5.4.1 Prevalence of diabetes, metabolic syndrome components, metabolic syndrome 
and related factors.  
There was a high prevalence of diabetes in this population, however this may be an 
underestimate as diabetes was diagnosed using fasting glucose levels only, rather than by 
the use of an oral glucose tolerance test. Given the high prevalence of obesity in the study 
population the high frequency of both diabetes and MetS is not unexpected. Hypertension 
was highly prevalent amongst these participants (65%), which has been described 
previously in South African women (6, 7), and appears to be increasing amongst sub-
Saharan African women (388). 
 
Nearly 90% of women in this study had a waist circumference ≥80.0 cm, whilst the 
prevalence of low HDL levels was also very high at 59.7%.  Similar results have been 
observed in other sub-Saharan African studies with raised waist circumference and low HDL 
levels being the commonest components of the MetS (41,42). 
 
The low prevalence of hypertriglyceridemia in this study cohort has also been observed in 
other investigations of the metabolic syndrome in African populations (389, 390). Elevated 
LDL levels and hypercholesterolemia were quite prevalent amongst the women in the study. 
This is an interesting observation because previous studies have noted low serum LDL and 
total cholesterol levels in African women (7, 391) . This difference may be because these 
studies were conducted in younger, premenopausal females and the current study clearly 
demonstrates that rising FSH levels correlate strongly and positively with both LDL and total 
cholesterol serum concentrations.   
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5.4.2 Differences in cardiometabolic variables across the MT stages 
Glucose, triglyceride, total cholesterol, LDL, systolic and diastolic blood pressure were 
significantly higher in post- than premenopausal women as shown by ANOVA, and these 
differences were related to age (glucose, LDL & systolic blood pressure), FSH (cholesterol 
and LDL), and estradiol (diastolic blood pressure). This suggests that differences in 
cholesterol and blood pressure levels across the menopause may be related to hormone 
levels. Previous research has shown an association between FSH and lipid levels in 
premenopausal females (182), and between estradiol and diastolic blood pressure (392). 
The finding that differences in glucose levels are related to age in the current study has been 
confirmed in a retrospective analysis (393), while other research shows that increased levels 
of LDL and systolic blood pressure are also related to age (394). A large longitudinal study 
found that glucose and blood pressure were not related to reproductive aging, but total 
cholesterol and LDL levels were, independent of age (395). However, that study did not 
measure FSH or estradiol levels and therefore could not adjust for their effects. The higher 
triglyceride levels in the postmenopausal females in SWEET were not explained by the other 
variables measured, including age. Similarly, a large longitudinal study has shown that 
triglycerides rose across the MT independent of the effect of age (396). 
 
The MT does not appear to be a risk factor for insulin resistance, as observed in this and 
previous studies (393, 397), though others have shown that it is positively associated (378).  
Leptin levels did not change between pre- and postmenopausal women in this present 
cohort, whilst serum adiponectin levels tended to be slightly higher in the postmenopausal 
groups, which has been seen in other studies (238).   
 
5.4.3 Relationship between anthropometric and cardiometabolic variables  
In this study waist circumference was positively associated with glucose, HbA1c, HOMA, 
and systolic and diastolic blood pressure, visceral fat was positively associated with HBA1c 
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and triglyceride levels and hip circumference was negatively associated with HOMA; BMI 
correlated negatively with triglyceride level. These data suggest that in this population body 
fat distribution rather than total body fat mass is the principle anthropometric correlate of 
cardiometabolic disease risk factors, confirming data from many other studies in pre- and 
postmenopausal females (239). The negative association of hip circumference with HOMA 
suggests that gluteofemoral fat may protect against insulin resistance, a finding supported by 
other studies (398). An unusual finding in the participants was the negative relationship 
between BMI and triglycerides, and the dependence of this relationship on visceral fat. The 
positive relationship between body fat and triglycerides is well described in the literature and 
the reverse phenomenon observed in this investigation may therefore be specific to this 
population and/or may be a result of the unique structure of the regression model used in the 
present study. Further analyses are required to explain these findings. 
 
Lean mass correlated positively with HOMA and negatively with HDL levels in multivariate 
regression models. Previous studies have shown that lean mass is positively associated with 
metabolic syndrome risk, independently of fat mass in a Chinese population (399) and that 
HDL levels correlate negatively with body lean mass (400).These data suggest that the 
assessment of body composition is important for isolating the true anthropometric markers of 
disease risk in this population.  These findings highlight the fact that fat mass is not the only 
relevant anthropometric measure when studying the etiology of cardiometabolic diseases, 
and that the use of variables such as BMI, that do not discriminate between lean and fat 
mass, must be used with caution.   
 
5.4.4 Relationship between adipokines and cardiometabolic variables  
Leptin levels correlated positively with HOMA in the SWEET participants, confirming 
previous studies demonstrating the correlation of leptin with insulin levels (401), and the 
worsening of insulin resistance (206). In the current study adiponectin levels were 
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associated with several metabolic variables and may therefore play an important role in the 
etiology of MetS in this population. As shown in other research studies, adiponectin was 
negatively associated with glucose, HbA1c, HOMA, LDL and triglycerides and positively 
associated with HDL levels (402).    
 
5.4.5 Relationship between hormones and cardiometabolic variables  
The current study shows that SHBG was negatively associated with glucose and triglyceride 
levels. A previous study has shown that in both pre- and postmenopausal obese females 
serum SHBG correlated negatively with glucose levels (403). It has also been shown that 
SHBG correlates negatively with triglyceride levels in postmenopausal females (201). Other 
research has shown that lower levels of SHBG may increase the risk of MetS in menopausal 
women (193).  
 
Cholesterol and LDL but not HDL or triglyceride levels both correlated positively with FSH 
levels in this population of midlife African females. An American study of premenopausal 
females has shown that cholesterol and LDL levels were higher in those with the highest 
FSH levels, but this was not observed for HDL and triglyceride levels (54). These data in 
combination with the ANOVA results described previously strongly suggest that rising FSH 
levels during the menopause may drive the increase in cholesterol levels observed during 
the MT. The molecular mechanisms involved in the association between FSH and 
cholesterol levels are not known.    
 
A negative association was found between triglyceride and DHEAS levels within the current 
study. A similar relationship was observed in a cross sectional study of 217 obese Italian 
women, but this association was not maintained in a multivariable regression analysis (404), 
whilst in another Italian study, DHEAS levels correlated negatively with triglyceride levels in 
women over 90-years-of-age (405).  
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In the present study, estradiol levels were found to correlate negatively with diastolic blood 
pressure. A number of studies have shown similar relationships, and estradiol is known to 
have a vasodialatory effect (61). These results suggest that increasing blood pressure 
across the MT is related to falling estradiol levels, and this is confirmed by the ANCOVA 
results described earlier.    
 
5.4.6 Relationship of HIV and vasomotor symptoms with cardiometabolic variables  
Cholesterol levels were negatively associated with HIV infection in the participants, as were 
HDL levels. Infection with HIV is often associated with reduced HDL, LDL and total 
cholesterol levels (261). In this investigation, higher systolic blood pressure was associated 
with VMS. Increased cardiovascular disease risk has been linked to VMS in previous studies 
(233). However, the mechanisms involved in this association are not fully understood.   
 
5.4.7 Relationship of socioeconomic status, smoking and contraceptive use with 
cardiometabolic variables  
Both HOMA and systolic blood pressure were negatively related to employment status in the 
participants, and in a very large cross-sectional study of Korean women, it was shown that 
employment status was associated with a lower risk of metabolic syndrome (406). Diastolic 
blood pressure was positively but weakly associated with education level in the SWEET 
participants, as has been shown in women from a sub-sample of a large longitudinal South 
African study (407). These current data also showed that smoking was positively associated 
with triglycerides, as described in a population-based study (248), and with hypertension, as 
shown in a very large prospective cohort study (408). In the present study, there was a weak 
negative association between HDL levels and contraceptive use, and data have shown that, 
depending on the formulation, oral contraceptive use may reduce HDL levels (409).  
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5.4.8 Risk factors for metabolic syndrome  
Similar risk factors for MetS, as described in other studies, were found in the SWEET 
participants These were age (139), BMI, visceral fat, HOMA ((410) and smoking (249).  
Lower levels of adiponectin have been shown to increase risk of MetS (411), as also 
observed in the current study. As described in other studies, women in the postmenopausal 
group appeared to be at greater risk for metabolic disease (139), but this effect was 
attenuated with the addition of age to the regression model. While some researchers have 
not found menopause to be a risk factor for MetS (144), others, which include a study 
describing an increased prevalence of MetS in a group of sub-Saharan African women, 
suggested it plays a significant role (380, 395). However, MT was not accurately staged in 
those African women. Although MetS risk in the current study may not be higher in women 
post FMP than those who are pre FMP, individual components of the syndrome are elevated 
in the former group. Thus, triglyceride levels were higher in women post FMP, whilst diastolic 
blood pressure was also higher due to lower estradiol levels. Furthermore, the MetS-related 
factors cholesterol and LDL were higher in postmenopausal women due to high FSH levels.   
 
5.4.9 Study limitations  
A limitation of this study was its cross-sectional design, although the sample number was 
large and menopause stage was accurately verified (354). (354). Another limitation was the 
inability to collect serum FSH and E2 samples during the primary follicular stage of the 
menstrual cycle (days 2- 5) in premenopausal women, but timing of E2 and FSH 
assessment may not be crucial since in the menopause transition stage, ovarian function 
becomes increasingly dysfunctional making it difficult to accurately determine follicular stage 
(50). Despite this, women in the early stages of the MT had much higher levels of E2 and 
much lower levels of FSH than found in women in the early and late postmenopausal stages 
(6). An additional limitation was that information on HIV status was only available in 58% of 
the participants. Another limitation of the study was that the HOMA method to calculate 
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insulin resistance was used rather than the glucose clamp method, which is the gold 
standard (412). However this procedure is both invasive and time consuming (413), making 
it impractical for large population sizes, such as that of this cohort. Furthermore, the HOMA 
method has been shown to be an accurate procedure for assessing the level of insulin 
resistance (414) Computed tomography (CT) scans and magnetic resonance imaging (MRI) 
are gold standard measurements in assessing visceral fat, however they are expensive and 
often unavailable, while results from ultrasound have been shown to be highly reproducible 
(374). A positive aspect of the current study was the wide variety of relevant serum 
hormones that were assessed, and that cardiometabolic, anthropometric, and demographic 
variables were measured in a population group of late reproductive and menopausal 
women, for whom no such data was formerly available.  
 
5.5 Conclusions 
Certain MetS components and related factors were present at higher levels in women post 
menopause and were related to changes in FSH (LDL and cholesterol) and estradiol 
(diastolic blood pressure). These data suggest that the hormonal changes that characterize 
menopause may play a role in the etiology of specific MetS components in this population. 
Furthermore, lower levels of adiponectin were associated with MetS and its individual 
components. Although the association between reproductive and chronological aging and 
MetS is complex, age attenuated the already weak association of the MT with MetS in the 
current study. Thus, within this population the MetS is associated with chronological aging, 
whereas individual components of the syndrome are associated with reproductive aging. 
Lifestyle interventions to reduce obesity, smoking prevention programs and more regular 
monitoring of metabolic risk factors in this group may be useful in lowering cardiometabolic 
risk factors and hence morbidity. Furthermore, a previous study has shown a poor 
understanding of the health consequences of the menopause in this population (6) and 
therefore education programs covering this issue would be appropriate.  
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6 Discussion 
The final chapter of this thesis presents a consolidation of the findings discussed in the 
empirical research found in chapters 3, 4 and 5. Four key objectives were identified (section 
1.11.1) and each will be analyzed and discussed. The relevance of this body of research will 
be examined and a revised conceptual framework will be presented. The relevance of the 
research from a South African perspective will be described, and the generalizability of the 
findings, in relation to other sub–Saharan African countries, will be discussed. The limitations 
and opportunities for future research in this field will be examined, followed, finally, by the 
conclusion.   
 
6.1 Consolidated findings  
The SWEET study aimed to examine the metabolic, anthropometric and hormonal effects of 
the MT in urban black women. These objectives were described in four research questions, 
and the results obtained from studies set up to meet these objectives were described in 
scientific papers in chapters 3, 4 and 5. A summary of these findings is shown in Table 6.1.   
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Table 6.1 Summary of consolidated findings 
 
 
Number 
 
 
Objectives 
 
Main Study Findings 
 
Chapter 
  
1 
To accurately stage 
reproductive aging using 
bleeding patterns and 
assess usefulness of 
STRAW + 10 criteria in 
staging MT in black urban 
South African women, and 
measure FSH and E2 
levels as supportive criteria 
to determine MT stage 
 
• Menopause can be accurately staged 
in black urban African women using 
self-reported menstrual cycle changes  
• Recollected age at FMP difficult to 
assess accurately 
• Serum FSH levels significantly higher, 
and serum E2 levels lower in post- 
compared to premenopausal women 
 
3 
  
2 
To determine whether 
obesity or HIV infection 
has an effect on the FMP 
and menopausal 
symptoms, particularly 
VMS  
• Obesity highly prevalent but not related 
to the MT  
• BMI lower in the post- than 
premenopausal women  
• Age at FMP appears to be related to a 
lower BMI (<25 kg/m2) 
• Prevalence of severe/very severe VMS, 
sleep problems, irritability and joint pain 
significantly higher in obese women  
(BMI>35.0 kg/m2) 
• HIV-positive women did not have worse 
VMS than HIV- negative women  
3 
  
3 
To determine whether 
general body adiposity, 
BFD, lean muscle mass 
and BMD are associated 
with stages of the MT and 
if so what factors may play 
a role in these associations  
• Whole body BMD and BMC 
significantly lower in the 
postmenopausal groups  
• BMI lower in post- than premenopausal 
women in SWEET women 
• Lean mass lower at all body sites in the 
menopausal transition and post FMP 
stages  
• Levels of SHBG and DHEAS 
significantly lower in postmenopausal 
women  
• SHBG and DHEAS serum levels both 
negatively associated with total fat 
mass. SHBG correlates negatively with 
total lean mass while DHEA correlates 
positively with it 
• Differences in BMD and lean mass 
across the MT groups strongly related 
to serum levels of E2 and FSH, 
respectively 
• BMC correlated positively with serum 
E2 levels 
4 
  
4 
To determine the 
prevalence of the MetS, 
the level of its individual 
components and 
associated metabolic 
factors in African females 
at different stages of the 
MT and what factors play a 
role in modulating the 
levels of these variables 
• High prevalence of MetS, IFG and 
diabetes 
• High waist circumference and 
dyslipidemia common components of 
MetS   
• FSH levels during MT associated with 
increased cholesterol levels 
• E2 levels negatively related to diastolic 
blood pressure 
 
 
5 
 132 
6.2 Emerging research themes from the SWEET findings 
 
This section will examine the study findings in relation to the objectives delineated in Chapter 
1 and described in Table 6.1, and the specific research themes that have emerged from the 
study.  These emerging themes include: valid and reliable measurements to accurately 
stage the MT in black urban South African women; body composition changes and their 
relationship to the MT in this population, the prevalence of metabolic syndrome, its 
association with chronological and /or reproductive aging, and the increased risk of CVD in 
midlife sub-Saharan African women. 
 
6.2.1 Crucial aspects in understanding and staging the menopause transition in 
black, urban South African women 
 
 
This section explores selected findings related to staging reproductive aging accurately in 
black urban South African women, and some of the difficulties encountered when staging 
ovarian aging, determining accurate recall of age at menopause. In addition, the cultural 
perceptions that may impact the understanding and description of menopausal symptoms in 
this population will be examined.   
 
6.2.1.1 STRAW+10 
Accurate staging of reproductive aging is vital in understanding the impact of the MT stage 
and its relationship to a wide variety of variables, which may in turn be related to an 
increased risk of morbidity and mortality in midlife women. In a low-resource setting, where 
the public healthcare system is overburdened, it is costly and impractical to use biomarkers 
to assess MT. Bleeding criteria appear a more appropriate method to stage ovarian aging. 
This study has shown that STRAW+10 criteria are a cost-effective and easy way to stage 
the MT for application in large epidemiological studies examining reproductive and 
chronological aging in black African women.  Although less than half the women in the 
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cohort understood what menopause meant, most were able to describe changes in their 
bleeding patterns accurately enough to be allocated to a specific MT stage group.  
 
If, however, this method of staging ovarian aging becomes commonly used, several issues 
of concern emerged during the research process, which should be addressed. Clinical 
knowledge in interpreting the responses of the SWEET participants cannot be 
underestimated and it is important that questionnaires in future studies incorporating the 
STRAW +10 criteria should be both simple to use by team members without a clinical 
background, and easily understood by the participants. The terminology recommended by 
STRAW +10 is often medical, making it difficult for a layperson to understand. Initially, when 
piloting the questionnaires for SWEET, it was found that the terms used were complex and 
difficult to understand by the demographic group representative of the women who would be 
recruited into SWEET. English was the second language for these women, and in this pilot 
group, even when the respondents had a tertiary education or a nursing background, the 
criteria were difficult to interpret. As described earlier, each participant in SWEET was 
questioned about her menstrual cycle, during one-on-one interviews, by a single interviewer, 
who had a clinical background of dealing with women in the MT. The close-ended questions 
of the questionnaire that asked the participant to describe her bleeding patterns were 
followed by open-ended questions that enabled the interviewer to define these bleeding 
patterns more accurately. However, in future research, where researchers may not have the 
requisite clinical background, the terminology needs to be simplified and all questions should 
be contextualized.  An explanation of what is being asked and the reason for this should be 
given.  Clarification could be achieved first by explaining the norms of a regular cycle, and 
then by asking the participants how their cycles have changed.  Contraceptive use may be a 
confounder in response to questions on menstrual cycle regularity, and this should be 
specifically addressed in questions on bleeding patterns.  
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In addition, since the purpose of the STRAW +10 criteria is to stage reproductive aging using 
bleeding patterns, there should be a section in the staging questionnaire that addresses the 
possibility of a surgical or chemically induced menopause, and a clear description of what 
researchers mean by ‘natural menopause’. Reasons for interrupted or changing menstrual 
cycles should be included in questions about changes in bleeding patterns.  There are many 
explanations as to why menstrual cycles change; for example stress, medications or breast-
feeding. Different causes should all be included. Subsequent to the presentation of the 
STRAW +10 criteria at the NAMS meeting in 2013, several discussions on how to improve 
the validity of the STRAW + 10 document have been held between researchers at different 
international universities, who are conducting studies which rely on accurate staging of the 
MT using bleeding criteria. 
 
A disturbing revelation of the data collection process was the imperfect understanding that 
many of the women had of reproductive aging and fertility, and a belief that after the age of 
40 they were no longer fertile, especially when their menstrual cycles began to alter. In fact, 
several of the women were older primigravida, and had unexpectedly become pregnant in 
their mid to late forties because they thought their age would be a contraceptive. In regards 
to this, it is suggested that satellite clinics could be provided with simple information sheets 
explaining what happens to fertility during late reproductive aging.  
 
6.2.1.2 Age at FMP 
An interesting finding of this study was the difficulty these women had in recalling their age 
at FMP, and the apparent difference in age at FMP between sub-Saharan African women 
and their European and Western counterparts.  The latter groups experience their FMP at 
least 2 -3 years later than the African women (64, 288). Early menopause may be related to 
socioeconomic factors such as poverty, education, inadequate healthcare and ethnic 
differences. Recall of age at FMP is complex and questionnaires using improved bleeding 
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criteria terminology, as suggested above, should yield more relevant data explaining why 
some women experience it earlier. The Department of Health, as discussed in Chapter 2, 
has identified a need for midlife women to be given more information about menopause, but 
there have been no clear guidelines on how this can be achieved. Primary health care 
providers in South Africa should be trained in this area of reproductive health so that they 
are able to elicit the appropriate information from their patients, which may improve accuracy 
of recall of age at FMP. Since an early menopause may be related to greater morbidity and 
mortality as explained in Chapters 1 and 3, more emphasis on extensive questioning about 
the age of the mothers or siblings of participants, trauma, sexual abuse, childhood and adult 
poverty may help to better understand why some women have an earlier age at FMP. If, 
bleeding criteria become more commonly used to help black African women become aware 
of their reproductive status, in spite of the fact that annual medical or gynecological check-
ups are not the norm as in many high-resource countries, this knowledge may help to 
improve their recall of age at FMP, which has been shown to be important in predicting 
future morbidity and mortality.  As discussed above, primary health care nurses, equipped 
with adequate training and information about the MT, could, during a routine clinic visit, use 
a brief questionnaire, relating to a patient’s menstrual cycle, to gather information about their 
reproductive status. This information could be included in the patients’ medical records for 
future reference.  
 
6.2.1.3 Menopause symptoms. 
In examining the symptoms that are most prevalent in cross-cultural comparisons, VMS was 
the defining symptom of the MT in the SWEET participants, as found in Western women. 
However, it is not clear why more late reproductive stage black African women described 
themselves as having hot flushes, as compared to other late reproductive women in different 
population groups (99, 100), where the MRS was used to determine prevalence and severity 
of VMS. Hot flushes generally become more prevalent in the late menopausal transition 
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stage (56).  It was thought that many of the women in this study, especially those who were 
more obese, might not have distinguished a hot flush from general body temperature 
changes and feelings of heat.  They appeared to understand what VMS were, especially 
night sweats, and their description of VMS correlated significantly with FSH levels. Some 
researchers have suggested that hot flushes and night sweats should not be combined into 
one term under the heading of VMS (349). However, the women in SWEET appeared to be 
very clear about the difference between these two when questioned, so the reason for the 
finding remains unclear.  It is possible that cultural perceptions and expectations may play a 
role in the responses of these women. 
 
The problem of comparing symptomology across different ethnicities and cultures was 
highlighted in the fact that vaginal atrophy, which is a common complaint in menopause in 
Western women, and is usually very prevalent in late menopause (56), did not appear to be 
of significance to the women in SWEET. This may be related to their partners’ sexual 
preferences and cultural perceptions, where older women may be seen as less desirable 
than those who are younger.  Many women reported that they had ‘finished’ with sex and 
had not been sexually active for many years and did not know if they had vaginal atrophy or 
the urinary complications that often occur if this is present. No connection was made 
between any vaginal atrophy or urinary issues they were experiencing and the MT. Unlike 
their Western counterparts, where a wide body of research reports distress at sexual 
inactivity and loss of libido, which is often related to vaginal atrophy (415, 416), this did not 
appear to concern many of the SWEET participants. Although sexually active women 
reported sexual problems in early postmenopause, they did not generally relate these to 
dyspareunia. 
 
The fact that the participants in SWEET appeared to experience VMS earlier than was found 
in other women where data on menopausal symptoms were collected using the MRS, may 
also be related to both idiomatic and translation issues as well as cultural perspectives. 
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Apart from VMS, only two menopausal symptoms were significantly associated with MT 
stage in SWEET participants. These were sexual problems and irritability  
 
In Western research, depression and mood swings during the menopause transition have 
been well described, and an increase in depression and mood changes in the 
perimenopause has been found (346). However, apart from irritability, none of the symptoms 
described in the psychological domain of the MRS (depression, irritability, anxiety, and 
mental exhaustion), were associated with menopause stage in the study participants.  An 
unexpected outcome of the research was that irritability appeared to significantly increase in 
the late postmenopausal stage.  This differs from other research where irritability is more 
generally shown in premenopausal women and the symptom of depression is more 
commonly found in late menopausal women (347). The fact that the symptom of irritability 
rather than depression was associated with MT stage in this population, and this symptom 
seemed to increase in the late menopausal stage, where it is not usually described, may 
have been due to a misinterpretation of the word, ‘irritability’ and/or a different cultural 
perception of the meaning of ‘depression’. Several research studies describe the differences 
in the way in which different women from different cultures experience and identify 
menopausal symptoms (122), particularly those in the psychological domain (226), and 
recommend that cultural differences should be taken into account when identifying 
symptoms (128). 
 
Mental health does not appear to have been studied in the context of reproductive aging in 
these black African women, although in Western studies, there is a greater risk of 
depression at onset of menopause, even in women with no previous history of depression 
(417), and there a strong association between mood and the effect of falling estrogen levels 
on key neurotransmitters has been shown (346). If greater attention is paid to the physiology 
of the MT and its biomarkers in this population, it may follow that attendant psychological 
aspects may emerge, and may be found to play a far greater role than has been shown in 
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this study. However, it is essential to understand whether menopause and its accompanying 
symptoms have the same meaning and importance for black African women, as they 
appear to have for Western women.   
 
6.2.2 Body composition changes and the MT  
 
The overarching theme arising from this study was the very high prevalence of obesity in 
these midlife black urban women, which has been fully discussed in Chapters 3-5. It has 
been well described how obesity affects many aspects of reproductive aging and increases 
the risk of metabolic disease in these aging black African women. It is an issue of paramount 
importance in the healthcare sector (242, 245) and issues contributing to obesity in these 
women should be addressed. 
 
6.2.2.1 Obesity and lifestyle 
 
Addressing and dealing with the problem of obesity in these women is difficult. The nutrition 
transition has meant that there has been an increase in the consumption of both high 
carbohydrate and high fat diets (418), and these diets are very common in urban black 
South African populations (245).  Fast foods, extremely high in fat and carbohydrates are 
widely available in Soweto, which means they are easy to obtain and relatively inexpensive 
(419).   The perception of obesity amongst South African women is also problematic, since 
they are less likely than their white counterparts to view themselves as obese (420). In 
addition the stigma attached to HIV infection and its accompanying weight loss means that 
thinness is associated with ill-health, and a knock-on effect of this perception is that being 
obese is viewed as a sign of health and wealth in African communities (244).  
 
Women in SWEET who had a BMI ≥ 30kg/m2 were referred to the Dietetic Clinic, in the 
Department of Nutrition, at the Chris Hani Baragwanath Hospital, for nutritional counselling 
and information to help them lose weight. However, this recommendation although well 
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intentioned, may not have been effective for several reasons, including lack of easy access 
to the clinic, the long waiting period due to over-crowding and lack of efficient monitoring and 
evaluation of the dietetic regimen. In addition, there has been no follow-up in the SWEET 
participants to see whether this intervention was helpful. It may be more effective to train 
both primary healthcare nurses and community organizations to explain the principals of 
healthy eating and benefits of regular exercise to women who are premenopausal rather 
than wait until they are postmenopausal, as these interventions may help to lower the future 
risk of metabolic disease. Studies have shown that weight loss during the MT and post 
menopause may also result in unhealthy loss of lean mass (171). The high energy, low 
nutrient diets that are economically viable in this population (421), may lead to further loss of 
lean mass.  In addition these obese women may not exercise, as they should. 
Socioeconomic factors such as the cost of high protein, nutritionally balanced diets, lack of 
places to exercise and concerns about safety in many areas in Soweto may compromise 
recommended weight loss and exercise regimens.  The importance of adapting dietary 
recommendations to specific socioeconomic and diverse ethnic food preferences should 
also be considered. However, weight loss regimens used with appropriate lifestyle 
interventions should be seriously considered as they may improve health in these aging 
women (422). 
 
6.2.2.2 Lean mass 
 
The loss of lean mass across the MT described in SWEET participants has significant health 
implications in black African women. Loss of skeletal muscle has been shown to be related 
to loss of strength in aging women, which in turn are related to infirmity and weakness (423). 
In addition, the loss of BMD, which was also described in these women may increase bone 
fragility (269). A further problem that may arise is that the loss of muscle strength and 
functioning which may result from loss of skeletal muscle mass may increase risk of falling. 
Data have shown that physical activity and resistance exercise is recommended to retain 
lean mass. Although data from this cohort have shown that these women are physically 
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active (424), the intensity of the exercise was not measured, and there appear to be few 
studies identifying the levels and type of exercise, including resistance training, undertaken 
by these women (245). Thus, weight loss regimens in these women must be carefully 
controlled to prevent increased loss of skeletal muscle mass, and the type and intensity of 
exercise should also be monitored. 
 
6.2.3 Metabolic Syndrome and morbidities  
 
The high prevalence of MetS and related metabolic variables described in this cohort are of 
concern. Little attention has been paid to health risks in midlife black African women, 
consequently they and their primary healthcare providers, have scant understanding of the 
association between obesity and risk for metabolic disease, which are commonly explained 
to aging women in healthcare systems in high resource countries. The effect of obesity in 
these women has been discussed and the importance of weight loss regimens and 
increased exercise in lowering the risk for this has been explored. However, these alone 
may not be enough in preventing MetS and related NCDs.   Annual check-ups, which include 
anthropometric measures and relevant biomarkers may help to increase awareness of 
health risks and prevent the high rate of morbidity in this population of midlife women.  
However, the costs of these and the lack of adequate trained healthcare practitioners may 
be beyond the scope of the public healthcare system in implementing this.  Therefore, 
workshops to train community organizations and primary healthcare nurses to explain the 
risks of reproductive and chronological aging to women may be more practical.   
 
6.2.3.1 Aging, mortality and morbidity  
 
It is well described in the literature that chronological aging is related to an increased risk of 
NCDs, including diabetes, hypertension, osteoporosis and cancers (425).  However, the 
SWEET study has clearly shown that risks for some of these NCDs are related to the 
trajectory of reproductive aging in these women, and the importance of age at FMP on future 
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health risks cannot be underestimated (214), although age at FMP and the association with 
cardiometabolic risk factors were not examined in the SWEET participants due to poor recall 
of the date of the FMP in the study participants. Many research studies suggest that an HT 
regimen may ameliorate the health consequences of an early menopause (202) but 
international menopause and endocrine societies, though they are considering the 
importance of the timing hypothesis in prescribing HT in early, healthy postmenopausal 
women, are clear that HT should not be prescribed to prevent osteoporosis, or 
cardiovascular disease. The consensus is that the primary use of HT is to alleviate VMS and 
vaginal atrophy (61). While recent research suggests that older women may benefit from 
judicious use of HT (426), women using HT should be regularly monitored with annual 
gynecological examinations (38), which is not the norm in the this population as discussed in 
Chapter 2.  
 
6.2.3.2 Lifestyle interventions  
 
Research has shown that lifestyle interventions, such as healthy eating and regular exercise 
in obese midlife women can improve risk for MetS and future CVD (422). There are also 
other lifestyle interventions that can reduce the risk of MetS. Thus, there was a high 
prevalence of SWEET participants who used a smokeless tobacco (snuff), high in nicotine, 
which was related to both low bone density and higher visceral fat levels in this population, 
suggesting that it is imperative to educate these women in the dangers of this product. 
However, this may present some difficulties. Depending on their motivation for using snuff, 
religious or cultural reasons may trump healthcare concerns in these women, and care 
should be taken to understand cultural sensitivities in this regard.  In addition, although 
smoking in this cohort is not as prevalent as snuff use, it is associated, as discussed in 
Chapter 5, with several metabolic risk factors including MetS, increased triglyceride levels, 
and raised systolic and diastolic blood pressure. Regulations in South Africa have helped to 
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reduce the incidence of smoking, but a recent survey recommended that these regulations 
should be more strongly enforced (6).   
 
6.3 Conceptual relevance  
The conceptual framework diagram (Figure 1.12) in Chapter 1, attempted to give an 
overview of the theoretical relationship of cardiometabolic disease and risk factors with the 
MT. It was hoped that this framework would serve as a guide to the various experimental 
components that have been discussed in this study. However, after this study, certain 
adjustments were necessary (Figure 6.1).  
 
It was hypothesized that HIV infection would affect age at FMP, prevalence and severity of 
VMS but this was not found. Although no effect of HIV infection or treatment on the 
prevalence and severity of VMS was seen, this may have been due to the small sample of 
HIV-positive women in the cohort. In addition the effect of HIV infection on age at FMP could 
not be tested, because all the women were diagnosed after onset of menopause. However, 
body composition and metabolic variables were related to HIV and ART.  
 
Although a wide range of menopausal symptoms are generally associated with the MT only 
three were significant in these women. These were VMS, irritability and sexual problems, 
and these three menopausal symptoms have been added to Figure 6.1. 
 
The effect of snuff use on BMD was significant, as was its effect on visceral fat. In addition, 
smoking was associated with triglycerides, hypertension and MetS (Figure 6.1). 
 
Figure 1.12 showed a theoretical relationship of certain demographic variables on MT risk 
factors.  This study found that demographic factors such as employment status and levels of 
education were associated with certain metabolic variables such as blood pressure, visceral 
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adiposity and waist circumference and this has been shown in Figure 6.1. . The role that 
cultural differences may play in the description and perception of menopause symptoms has 
been discussed earlier. 
 
As expected, the roles of both chronological and reproductive aging, as shown in the initial 
conceptual framework diagram (Figure 1.12) were significant.   
 
 
  Figure 6.1 Adapted conceptual framework describing the findings of the research.  
 
 
6.3.1 Novel findings 
 This research highlighted several new and important findings in midlife black, urban South 
African women.  
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While an increase in BMI across the MT has been widely described in Western literature 
(358, 359), this was not observed in the current study. Indeed, BMI was lower in 
postmenopausal compared to premenopausal females.  
 
Only three menopausal symptoms, VMS, sexual problems and irritability were significantly 
related to the MT. It was expected that VMS would be related to the MT, but the finding that 
sexual problems and irritability were related to MT was surprising. Irritability is usually found 
in premenopausal women (347), not in late postmenopausal women, while sexual problems 
and low libido are generally related to vaginal atrophy (415). In addition, data have shown 
that VMS are associated with sleep disorders and mood problems (427), but these problems 
were not shown to be related to MT stage in this study population.  
 
Higher serum FSH levels were associated with lower lean mass, as previously reported in 
only 2 other studies (146, 367) and with higher levels of total cholesterol and LDL-
cholesterol, as also reported in only one other study that was conducted in premenopausal 
females (182).  
 
A further novel finding was the effect of snuff use on both visceral fat and lowered BMD in 
midlife women.  
 
6.4 Contextual relevance  
6.4.1 Local, national and international relevance 
The SWEET findings may help clinicians and researchers in the field of women’s health, to 
have a better understanding of the association between reproductive aging in black midlife 
South African women and their increased risk of cardiometabolic disease. There is a high 
prevalence of obesity and MetS in these women, but until now there was no information as 
to whether the MT is related to NCDs.  
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There are different methods to stage the MT, but many use blood assays, which are invasive 
and costly, especially in a low-resource country like South Africa, where funding for 
healthcare is limited.  This research has shown that STRAW +10 criteria are accurate in 
staging reproductive aging and do not rely on blood assays for verification of MT stage, 
resulting in savings of both resources and manpower. Furthermore, STRAW+10 criteria 
have not previously been used to stage reproductive aging in sub-Saharan African women 
and this method may be generalizable to populations of both rural and urban women in 
these countries.  
 
The inability of most of the study participants to accurately recall age at FMP has highlighted 
a neglected area in women’s health care in this country and possibly in other sub-Saharan 
countries. Annual screening, identifying important biomarkers, metabolic risk factors, and 
informing women of their healthcare risks as they transition into menopause do not appear to 
be the norm in South Africa or other sub-Saharan countries. However, an understanding of 
midlife women’s health risks is vital, especially as improved care for HIV-infected populations 
means that aging women are living longer and are thus at greater risk for NCDs. In addition, 
ART use was related to lower BMC. This, in conjunction with the high prevalence of obesity 
in these women, and the finding that lean mass and BMD were lower in premenopausal than 
postmenopausal women is of concern, but may help to emphasize the need for lifestyle 
interventions such as appropriate muscle strengthening exercise, weight loss regimens and 
bone density screening. 
 
Poor education and high unemployment are both challenges in South Africa, and the finding 
that these are related to metabolic risk factors in midlife black urban women, is of concern, 
highlighting a need to be cognisant of the socioeconomic and education status of aging 
women in this population.  
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This study has shown that certain lifestyle variables are related to metabolic disease, 
although smokeless tobacco use has been investigated in black South Africans, its effect on 
visceral adiposity and BMD have not been shown specifically in aging black women, who are 
already at risk for metabolic disease and osteoporosis. Smoking, though less prevalent in 
the study participants, is also related to metabolic variable, underlying the importance of 
continuing to monitor and educate this population about the risks of any type of tobacco use. 
 
6.5 Limitations and advantages of the study  
The limitations and advantages of this study have been fully described in chapters 3-5. 
However other shortcomings and positive attributes of the study should be explored.  The 
fact that English was the second language of the participants meant that aspects of both the 
understanding of the question and the response might have been ‘lost in translation’. In 
addition, those team members who were trained to interpret the questions and answers did 
not speak English as their first language. However, rigorous training in the description and 
interpretation of the answers was given to team members, who were available to act as 
interpreters. The importance of not adding additional explanations or ‘improving’ the question 
or answers was stressed. Since English is the most commonly used language in South 
Africa, loss of idiomatic meaning and misinterpretation was rare and the team members 
were all widely experienced in the research field. The questionnaires were piloted among 
women who spoke English as a second language and where possible, words and 
terminology were simplified. An additional limitation was that CD-4 counts were not obtained. 
 
In terms of the positive aspects of this study, this is the first time that the effects of a wide 
range of hormonal, anthropometric and metabolic variables and their relationship to 
reproductive aging in black urban South African women have been assessed.  The large 
sample number provided sufficient statistical power to allow us to observe multiple 
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associations between these different variables and the MT.  
  
6.6 Future research studies  
Due to the fact that research into reproductive aging has not previously been undertaken in 
this population, a wide range of possible future research studies became apparent during the 
course of this investigation. The following topics may generate some useful data: 
 
6.6.1 Longitudinal research to confirm validity of the SWEET findings 
 
The development of a large, longitudinal study investigating both chronological and 
reproductive aging in this group of women would be useful to confirm whether the findings 
from SWEET, which is a cross-sectional study, are valid and thus generalizable to other sub-
Saharan women.  
 
6.6.2 Improved research tools to accurately stage age at FMP 
Use of an improved staging instrument should help to define the menopause transition 
stages more accurately and allow more accurate recall of age at FMP. Studies have shown 
that earlier age at menopause is related to increased morbidity and mortality (62), so 
research examining the relationship between metabolic risk factors that are prevalent in 
these women and age at FMP using more accurate recall data may be important. Additional 
information relating to the age at menopause of the mothers, close female relatives or 
siblings of participants should be obtained, since data have shown that heritability is strongly 
associated with age at FMP (65).  Trauma, sexual abuse, childhood and adult poverty are 
also associated with earlier menopause (62), and data on these are necessary to better 
understand why some women have an earlier age at FMP. Use of menstrual calendars in a 
longitudinal study may be helpful, and possibly an examination of genetic factors which 
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might affect age at FMP. Ethics permission to collect DNA from this group of women was 
given and the DNA has been stored for future analysis.  
 
6.6.3 Research using objective hot flush measurements to assess MRS validity and 
the effect of cultural perception on the description of menopause symptoms 
 
The MRS, which was used to assess prevalence and severity of menopausal symptoms in 
the research, has been internationally validated, However language differences and cultural 
perceptions of the menopause may affect responses, so a study investigating objective hot 
flushes, using a small external monitoring device (428), as compared with self-reported hot 
flushes in midlife black African women, may be helpful in assessing the validity of the MRS, 
and improving understanding of cultural differences in the perception of hot flushes.  
 
6.6.4 HIV and the MT 
The high prevalence of HIV infection in this group of women suggests that the effect of the 
disease on both chronological and reproductive aging in these midlife black women is highly 
relevant. Furthermore, only 55% of woman with HIV were receiving ART suggesting that the 
effects of the virus and of ART both require further investigation in this population. Research 
on the effect of HIV infection on reproductive aging and its related variables was an 
important aspect of the study, but the small sample number of subjects who allowed us to 
perform an HIV test limited the interpretation of the results. Future studies may have a 
longitudinal design and a large sample of premenopausal women, aged ≥ 45 years should 
be recruited.  Voluntary HIV testing should be offered but the numbers should be large 
enough to allow sufficient power.  Both HIV-positive and HIV-negative women should be 
followed up to FMP and 12 months beyond.  Given the association of ART with BMC and 
BFD in some SWEET participants, research should determine the effects of different ART 
regimens on hormone levels, FMP, cardiometabolic and anthropometric variables in this 
 149 
population. In addition, the role of HIV and ART in reproductive aging should be 
investigated. 
 
6.6.5 Contraceptive use and body composition in sub-Saharan African women 
Contraceptive use was determined in this study, and was shown to be associated with lower 
HDL levels, but previous treatment and type of contraceptive was not ascertained. It would 
be important to determine if particular contraceptives were responsible for this association. 
Given the trend for lower BMD across all MT groups, and the fact that Depo-Provera, which 
is known to affect bone density (429, 430), was widely used by the public healthcare system 
in South Africa, an investigation into length of use and bone density may further clarify any 
association between contraceptive use and bone loss.  
 
6.6.6 HT regimens and VMS, bone density and CVD 
 
Research into the possibility of prescribing HT to this population group, and the 
accompanying risks and benefits is important, especially in relation to bone density loss and 
alleviation of VMS. The use of HT may also lower risk of metabolic disease and improve 
quality of life in this group of women. 
 
6.6.7 The role of FSH in sarcopenia in black African women  
Lower lean mass in postmenopausal women in this population was significantly related to 
rising levels of FSH. This finding is interesting and requires further investigation because the 
molecular mechanisms involved are not understood.  There is no research indicating that 
FSH receptors are present in lean muscle tissue. Thus, studies have shown that the FSH 
receptors are found only in the tissues of the testes or ovaries (431). It is possible that FSH 
receptors may be expressed in low levels in muscle and this requires further investigation. It 
is also possible that there may be an indirect mechanism by which FSH affects lean mass.  
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In addition, further longitudinal research on the lower lean mass observed in the 
postmenopausal women in this study is needed to examine whether these women are at 
greater risk of falling due to the decrease in muscle function that has been shown to occur 
with skeletal muscle loss. In addition, further research could investigate whether decreased 
muscle strength may lead to greater bone fragility in this population. 
 
6.6.8 BMD and BMC in midlife black African women 
 
The lower BMC and BMD in postmenopausal SWEET participants suggest a need for 
additional research. There are several factors that must be investigated. Firstly, DXA 
machines have no set parameters for scans in black South African women.  The parameters 
for African American women are not appropriate as they are generally taller with heavier 
bones, so Caucasian parameters have been used in black South Africans for convenience, 
but there are clear ethnic differences in micro bone architecture, bone density and bone 
mineral metabolism (432) that may impact data. Popular medical wisdom from the last 
century assumed that black South African women had higher bone density than their 
Caucasian counterparts (294, 295). Studies have now disproved this, but menopause was 
not accurately staged in the latter studies (296, 298). It seems as though lower levels of 
estrogen are implicated in decreased bone density shown in the SWEET women, but HT, 
which protects against bone loss in the MT, is not usually prescribed in this population.  In 
addition, the negative effects of snuff use on BMD in this population should be further 
investigated. 
 
6.6.9 Aspects of cognition and executive function in black midlife South African 
women.  
Data on cognition, verbal memory and learning, working memory and executive function are 
widely available in midlife Western women (82).  Relationships of these variables to 
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reproductive aging, hormonal levels and VMS, have not yet been determined in black urban 
African women. Further research using appropriately validated instruments for this 
population group may improve the understanding of the above functions in aging women, 
and clarify whether reproductive or chronological aging, or both have an effect on them in 
sub-Saharan women. Mechanisms for these potential changes should also be examined.  
 
6.7 Conclusions  
This study found that STRAW+10 criteria can be used to stage the MT in black urban South 
African women. Obesity is not associated with the MT in this population.  However, the MT is 
characterized by sarcopenia, reduced BMD and increased cardiometabolic risk, all of which 
are driven by changes in hormone levels, specifically E2 and FSH, and by chronological 
aging. Lifestyle factors, including smoking, snuff use and ART also play a role in the 
increased risk of MetS in these women.  
 
The public healthcare system in South Africa has not focused on the effects of chronological 
and reproductive aging in midlife black women, but given the indication of increased 
morbidity in this group, further research is urgently needed to determine the interventions 
needed to lower these health risks. These data suggest that midlife African females require 
more frequent screening for cardiometabolic disease and intervention studies to reduce 
prevalence of obesity and snuff use. 
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HIV COUNSELLING FORM 
 
 
 
Hello! My name is ______________________. First, we would like to discuss some matters with you. 
Information collected will be not be used in any identification form outside this facility. Therefore 
confidentiality will be maintained. We will provide you with information you need to know about HIV 
and AIDS. This will then be followed by information to help you understand your risk exposure to 
HIV and then you could be able to take an HIV test.  
 
 
 
CLIENTS HIV HISTORY 
 
Have you been tested for HIV 
before? 
Yes No If Yes, when did you test? 
 
What was the HIV results 
 
 
Negative  
 
 
Positive 
If positive, do you have a copy of 
the results 
 
Yes  
 
No 
If no, would you like to do 
another test? 
No  Yes 
What was your reason for testing  
Illness 
 
Insurance 
Partner 
died 
Pregnancy 
( Females Only) 
Employment General 
Check 
up 
If other please state reason  
 
 
 
 
 
CLIENT SUPPORT SYSTEM 
 
Have you ever had a loss in your life? Yes No  
If yes, Who  
 When  
If the test is HIV positive, will you tell someone? Yes No If Yes 
Who? 
 
Who else will you tell if you are HIV positive?  Family Partner Friend Other 
(State) 
 
How will you tell this person you trust?  
Do you think you will get support from that person? Yes  No Would you like us to offer 
support? 
Yes  
 
No 
 
 
 
 
 
 
 
 
 
Bt20 ID 
SWEET study 
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PRE COUNSELLING SESSION 
 
UNDERSTANDING HIV AND AIDS 
 
COUNSELLOR TO USE CUE CARDS FOR COUNSELLING 
 
Understanding of HIV/AIDS, client should be 
explaining mode of transmission and exchange of 
fluids. 
 Meaning of Window Period (What is it?)  
Benefits for HIV Testing   Importance of knowing ones HIV status 
(What does it mean?) 
 
Meaning of HIV testing  Meaning of HIV Negative Result  
Meaning of Confidentiality. (Counsellor to clarify 
confidentiality) 
 Meaning of HIV Positive Result  
  Perception of risk to HIV exposure. (Does the 
client think they are at risk to HIV infection?) 
 
 
 
 
 
HIV TESTING 
 
Counsellor:  Explain rapid testing processes. A rapid test for HIV will be done by the DPHRU lab. 
About a teaspoon full of blood will be collected (5ml to 10ml) and tested on specific HIV testing kits to 
check for HIV antibodies. Test results will be given to you in private when you check out today by a 
registered trained counsellor. If the report states negative it means that there are no antibodies to HIV. 
The window period will be explained. If the report states positive, it means that you are HIV positive 
and that there are antibodies to HIV. You will be given a letter to refer you to a clinic specialising in 
HIV treatment and you will be given a second test at the clinic to confirm this result.  Sometimes we 
cannot clearly tell if the results are negative or positive. We will then repeat the test and if it is still 
indeterminate we will refer you to a clininc for a second testing that will help confirm the results                                                                
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PATIENT CONSENT 
 
I agree to have the HIV Rapid test. The procedure to be carried out has been explained to me. The 
possible discomforts, risks and benefits involved in taking part in the test have also been described to 
me. I understand that I can leave the study at any point. I also understand that if I have any questions 
concerning the test then the investigator will explain these to me 
 
Contact details of researcher: 
 
If you have any questions or queries at any time during the study, please contact me at 011-8851498 or 
0828524857or call our department at 011-4898500. 
 
 Contact details of Human Research Ethics Committee (Medical)/ HREC: 
 
If you have any other queries or wish to complain about the conduct of the study or researcher, you 
may contact the HREC chair, Prof Cleaton-Jones through the secretary Ms Anisa Keshav at 011-717 
1234. 
 
 
 
Date:                                 Patient:    
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POST TEST COUNSELING SESSION 
 
NB.   COUNSELOR: Identi fy  Client with Name and ID number against  HIV Test  
Results  
 
 
HIV NEGATIVE TEST RESULT 
We spoke earl ier  about what HIV posi t ive and HIV negat ive results  mean. Explain 
again.  Your results  are back and you are HIV negat ive;  you do not have the HIV virus 
in your body 
 
 
COUNSELORS KEY TASKS CLIENTS NOTES COMMENTS 
Explain the implications of the negative test result   
Identify and prioritize the behaviours that correspond to 
the client’s risk 
  
Motivate the client to develop a risk reduction plan   
Encourage clients to discuss their HIV status with current 
and future partners 
  
  
 
POST TEST COUNSELLING 
 
HIV POSITIVE TEST RESULTS 
We spoke earl ier  about what HIV posi t ive and HIV negat ive results  mean. Explain 
again.  Your results  are back and you are HIV posi t ive;  you do have the HIV virus in 
your body 
 
 
 
COUNSELORS KEY TASKS 
 
CLIENTS NOTES 
COMMENTS 
 
Inform client that the test results are available 
 
 
  
Provide results clearly and simply  
 
 
 
Review the meaning of the result  
 
 
 
Allow the client time to absorb the meaning of the result  
 
 
 
Explore the client’s understanding of the result  
 
 
 
Assess how client is coping with the result  
 
 
 
Acknowledge the challenges of dealing with an initial 
positive result 
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IDENTIFY SOURCES OF SUPPORT 
                       
 
COUNSELORS KEY TASKS CLIENTS 
NOTES 
COMMENTS 
Identify current health care resources   
Address the need for health care providers to know client’s test 
result 
  
Explore client’s access to medical services   
Identify needed medical referrals   
Discuss situations in which the client may want to consider 
protecting his or her own confidentiality 
  
Discuss options of support groups (i.e. post test club)   
Provide appropriate referrals   
 
 
 
REFERRAL TO OTHER PROGRAMS 
 
Refer the cl ient  with let ter  to Thandekile Essien and the cl inic (ZAZI VCT service at  
Baragwanath Hospita l) ;  she wil l  then ensure that  the cl ient has the appropriate 
support .  
 
 
 
COUNSELLORS NOTES: 
 
 
……………………………………………………………………………………………………………………………………
………………………………… 
 
……………………………………………………………………………………………………………………………………
……………………………….. 
 
……………………………………………………………………………………………………………………………………
……………………………….. 
 
……………………………………………………………………………………………………………………………………
……………………………….. 
 
……………………………………………………………………………………………………………………………………
……………………………….. 
 
Counsel lor’s  Signature:…………………………………… 
 
 
                THANK  THE CLIENT FOR USING OUR SERVICES  
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MENOPAUSE	  AND	  CERVICAL	  
CANCER	  INFORMATION	  SHEET	  
	  
What	  is	  menopause?	  
The	  word	  menopause	  means	  the	  last	  day	  of	  a	  woman’s	  last	  period	  ever.	  Some	  women	  call	  it	  the	  
‘change	  of	  life’.	  
	  
What	  happens	  when	  you	  are	  in	  menopause?	  
When	  you	  reach	  menopause	  you	  can’t	  become	  pregnant	  any	  more.	  	  
You	  don’t	  usually	  become	  menopausal	  suddenly.	  The	  changes	  in	  your	  body	  happen	  slowly	  as	  you	  
move	  towards	  the	  time	  of	  menopause.	  This	  time	  is	  called	  perimenopause	  and	  during	  it	  you	  may	  
notice	  physical	  and	  emotional	  changes	  happening	  to	  you.	  These	  happen	  as	  the	  hormones	  in	  your	  
body	  that	  are	  connected	  to	  childbearing	  start	  to	  rise	  and	  fall.	  Some	  hormones	  are	  responsible	  in	  
helping	  you	  have	  regular	  periods	  and	  causing	  ovulation	  (when	  you	  are	  able	  to	  have	  a	  baby).	  	  
During	  perimenopause	  you	  may	  experience	  uncomfortable	  symptoms:	  
	  
 Hot	  flushes	  and	  night	  sweats,	  
 Tender	  breasts.	  	  
 Irritability	  and	  emotional	  feelings	  	  
 Battling	  to	  sleep	  well	  or	  to	  stay	  asleep.	  	  	  
 Weight	  gain	  	  
 Changes	  in	  periods	  –	  they	  can	  be	  very	  heavy,	  much	  lighter	  or	  stop	  for	  a	  few	  months	  
and	  then	  start	  again.	  	  
	  
The	  time	  it	  takes	  to	  become	  menopausal	  can	  be	  short	  -­‐	  up	  to	  two	  years,	  or	  long	  -­‐	  up	  to	  14	  years.	  
All	  women	  are	  different,	   so	  your	  menopause	  experience	  may	  not	  be	   the	   same	  as	  your	   friends.	  
Although	  you	  and	  many	  other	  women	  may	  struggle	  in	  the	  years	  leading	  up	  to	  menopause,	  some	  
women	  have	  no	  problems	  at	   all.	  Once	  you	  are	   fully	   into	  menopause	   the	  hot	   flushes	  and	  other	  
symptoms	  usually	  stop,	  though	  some	  women	  may	  suffer	  from	  a	  dry	  vagina,	  a	  low	  sex	  drive	  (not	  
wanting	  to	  have	  sex)	  and	  sometimes	  urinary	  problems	  (pain	  when	  urinating	  or	  urinary	  infections)	  
	  
Don’t	  become	  pregnant	  by	  mistake	  
Even	   if	  a	  your	  periods	  are	  not	  regular	  you	  can	  still	  become	  pregnant,	   so	  until	  you	  are	  
sure	  that	  you	  are	  fully	  menopausal	  and	  haven’t	  had	  a	  period	  for	  at	  least	  12	  months,	  you	  
should	  still	  use	  contraception	  during	  sex	  
	  
How	  do	  you	  know	  when	  you	  are	  menopausal?	  
If	  you	  are	  in	  your	  mid-­‐40’s	  or	  older	  and	  haven’t	  had	  a	  period	  for	  12	  months	  you	  can	  usually	  be	  
confident	  that	  you	  are	  menopausal.	  However,	  certain	  things	  such	  as	  losing	  too	  much	  weight,	  lots	  
of	  stress	  and	  unhealthy	  life	  style,	  habits	  like	  smoking	  and	  drinking	  too	  much	  alcohol,	  can	  also	  
cause	  your	  periods	  to	  stop.	  So	  be	  aware	  if	  there	  are	  other	  reasons	  for	  your	  periods	  to	  stop	  or	  
change.	  	  It	  is	  important	  to	  know	  that	  menopause	  symptoms	  can	  be	  very	  similar	  to	  some	  changes	  
caused	  by	  certain	  health	  problems,	  and	  may	  not	  be	  caused	  as	  your	  ovaries	  are	  getting	  older.	  If	  
you	  don’t	  think	  that	  you	  are	  moving	  towards	  your	  menopause,	  you	  must	  explain	  this	  to	  your	  
doctor	  or	  clinic	  sister	  and	  they	  may	  do	  some	  blood	  tests	  to	  help	  confirm	  whether	  you	  are	  in	  
menopause	  
	  
Dealing	  with	  hot	  flushes	  and	  night	  sweats	  	  
 Wear	   loose	   comfortable	   clothes	   that	   are	   made	   of	   pure	   cotton,	   so	   that	   the	   fabric	  
breathes.	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Wear	  layers	  so	  you	  can	  remove	  something	  if	  you	  get	  too	  hot.	  
 Carry	  a	  small	  spray	  bottle	  of	  water	  and	  spray	  it	  on	  the	  back	  of	  your	  neck	  and	  wrists	  and	  
knees	  when	  you	  feel	  a	  hot	  flush	  coming	  on.	  Keep	  one	  next	  to	  your	  bed	  at	  night.	  
 Don’t	  have	  spicy	  or	  very	  hot	  food	  and	  drink	  tea	  or	  coffee	  at	  room	  temperature.	  
 Don’t	  overeat	  or	  drink	  too	  much	  alcohol	  or	  coffee.	  
 Don’t	  smoke.	  
 Exercise	  regularly.	  
 Stress	  can	  trigger	  a	  hot	  flush,	  so	  try	  to	  relax	  and	  stay	  calm.	  
 Hormone	  Therapy	  (HT)	  is	  the	  most	  effective	  treatment	  if	  you	  are	  really	  battling	  with	  hot	  
flushes.	  Your	  doctor	  will	  advise	  you	  of	  the	  risks	  and	  benefits.	  	  
 If	   you	   take	   HT,	   you	   must	   have	   a	   thorough	   medical	   examination	   and	   then	   an	   annual	  
gynaecological	  examination	  and	  a	  mammogram.	  Tell	  your	  doctor	  your	  family	  and	  medical	  
history.	   Take	   the	   smallest,	   effective	   amount	   of	  HT	   for	   the	   shortest	   possible	   time.	   Each	  
year	  check	  to	  see	  whether	  you	  still	  have	  hot	  flushes	  and	  need	  to	  use	  it.	  
 For	  women	  who	  can’t	  take	  HT,	  there	  are	  other	  treatments;	  ask	  your	  doctor	  or	  clinic	  sister	  
about	  them.	  	  
	  
INFORMATION	  ABOUT	  THE	  PAP	  SMEAR	  AND	  CERVICAL	  CANCER	  
What	  is	  a	  pap	  smear?	  
The	  Pap	  smear	  is	  the	  best	  way	  to	  see	  whether	  you	  have	  cancer	  or	  pre	  cancer	  of	  
your	  cervix.	  The	  cervix	  is	  the	  part	  of	  your	  body	  that	  connects	  your	  vagina	  to	  your	  
womb.	  Most	  invasive	  cancers	  of	  the	  cervix	  can	  be	  detected	  early	  if	  you	  have	  Pap	  
tests.	  In	  this	  procedure	  some	  cells	  from	  your	  cervix	  are	  scraped	  off	  painlessly.	  	  
These	  are	  then	  sent	  to	  be	  checked.	  
You	  are	  at	  risk	  for	  cervical	  cancer	  if	  you:	  
Ø Smoke	  
Ø Have	  many	  sexual	  partners	  
Ø If	  your	  partner	  has	  many	  sexual	  partners	  
If	  possible,	  you	  should	  have	  a	  Pap	  smear	  once	  a	  year	  to	  check	  for	  
cervical	  cancer.	  You	  can	  ask	  at	  your	  local	  clinic	  for	  them	  to	  do	  the	  pap	  smear.	  
You	  can	  have	  3(three)	  pap	  smears	  in	  your	  lifetime	  at	  the	  ages	  of	  30,	  40	  and	  
50.	  These	  are	  free	  of	  charge.	  If	  you	  or	  your	  sexual	  partner	  has	  another	  new	  
partner	  or	  partners,	  then	  you	  should	  have	  a	  Pap	  smear	  once	  a	  year.	  
Signs	  that	  you	  may	  have	  a	  problem	  (if	  you	  have	  any	  of	  these	  signs	  you	  
should	  see	  to	  a	  doctor):	  
Ø Painful	  sex	  	  
Ø Bleeding	  after	  sex	  	  
Ø Pain	  while	  urinating	  	  
Ø Pain	  in	  your	  lower	  back	  	  
Ø Unusual	  bleeding	  	  
Ø Unusual	  discharge	  from	  your	  vagina	  
If	   you	   or	  your	   sexual	   partner	   have	   other	  new	  partners,	   then	  you	  should	   have	  a	  
Pap	  smear	  once	  a	  year.	  After	  age	  65-­‐70,	  you	  can	  stop	  having	  Pap	  smears	  as	  long	  
as	  you	  have	  had	  three	  negative	  tests	  within	  the	  past	  10	  years.	   If	  you	  have	  a	  new	  
sexual	  partner	  after	  age	  65,	  you	  should	  begin	  having	  Pap	  smear	  screening	  again.	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